Cells, tissues, organs, and animals with one or more modified genes for enhancing xenograft survival and tolerance

JP2023549536A5Active Publication Date: 2024-11-20EGENESIS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528956
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-23
Filing Date
2021-11-12
Publication Date
2024-11-20
Estimated Expiration
2041-11-12

AI Technical Summary

Technical Problem

The shortage of human organs and tissues for transplantation and the immunological incompatibilities in xenotransplantation, particularly between pigs and humans, have hindered the clinical use of porcine cells, tissues, and organs due to hyperacute rejection, thrombotic microangiopathy, and chronic vasculopathy.

Method used

Genetic modifications in pigs, including coagulation, complement control, and innate immunity cassettes, are introduced to express proteins that reduce graft-associated clotting, complement deposition, and innate immune responses, enhancing immunological compatibility and graft survival.

Benefits of technology

The genetic modifications improve xenograft survival by reducing immune responses and improving compatibility, potentially providing a sustainable supply of transplantable organs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure relates to cells, tissues, organs, and / or animals with one or more modified genes for enhancing xenograft survival and / or tolerance. Additionally, the present disclosure relates to methods of making and using cells, tissues, organs, and / or animals with one or more modified genes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] Cross-reference of related applications This application is filed in US Provisional Application No. 63 / 113,650, filed on November 13, 2020; US Provisional Application No. 63 / 218,080, filed on July 2, 2021; and US Provisional Application No. 63 / 218,080, filed on September 23, 2021. Claims priority to U.S. Provisional Application No. 63 / 247,544, filed in . Each of the aforementioned applications is incorporated herein by reference in its entirety.

[0002] Description of electronically submitted text files

[0002] The contents of the text file electronically submitted with this specification is incorporated herein by reference in its entirety: Computer-readable copy of the Sequence Listing (Filename: EGEN_023_03WO_SeqList_ST25.txt, Date of Record: 2021 November 12th, file size approximately 2.35 MB). [Background technology]

[0003]

[0003] The shortage of human organs and tissues for transplantation has increased over the past several decades, making it one of the most important unmet medical needs. Xenotransplantation has the potential to provide an almost unlimited supply of transplanted organs for patients with chronic organ failure. Similarity in organ size and physiology, combined with genetic engineering to eliminate molecular incompatibility, selects pigs as donors for kidney xenotransplants. Preclinical studies have demonstrated that pig kidney xenografts sustained life in non-human primate recipients for weeks to months (Higginbotham 2015, Iwase 2015b). However, as a result of the evolutionary distance between pigs and humans, pig organs are susceptible to acute body fluids consisting of (i) hyperacute rejection, (ii) type II endothelial cell (EC) activation with impaired thrombotic control and leukocyte recruitment. (iii) thrombotic microangiopathy consisting of intravascular thrombosis with platelet consumption and EC activation, fibrin deposition, and thrombosis due to lack of thrombus control; and (iv) chronic vasculopathy. It causes rejection by the human immune system in various forms. These adverse events are due, at least in part, to molecular incompatibility between donor and recipient, particularly with respect to genes involved in complement, coagulation, inflammation, and immune response systems. The clinical use of xenogeneic organs (eg, pigs) has been hampered by these immunological incompatibilities, which have so far prevented the use of porcine cells, tissues, and vascularized porcine organs in clinical xenotransplantation.

[0004]

[0004] Over the past two decades, several genetic modifications have been identified that reduce interspecific incompatibility between pigs and humans. However, these previously identified genetic modifications have not achieved long-term xenograft survival. Furthermore, technical limitations associated with large-scale genome engineering have prevented the incorporation of these modifications into single animals. [Summary of the invention]

[0005] There is a need to develop porcine cells, tissues, organs, and / or porcine animals with novel combinations of genetic modifications for use in xenotransplantation, and to develop related methods.

[0006]

[0006] The present disclosure provides cells, tissues, organs, and animals containing genetic modifications that result in enhanced immunological compatibility, and vectors and methods for use in producing these cells, tissues, organs, and animals. , and the use of these cells, tissues, organs, and animals in xenotransplantation.

[0007]

[0007] Genetic modification improves the compatibility of xenotransplants through several modifications introduced into pigs. This modification eliminates expression of antigens known to stimulate host anti-graft responses. Furthermore, overexpression of the protein controls further responses to the graft and facilitates optimization of graft survival in the transplanted host. Disclosed herein are cassettes that express proteins that provide modulation of host responses. The cassette can be used in combination with a nucleic acid, also referred to herein as payload, that is introduced into the pig genome.

[0008]

[0008] The payload can include a coagulation cassette that expresses multiple proteins, each capable of controlling one or more aspects of the host coagulation response. For example, expressed proteins that reduce or eliminate graft-associated clotting can include THBD and TFPI. THBD reduces blood clotting by converting thrombin from a procoagulant to an anticoagulant enzyme. TFPI prevents the initiation of blood clotting by inhibiting factor VIIa and prothrombinase.

[0009]

[0009] The payload can include a complement control cassette that expresses multiple proteins each capable of regulating one or more aspects of the host complement response, reducing complement deposition and can reduce anti-graft immune responses. Proteins expressed to reduce or eliminate complement deposition on the graft may include CD46, CD55, or CD59. CD46 is a cofactor that assists in the inactivation of complement components C3b and C4b by serum factor I. By limiting the amplification of convertases of the complement cascade, CD55 indirectly prevents membrane attack complex formation. Membrane attack complexes are formed on the surface of cell membranes after complement activation and enable complement-mediated cell lysis. CD59 prevents C9 from polymerizing to form membrane attack complexes.

[0010]

[0010] The payload may include an innate immunity cassette that reduces the host's innate immune response to the graft. Expressed proteins to suppress innate immune attack on the graft can include B2M, HLA-E, and CD47. B2M and HLA-E reduce natural killer (NK) cell-mediated lysis of transplanted cells. CD47 suppresses macrophage phagocytosis. Optionally, the cassette may be an innate immune and inflammation cassette, and in addition to innate immune regulatory components may express additional proteins that reduce inflammation; for example, A20 and HO1. A20 reduces NF-κB activation in response to external stimuli. HO1 prevents vascular inflammation by cleaving heme groups to produce biliverdin, carbon monoxide, and releasing ferrous iron.

[0011]

[0011] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding TFPI selected from the group consisting of SEQ ID NOS: 94-96, 103, and 187; (iv) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (v) SEQ ID NOs: 1- a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from 10, 12-14, and 159-162; (b) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a second cistron encoding CD59, wherein the nucleic acid sequence of CD59 is selected from the group consisting of SEQ ID NO: 86, 108; (iii) SEQ ID NO: 126-145, 167-168; a promoter selected from 178-179, 231-238, and 250; (iv) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240; and combinations thereof; (v) a complement control cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (c) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; (iii) SEQ ID NO: 126 with a promoter selected from ~145, 167~168, 178~179, 231~238, and 250; (iv) from SEQ ID NO: 112~125, 154~156, 159~162, 190~192, and 239~240; an innate immunity cassette comprising a selected polyA sequence, and combinations thereof; and (v) at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0012]

[0012] In embodiments, the nucleic acid comprises at least two polycistronic cassettes. In embodiments, the nucleic acid comprises three polycistronic cassettes. In embodiments, the nucleic acid comprises a sequence selected from the group consisting of SEQ ID NOs: 24, 25, 29, 202, 203, and 207.

[0013]

[0013] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) SEQ ID NOs: 126-145, 167-168, 178- a promoter selected from 179, 231-238, and 250; (iv) a poly A sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240; (v) a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (b) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a second cistron encoding CD59, wherein the nucleic acid sequence of CD59 is selected from the group consisting of SEQ ID NO: 86, 108; (iii) SEQ ID NO: 126-145, 167-168; a promoter selected from 178-179, 231-238, and 250; (iv) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240; and combinations thereof; (v) a complement control cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (c) an innate immune and inflammation and apoptosis cassette, wherein (i) the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; a first cistron encoding a fusion protein; (ii) a second cistron encoding CD47, wherein the CD47 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; (iii) ) a third cistron encoding A20, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NO: 64-65, 104, 182, and 188; (iv) the nucleic acid sequence of HO1 is selected from the group consisting of SEQ ID NO: 63, a fourth cistron encoding HO1 selected from the group consisting of 109, 165, 183, and 189; (v) from SEQ ID NO: 126-145, 167-168, 178-179, 231-238, and 250 a selected promoter; (vi) a polyA sequence selected from SEQ ID NO: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (vii) SEQ ID NO: Innate immunity and inflammation and apoptosis cassette comprising at least one 2A polypeptide having a sequence selected from 1-10, 12-14, and 159-162 Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0014]

[0014] In embodiments, the nucleic acid comprises at least two polycistronic cassettes. In embodiments, the nucleic acid comprises three polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence SEQ ID NO: 26 or SEQ ID NO: 204.

[0015]

[0015] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) the nucleic acid sequence of CD39 is selected from the group consisting of SEQ ID NOs: 67-70 and 187; a third cistron encoding CD39 selected from the group consisting of SEQ ID NO: 106; (iv) a promoter selected from SEQ ID NOs: 126-145, 167-168, 178-179, 231-238, and 250; (v) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (vi) SEQ ID NOs: 1-10, 12 ~14, and at least one 2A polypeptide having a sequence selected from 159 to 162; (b) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a second cistron encoding CD59, wherein the nucleic acid sequence of CD59 is selected from the group consisting of SEQ ID NOs: 86, 108; (iii) the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 108; and (iv) a third cistron encoding CD55 selected from the group consisting of 85, 107, and 184; (v) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (vi) SEQ ID NOs: 1- a complement control cassette comprising at least one 2A polypeptide having a sequence selected from 10, 12-14, and 159-162; (c) an innate immune and inflammation and apoptosis cassette, wherein (i) the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NOs: 62, 66, 105; a first cistron encoding a fusion protein; (ii) a second cistron encoding CD47, wherein the CD47 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; (iii) ) a third cistron encoding A20, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NO: 64-65, 104, 182, and 188; (iv) the nucleic acid sequence of HO1 is selected from the group consisting of SEQ ID NO: 63, a fourth cistron encoding HO1 selected from the group consisting of 109, 165, 183, and 189; (v) a nucleic acid sequence of PD-L1 selected from the group consisting of SEQ ID NOs: 89 to 91; a fifth cistron encoding PD-L1; (vi) a promoter selected from SEQ ID NOs: 126-145, 167-168, 178-179, 231-238, and 250; (vii) SEQ ID NOs: 112-125 , 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (viii) selected from SEQ ID NOs: 1-10, 12-14, and 159-162; an innate immune and inflammation and apoptosis cassette comprising at least one 2A polypeptide having a sequence Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0016]

[0016] In embodiments, the nucleic acid comprises at least two polycistronic cassettes. In embodiments, the nucleic acid comprises three polycistronic cassettes. In embodiments, the nucleic acid comprises a sequence selected from the group consisting of SEQ ID NOs: 23, 27, 28, 201, 205, and 206.

[0017]

[0017] In this specification, (a) a coagulation cassette; (i) a first cistron encoding a THBD, wherein the nucleic acid sequence of the THBD is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ii) a second cistron encoding PROCR, wherein the nucleic acid sequence of PROCR is selected from the group consisting of SEQ ID NOs: 92, 93, and 181; (iii) SEQ ID NOs: 126-145, 167-168, 178-179; , 231-238, and 250; (iv) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240; (v) a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (b) an inflammation and apoptosis cassette, comprising: (i) a first cistron encoding A20, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; (ii) a second cistron encoding HO1, wherein the HO1 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 63, 109, 165, 183, and 189; (iii) SEQ ID NOs: 126-145, 167- a promoter selected from 168, 178-179, 231-238, and 250; (iv) a polyA selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240; (v) an inflammatory and apoptosis cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOS: 1-10, 12-14, and 159-162; (c) a complement control and innate immunity cassette, comprising: (i) a CD46 nucleic acid sequence selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; (iii) CD55; a third cistron encoding CD55, the nucleic acid sequence of which is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iv) SEQ ID NOs: 126-145, 167-168, 178-179; a promoter selected from 231-238, and 250; (v) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof and; (vi) a complement control and innate immunity cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0018]

[0018] In embodiments, the nucleic acids disclosed herein include at least two polycistronic cassettes. In embodiments, the nucleic acid comprises three polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence SEQ ID NO: 30 or SEQ ID NO: 208.

[0019]

[0019] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding PROCR, wherein the nucleic acid sequence of PROCR is selected from the group consisting of SEQ ID NOs: 92, 93, and 181; (iii) the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 92, 93, and 181; and a third cistron encoding TFPI selected from the group consisting of: (v) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (vi) SEQ ID NOs: 1-10, 12- 14, and at least one 2A polypeptide having a sequence selected from 159-162; (b) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a third cistron encoding CD55, wherein the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iii) SEQ ID NOs: 126 to 145; , 167-168, 178-179, 231-238, and 250; (v) a complement control cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (c) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; (iii) SEQ ID NO: 126 with a promoter selected from ~145, 167~168, 178~179, 231~238, and 250; (iv) from SEQ ID NO: 112~125, 154~156, 159~162, 190~192, and 239~240; an innate immunity cassette comprising a selected polyA sequence, and combinations thereof; and (v) at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0020]

[0020] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises three of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises a sequence selected from the group consisting of SEQ ID NOs: 31-34 and 209-212.

[0021]

[0021] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding PROCR, wherein the nucleic acid sequence of PROCR is selected from the group consisting of SEQ ID NOs: 92, 93, and 181; (iii) SEQ ID NOs: 126-145, 167-168, 178-179; a promoter selected from 231-238, and 250; (iv) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof and; (v) a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (b) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a third cistron encoding CD55, wherein the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iii) SEQ ID NOs: 126 to 145; , 167-168, 178-179, 231-238, and 250; (v) a complement control cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (c) an innate immune and inflammation and apoptosis cassette, wherein (i) the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NOs: 62, 66, 105; a first cistron encoding a fusion protein; (ii) a second cistron encoding CD47, wherein the CD47 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; (iii) ) a third cistron encoding A20, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NO: 64-65, 104, 182, and 188; (iv) the nucleic acid sequence of HO1 is selected from the group consisting of SEQ ID NO: 63, a fourth cistron encoding HO1 selected from the group consisting of 109, 165, 183, and 189; (v) from SEQ ID NO: 126-145, 167-168, 178-179, 231-238, and 250 a selected promoter; (vi) a polyA sequence selected from SEQ ID NO: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (vii) SEQ ID NO: Innate immunity and inflammation and apoptosis cassette comprising at least one 2A polypeptide having a sequence selected from 1-10, 12-14, and 159-162 Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0022]

[0022] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises three of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence SEQ ID NO: 37 or SEQ ID NO: 215.

[0023]

[0023] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) the nucleic acid sequence of CD39 is selected from the group consisting of SEQ ID NOs: 67-70 and 187; a third cistron encoding CD39 selected from the group consisting of SEQ ID NO: 106; (iv) a promoter selected from SEQ ID NOs: 126-145, 167-168, 178-179, 231-238, and 250; (v) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (vi) SEQ ID NOs: 1-10, 12 ~14, and at least one 2A polypeptide having a sequence selected from 159 to 162; (b) a complement control and inflammation and apoptosis cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a second cistron encoding CD59, wherein the nucleic acid sequence of CD59 is selected from the group consisting of SEQ ID NOs: 86 and 108; (iii) the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 86 and 108; a third cistron encoding CD55 selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; a fourth cistron encoding A20 selected from the group consisting of; a fifth cistron; (vi) a sixth cistron encoding PD-L1, in which the nucleic acid sequence of PD-L1 is selected from the group consisting of SEQ ID NOs: 89 to 91; (vii) SEQ ID NOs: 126 to 145; , 167-168, 178-179, 231-238, and 250; and (ix) at least one 2A polypeptide having a sequence selected from SEQ ID NOS: 1-10, 12-14, and 159-162. with apoptosis cassette; (c) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; (iii) SEQ ID NO: 126 with a promoter selected from ~145, 167~168, 178~179, 231~238, and 250; (iv) from SEQ ID NO: 112~125, 154~156, 159~162, 190~192, and 239~240; an innate immunity cassette comprising a selected polyA sequence, and combinations thereof; and (v) at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0024]

[0024] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises three of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence SEQ ID NO: 35 or SEQ ID NO: 213.

[0025]

[0025] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) SEQ ID NOs: 126-145, 167-168, 178- a promoter selected from 179, 231-238, and 250; (iv) a poly A sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240; (v) a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (b) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a third cistron encoding CD55, wherein the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iii) SEQ ID NOs: 126 to 145; , 167-168, 178-179, 231-238, and 250; (iv) a poly A sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192; , and combinations thereof; (v) a complement control cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (c) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; (iii) SEQ ID NO: 126 ~145, 167~168, 178~179, 231~238, and 250; (iv) a polypeptide selected from SEQ ID NOs: 112~125 and 154~156, 159~162, 190~192; A sequence, and combinations thereof; and (v) an innate immunity cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0026]

[0026] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises three of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises a sequence selected from the group consisting of SEQ ID NOs: 36, 40, 214, and 218.

[0027]

[0027] In this specification, (a) a coagulation cassette; (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; (ii) a TFPI nucleic acid sequence; a second cistron encoding TFPI, the sequence of which is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) SEQ ID NOs: 126-145, 167-168, 178-179, 231- 238, and a promoter selected from 250; (iv) a polyA sequence selected from SEQ ID NOs: 112 to 125, and 154 to 156, 159 to 162, 190 to 192, and combinations thereof; (v) a sequence a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from numbers 1-10, 12-14, and 159-162; (b) a complement control and inflammation and apoptosis cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a second cistron encoding a CD55 protein, wherein the CD55 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iii) a third cistron encoding A20, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; (iv) the nucleic acid sequence of HO1 is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; , 165, 183, and 189; (v) selected from SEQ ID NOs: 126-145, 167-168, 178-179, 231-238, and 250; (vi) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and combinations thereof; (vii) SEQ ID NOs: 1-10, 12 ~14, and at least one 2A polypeptide having a sequence selected from 159 to 162; (c) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; (iii) SEQ ID NO: 126 ~145, 167~168, 178~179, 231~238, and 250; (iv) a polypeptide selected from SEQ ID NOs: 112~125 and 154~156, 159~162, 190~192; A sequence, and combinations thereof; and (v) an innate immunity cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0028]

[0028] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises three of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises a sequence selected from the group consisting of SEQ ID NOs: 41, 42, 219, and 220.

[0029]

[0029] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) the nucleic acid sequence of CD39 is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a third cistron encoding CD39 selected from the group consisting of SEQ ID NO: 106; (iv) a promoter selected from SEQ ID NOs: 126-145, 167-168, 178-179, 231-238, and 250; ;(v) a polyA sequence selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and combinations thereof; (v) SEQ ID NOs: 1-10, 12-14, and a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from 159-162; (b) a complement control and inflammation and apoptosis cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a second cistron encoding CD59, wherein the nucleic acid sequence of CD59 is selected from the group consisting of SEQ ID NOs: 86 and 108; (iii) the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 86 and 108; a third cistron encoding CD55 selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; a fourth cistron encoding A20 selected from the group consisting of; a fifth cistron; (vi) a sixth cistron encoding PD-L1, in which the nucleic acid sequence of PD-L1 is selected from the group consisting of SEQ ID NOs: 89 to 91; (vii) SEQ ID NOs: 126 to 145; , 167-168, 178-179, 231-238, and 250; (viii) a poly A sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192; , and combinations thereof; (ix) a complement regulation and inflammation and apoptosis cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (c) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; (iii) SEQ ID NO: 126 ~145, 167~168, 178~179, 231~238, and 250; (iv) a polypeptide selected from SEQ ID NOs: 112~125 and 154~156, 159~162, 190~192; A sequence, and combinations thereof; and (v) an innate immunity cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0030]

[0030] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises three of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises a sequence selected from the group consisting of SEQ ID NOs: 38, 39, 173, 216, 217, and 226.

[0031]

[0031] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) SEQ ID NOs: 126-145, 167-168, 178- (iv) a polyA sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192, and combinations thereof; (v) a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (b) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a third cistron encoding CD55, wherein the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iii) SEQ ID NOs: 126 to 145; , 167-168, 178-179, 231-238, and 250; (iv) a poly A sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192; , and combinations thereof; (v) a complement control cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (c) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; (iii) SEQ ID NO: 126 ~145, 167~168, 178~179, 231~238, and 250; (iv) a polypeptide selected from SEQ ID NOs: 112~125 and 154~156, 159~162, 190~192; A sequence, and combinations thereof; (v) an innate immunity cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOS: 1-10, 12-14, and 159-162; (d) a cellular immunity and coagulation cassette comprising: (i) a first cistron encoding LEA29Y, wherein the LEA29Y nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 87-88; (ii) a CD39 nucleic acid sequence; a second cistron encoding CD39 whose sequence is selected from the group consisting of SEQ ID NO: 67-70 and SEQ ID NO: 106; (iii) SEQ ID NO: 126-145, 167-168, 178-179, 231-238; , and a promoter selected from 250; (iv) a polyA sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192, and combinations thereof; (v) SEQ ID NO: Cellular immunity and coagulation cassette comprising at least one 2A polypeptide having a sequence selected from 1-10, 12-14, and 159-162 Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0032]

[0032] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises at least three of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises four of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence SEQ ID NO: 43 or SEQ ID NO: 221.

[0033]

[0033] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) SEQ ID NOs: 126-145, 167-168, 178- (iv) a polyA sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192, and combinations thereof; (v) a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (b) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a third cistron encoding CD55, wherein the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iii) SEQ ID NOs: 126 to 145; , 167-168, 178-179, 231-238, and 250; (iv) a poly A sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192; , and combinations thereof; (v) a complement control cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (c) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; (iii) SEQ ID NO: 126 ~145, 167~168, 178~179, 231~238, and 250; (iv) a polypeptide selected from SEQ ID NOs: 112~125 and 154~156, 159~162, 190~192; A sequence, and combinations thereof; (v) an innate immunity cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOS: 1-10, 12-14, and 159-162; (d) an inflammation and apoptosis cassette, comprising: (i) a first cistron encoding A20, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; (ii) a second cistron encoding PD-L1, wherein the PD-L1 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 89-91; (iii) SEQ ID NOs: 126-145, 167-168, 178; a promoter selected from ~179, 231-238, and 250; (iv) a polyA sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192, and combinations thereof; (v) an inflammation and apoptosis cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0034]

[0034] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises at least three of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises four of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises a sequence selected from the group consisting of SEQ ID NOs: 44, 172, 222, and 225.

[0035]

[0035] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) SEQ ID NOs: 126-145, 167-168, 178- (iv) a polyA sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192, and combinations thereof; (v) a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (b) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a third cistron encoding CD55, wherein the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iii) SEQ ID NOs: 126 to 145; , 167-168, 178-179, 231-238, and 250; (iv) a poly A sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192; , and combinations thereof; (v) a complement control cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (c) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; (iii) SEQ ID NO: 126 ~145, 167~168, 178~179, 231~238, and 250; (iv) a polypeptide selected from SEQ ID NOs: 112~125 and 154~156, 159~162, 190~192; A sequence, and combinations thereof; (v) an innate immunity cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOS: 1-10, 12-14, and 159-162; (d) an apoptosis and coagulation cassette comprising: (i) a first cistron encoding an XIAP, wherein the nucleic acid sequence of XIAP is selected from the group consisting of SEQ ID NO: 110; (ii) the nucleic acid sequence of CD39 is selected from the group consisting of: a second cistron encoding CD39 selected from the group consisting of SEQ ID NO: 106; (iii) a promoter selected from SEQ ID NOs: 126-145, 167-168, 178-179, 231-238, and 250; (iv) SEQ ID NOs: 112-125, and polyA sequences selected from 154-156, 159-162, 190-192, and combinations thereof; (v) SEQ ID NOs: 1-10, 12-14, and Apoptosis and coagulation cassette comprising at least one 2A polypeptide having a sequence selected from 159-162 Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0036]

[0036] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises at least three of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises four of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence SEQ ID NO: 45 or SEQ ID NO: 223.

[0037]

[0037] In this specification, (a) a coagulation cassette comprising: (i) a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; ) a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) SEQ ID NOs: 126-145, 167-168, 178- (iv) a polyA sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192, and combinations thereof; (v) a coagulation cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (b) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a third cistron encoding CD55, wherein the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iii) SEQ ID NOs: 126 to 145; , 167-168, 178-179, 231-238, and 250; (iv) a poly A sequence selected from SEQ ID NO: 112-125, and 154-156, 159-162, 190-192; , and combinations thereof; (v) a complement control cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; (c) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; (iii) SEQ ID NO: 126 ~145, 167~168, 178~179, 231~238, and 250; (iv) a polypeptide selected from SEQ ID NOs: 112~125 and 154~156, 159~162, 190~192; A sequence, and combinations thereof; (v) an innate immunity cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOS: 1-10, 12-14, and 159-162; (d) an apoptotic and cellular immunity cassette, wherein (i) the nucleic acid sequence of A20 comprises a first cistron encoding A20 selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; (ii) a second cistron encoding LEA29Y, wherein the nucleic acid sequence of LEA29Y is selected from the group consisting of SEQ ID NOs: 87-88; (iii) SEQ ID NOs: 126-145, 167-168, 178-179; 231-238, and a promoter selected from 250; (iv) SEQ ID NO: 112-125, and a poly A sequence selected from 154-156, 159-162, 190-192, and combinations thereof; (v ) Apoptosis and cellular immunity cassette comprising at least one 2A polypeptide having a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162 Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0038]

[0038] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises at least three of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises four of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence SEQ ID NO: 46 or SEQ ID NO: 224.

[0039]

[0039] In embodiments, herein: (a) a coagulation and innate immunity cassette comprising: (i) a THBD nucleic acid sequence encoding a THBD protein selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; (ii) a second cistron encoding a CD47 protein, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83 and 180; (iii) the nucleic acid sequence of EPCR is selected from the group consisting of SEQ ID NO: 94; and (iv) a third cistron encoding an EPCR protein selected from the group consisting of ~96, 103, and 187; a selected promoter; (v) a polyA sequence selected from SEQ ID NO: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (vi) SEQ ID NO: a coagulation and innate immunity cassette comprising at least one 2A polypeptide encoded by a sequence selected from 1-10, 12-14, and 159-162; (b) an apoptotic and cellular immunity cassette comprising: (i) a first cistron encoding an A20 protein, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; (ii) a second cistron encoding an HO1 protein, wherein the HO1 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 63, 109, 165, 183, and 189; (iii) SEQ ID NOs: 126-145 , 167-168, 178-179, 231-238, and 250; and (v) at least one 2A polypeptide encoded by a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. With cassette; (c) a complement control cassette, wherein (i) the CD46 nucleic acid sequence encodes a CD46 protein selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a third cistron encoding a CD55 protein, wherein the CD55 nucleic acid sequence is selected from the group consisting of SEQ ID NO: 84, 85, 107, and 184; (iii) SEQ ID NO: 126; with a promoter selected from ~145, 167~168, 178~179, 231~238, and 250; (iv) from SEQ ID NO: 112~125, 154~156, 159~162, 190~192, and 239~240; a complement comprising selected polyA sequences, and combinations thereof; and (v) at least one 2A polypeptide encoded by a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. control cassette Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0040]

[0040] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises at least three of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises four of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence of SEQ ID NO: 174 or SEQ ID NO: 227.

[0041]

[0041] In embodiments, herein: (a) a coagulation and innate immunity cassette comprising: (i) a THBD nucleic acid sequence encoding a THBD protein selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; (ii) a second cistron encoding a CD47 protein, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83 and 180; (iii) the nucleic acid sequence of EPCR is selected from the group consisting of SEQ ID NO: 94; and (iv) a third cistron encoding an EPCR protein selected from the group consisting of ~96, 103, and 187; a selected promoter; (v) a polyA sequence selected from SEQ ID NO: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (vi) SEQ ID NO: a coagulation and innate immunity cassette comprising at least one 2A polypeptide encoded by a sequence selected from 1-10, 12-14, and 159-162; (b) an apoptotic and cellular immunity cassette comprising: (i) a first cistron encoding an A20 protein, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; (ii) a second cistron encoding a CTLA-4 protein, wherein the CTLA-4 nucleic acid sequence is selected from the group consisting of SEQ ID NO: 87-88, 174, and 186; (iii) SEQ ID NO: 126 with a promoter selected from ~145, 167~168, 178~179, 231~238, and 250; (iv) from SEQ ID NO: 112~125, 154~156, 159~162, 190~192, and 239~240; and (v) at least one 2A polypeptide encoded by a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; with cellular immunity cassette; (c) a complement control cassette, wherein (i) the CD46 nucleic acid sequence encodes a CD46 protein selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a third cistron encoding a CD55 protein, wherein the CD55 nucleic acid sequence is selected from the group consisting of SEQ ID NO: 84, 85, 107, and 184; (iii) SEQ ID NO: 126; with a promoter selected from ~145, 167~168, 178~179, 231~238, and 250; (iv) from SEQ ID NO: 112~125, 154~156, 159~162, 190~192, and 239~240; a complement comprising selected polyA sequences, and combinations thereof; and (v) at least one 2A polypeptide encoded by a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. control cassette Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0042]

[0042] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises at least three of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises four of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence SEQ ID NO: 175 or SEQ ID NO: 228.

[0043]

[0043] In embodiments, herein: (a) a coagulation cassette, wherein (i) a first cistron encoding a THBD protein, wherein the nucleic acid sequence encoding the THBD protein is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; (ii) a second cistron encoding a TFPI protein, wherein the nucleic acid sequence encoding the TFPI protein is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) SEQ ID NOs: 126~ (iv) a promoter selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240; (v) a coagulation cassette comprising at least one 2A polypeptide encoded by a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; ; (b) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding a CD47 protein, wherein the nucleic acid sequence encoding the CD47 protein is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; (iii) ) a promoter selected from SEQ ID NOs: 126-145, 167-168, 178-179, 231-238, and 250; (iv) SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (v) at least one 2A polypeptide encoded by a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; an innate immunity cassette, including; (c) a complement control cassette, wherein (i) the CD46 protein-encoding nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a second cistron encoding a CD55 protein, wherein the nucleic acid sequence encoding the CD55 protein is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iii) a promoter selected from SEQ ID NOs: 126-145, 167-168, 178-179, 231-238, and 250; (iv) SEQ ID NOs: 112-125, 154-156, 159-162, 190-192 , and polyA sequences selected from 239-240, and combinations thereof; (v) at least one 2A poly sequence encoded by a sequence selected from SEQ ID NOS: 1-10, 12-14, and 159-162; Complement control cassette containing peptides Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0044]

[0044] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises at least three of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises four of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence of SEQ ID NO: 176 or SEQ ID NO: 229.

[0045]

[0045] In embodiments, herein: (a) a coagulation cassette, wherein (i) a first cistron encoding a THBD protein, wherein the nucleic acid sequence encoding the THBD protein is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; (ii) a second cistron encoding a TFPI protein, wherein the nucleic acid sequence encoding the TFPI protein is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; (iii) SEQ ID NOs: 126~ (iv) a promoter selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240; (v) a coagulation cassette comprising at least one 2A polypeptide encoded by a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; ; (b) an innate immunity cassette, wherein (i) the nucleic acid sequence encoding a B2M HLA-E fusion protein encodes a B2M HLA-E fusion protein selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) a second cistron encoding a CD47 protein, wherein the nucleic acid sequence encoding the CD47 protein is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; (iii) ) a promoter selected from SEQ ID NOs: 126-145, 167-168, 178-179, 231-238, and 250; (iv) SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240, and combinations thereof; (v) at least one 2A polypeptide encoded by a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162; an innate immunity cassette, including; (c) a complement control cassette, wherein (i) the CD46 protein-encoding nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, 253-258, 262-264; (ii) a second cistron encoding a CD55 protein, wherein the nucleic acid sequence encoding the CD55 protein is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; (iii) a promoter selected from SEQ ID NOs: 126-145, 167-168, 178-179, 231-238, and 250; (iv) SEQ ID NOs: 112-125, 154-156, 159-162, 190-192 , and polyA sequences selected from 239-240, and combinations thereof; (v) at least one 2A poly sequence encoded by a sequence selected from SEQ ID NOS: 1-10, 12-14, and 159-162; a complement control cassette containing a peptide; (d) an inflammation and apoptosis cassette, wherein (i) the A20 nucleic acid sequence is a first cistron encoding an A20 protein selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; (ii) a second cistron encoding an HO1 protein, wherein the HO1 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 63, 109, 165, 183, and 189; (iii) SEQ ID NOs: 126-145; and (iv) a promoter selected from SEQ ID NOs: 112-125, 154-156, 159-162, 190-192, and 239-240. an inflammatory and apoptosis cassette comprising a polyA sequence, and combinations thereof; and (v) at least one 2A polypeptide encoded by a sequence selected from SEQ ID NOs: 1-10, 12-14, and 159-162. Nucleic acids are provided that include one or more polycistronic cassettes selected from the group consisting of:

[0046]

[0046] In an embodiment, the aforementioned nucleic acid comprises at least two of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises at least three of the aforementioned polycistronic cassettes. In embodiments, the aforementioned nucleic acid comprises four of the aforementioned polycistronic cassettes. In embodiments, the nucleic acid comprises the sequence SEQ ID NO: 177 or SEQ ID NO: 230.

[0047]

[0047] Provided herein is a CD46 cistron-comprising nucleic acid comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 72, 73, 185, and 200. Provided herein is a THBD cistron-containing nucleic acid comprising or consisting of a nucleic acid sequence selected from any one of SEQ ID NOs: 99-102 and 166. In embodiments, provided herein are cells comprising a nucleic acid comprising a CD46 cistron comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 72, 73, 185, and 200. In embodiments, provided herein are cells comprising a nucleic acid comprising a THBD cistron comprising or consisting of a nucleic acid sequence selected from any one of SEQ ID NOs: 99-102 and 166. In embodiments, as used herein, a tissue, an organ comprising a cell comprising a nucleic acid comprising a CD46 cistron comprising or consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 72, 73, 185, and 200; or animals provided. In embodiments, herein, a tissue, an organ, or a tissue comprising a cell comprising a nucleic acid comprising a THBD cistron comprising or consisting of a nucleic acid sequence selected from any one of SEQ ID NOs: 99-102 and 166; Animals provided.

[0048]

[0048] In embodiments, the nucleic acids described herein include a 5' loxP site and a 3' loxP site selected from the group consisting of SEQ ID NOs: 146-150 and 244. In embodiments, the nucleic acids described herein include a 5' insulator site and a 3' insulator site selected from the group consisting of SEQ ID NOs: 49-58 and 163-164. In embodiments, the nucleic acids described herein include a 5' guide RNA (gRNA) target sequence and a 3' gRNA target sequence having a sequence selected from SEQ ID NOs: 47-48, and combinations thereof. In embodiments, a nucleic acid described herein comprises a ubiquitous chromatin opening element (UCOE) having a sequence of any one of SEQ ID NOs: 19-22, 157, and 193. In embodiments, the nucleic acids described herein include (i) a first inverted terminal repeat (ITR) located on the 5' side of a 5' polycistronic cassette and having the sequence of SEQ ID NO: 17 or 18 ) and (ii) a second ITR located on the 3′ side of the 3′ polycistronic cassette and having the sequence of SEQ ID NO: 15 or 16. In embodiments, the nucleic acids described herein include at least two polycistronic cassettes. In embodiments, the nucleic acids described herein include at least three polycistronic cassettes. In embodiments, the nucleic acids described herein include at least four polycistronic cassettes. In embodiments, the nucleic acids described herein include fluorescent proteins. In embodiments, a nucleic acid described herein comprises a green fluorescent protein having a sequence of SEQ ID NO: 111, 242, or 246.

[0049]

[0049] In embodiments, provided herein are vectors comprising any of the foregoing nucleic acids. In embodiments, provided herein are cells comprising any of the foregoing nucleic acids. In embodiments, provided herein is an islet cell comprising any of the foregoing nucleic acids. In embodiments, provided herein is a porcine cell comprising any of the foregoing nucleic acids. In embodiments, provided herein is an organ or tissue comprising any of the foregoing nucleic acids. In embodiments, provided herein is an animal comprising any of the foregoing nucleic acids. In embodiments, provided herein is a pig comprising any of the foregoing nucleic acids. In embodiments, provided herein is a pig comprising any of the foregoing nucleic acids, wherein the pig is free of PERV. In embodiments, provided herein is an animal comprising any of the foregoing nucleic acids, the animal comprising at least one inactivated carbohydrate antigen producing gene. In embodiments, herein, an animal comprising any of the foregoing nucleic acids, comprising at least one inactivated carbohydrate antigen-producing gene, wherein the inactivated carbohydrate antigen-producing gene is glycoprotein alpha-1,3 - Galactosyltransferase (GGTA1), cytidine monophosphate-N-acetylneuraminic acid hydrolase (CMAH), β-1,4-N-acetyl-galactosaminyltransferase 2 (β4GALNT2), or a combination thereof, an animal is provided.

[0050]

[0050] In embodiments, provided herein are the contiguous nucleic acid sequences of any of SEQ ID NOs: 23-46, 172-177, and 201-230. In embodiments, the contiguous nucleic acid sequence is at least about 1 kb. In embodiments, the contiguous nucleic acid sequence comprises at least 2 kb, at least 3 kb, at least 4 kb, at least 5 kb, at least 6 kb, at least 7 kb, at least 8 kb, at least 9 kb, at least 9 kb, at least 10 kb, at least 11 kb, at least 12 kb, at least 13 kb, at least 14kb, at least 15kb, at least 16kb, at least 17kb, at least 18kb, at least 19kb, at least 20kb, at least 21kb, at least 22kb, at least 23kb, at least 24kb, at least 25kb, at least 26kb, at least 27kb, at least 28kb, at least 29kb, at least 30kb, At least 35kb, at least 40kb, at least 45kb, at least 50kb, at least 55kb, at least 60kb, or at least 65kb long. In embodiments, the contiguous nucleic acid sequences encode one or more polycistronic cassettes as described above. In embodiments, the contiguous nucleic acid sequences encode at least two polycistronic cassettes as described above. In embodiments, the contiguous nucleic acid sequences encode at least three polycistronic cassettes as described above. In embodiments, the contiguous nucleic acid sequences encode at least four polycistronic cassettes as described above.

[0051]

[0051] In embodiments, chromosomally integrated forms of any of SEQ ID NOs: 23-46, 172-177, and 201-230 are provided herein.

[0052] In embodiments, herein, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, Contiguous nucleic acid sequences are provided that are 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical. In embodiments, provided herein are contiguous nucleic acid sequences that are 95% identical to any of SEQ ID NOs: 23-46, 172-177, and 201-230. In embodiments, provided herein are contiguous nucleic acid sequences that are at least 96% identical to any of SEQ ID NOs: 23-46, 172-177, and 201-230. In embodiments, provided herein are contiguous nucleic acid sequences that are at least 97% identical to any of SEQ ID NOs: 23-46, 172-177, and 201-230. In embodiments, provided herein are contiguous nucleic acid sequences that are at least 98% identical to any of SEQ ID NOs: 23-46, 172-177, and 201-230. In embodiments, provided herein are contiguous nucleic acid sequences that are at least 99% identical to any of SEQ ID NOs: 23-46, 172-177, and 201-230. In embodiments, the term herein refers to at least two polycistronic cassettes of contiguous nucleic acid sequences that are at least 95% identical to any of SEQ ID NOs: 23-46, 172-177, and 201-230. Provided are contiguous nucleic acid sequences encoding. In embodiments, the term herein refers to at least three polycistronic cassettes of contiguous nucleic acid sequences that are at least 95% identical to any of SEQ ID NOs: 23-46, 172-177, and 201-230. Provided are contiguous nucleic acid sequences encoding. In embodiments, as used herein is a polycistronic cassette of at least four contiguous nucleic acid sequences that are at least 95% identical to any of SEQ ID NOs: 23-46, 172-177, and 201-230. Provided are contiguous nucleic acid sequences encoding. In embodiments, as used herein, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOS: 23-46, 172-177, and 201-230. A contiguous nucleic acid sequence is provided.

[0052]

[0053] In embodiments, provided herein are contiguous nucleic acid sequences encoding polycistronic gene product polypeptides expressed by any of the polycistronic cassettes. In embodiments, provided herein are polypeptides comprising one or more of the proteins encoded by any cistron of a polycistronic cassette described herein.

[0053]

[0054] In embodiments, at least 95%, at least 96%, at least 97%, at least 98%, at least 99 %, or 100% identical and at least 80%, at least 85%, at least 90%, at least 91%, at least 92% identical to any one of the coding sequences SEQ ID NOs: 23-46, 172-177, and 201-230 , at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical.

[0054]

[0055] In embodiments, described herein is a method of genetically modifying a cell, comprising: (i) knocking out a porcine endogenous retrovirus (PERV) element; (ii) glycoprotein alpha-1,3-galactosyltransferase. knocking out the gene (GGTA1), cytidine monophosphate-N-acetylneuraminic acid hydrolase (CMAH), β-1,4-N-acetylgalactosaminyltransferase 2 (β4GALNT2), or any combination thereof; ; (iii) there is provided a method comprising the step of knocking in any one or more polycistronic cassettes according to any one of claims 1 to 14. In embodiments, step (i) is performed first, step (ii) is performed second, and step (iii) is performed third. In embodiments, step (i) is performed first, step (ii) is performed third, and step (iii) is performed second. In embodiments, step (i) is performed second, step (ii) is performed first, and step (iii) is performed third. In embodiments, step (i) is performed second, step (ii) is performed third, and step (iii) is performed first. In embodiments, step (i) is performed third, step (ii) is performed first, and step (iii) is performed second. In embodiments, step (i) is performed third, step (ii) is performed second, and step (iii) is performed first. In embodiments, provided herein are genetically modified cells produced by any of the aforementioned methods. In embodiments, provided herein are animals, organs, or tissues that include genetically modified cells. In embodiments, the animal is a pig or a human.

[0055]

[0056] In embodiments, provided herein is a landing pad that is a nucleic acid that includes a first loxP site, a second loxP site, a promoter, and a polyA sequence. In embodiments, the landing pad includes an insulator array. In embodiments, the landing pad includes a fluorescent protein. In embodiments, the landing pad comprises the nucleic acid of SEQ ID NO: 248 or 249. In embodiments, provided herein are genetically modified cells that include a landing pad. In embodiments, provided herein are tissues, organs, or animals that include genetically modified cells that include landing pads.

[0056]

[0057] In embodiments, provided herein are nucleic acids that include a first loxP site, a second loxP site, and one or more of the polycistronic cassettes described herein. In embodiments, provided herein are genetically modified cells comprising the aforementioned nucleic acids. In embodiments, provided herein are tissues, organs, or animals comprising the aforementioned genetically modified cells. In embodiments, the nucleic acid has a sequence of any one of SEQ ID NOs: 201-230, or at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, with any one of SEQ ID NOs: 201-230, Includes nucleic acids that are at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical. In embodiments, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93% with any one of SEQ ID NOs: 201-230, or with any one of SEQ ID NOs: 201-230. Provided herein are genetically modified cells comprising nucleic acids that are at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical. In embodiments, as used herein, at least 80%, at least 85%, at least 85%, at least 90%, at least 91 nucleic acids of any one of SEQ ID NOs: 201-230, or with any one of SEQ ID NOs: 201-230. %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical, Organs or animals are donated. [Brief explanation of drawings]

[0057] [Figure 1A]

[0058] Figure 1A shows a coagulation cassette under the control of the mmEF1α1 (designated mEF1α1) promoter containing cistrons for TFPI, THBD, and CD39, a complement control cassette under the control of the hEF1α1 promoter containing cistrons CD46, CD55, and CD59; and B2M HLA-E fusion protein, CD47, A20, HO1, and an exemplary nucleic acid comprising an innate immune and inflammation and apoptosis cassette under the control of a CAG promoter that includes the cistrons of A20, HO1, and PD-L1. The genes in each cassette are separated by nucleic acid sequences encoding 2A peptides (E2A, T2A, F2A, P2A) or internal ribosome entry sites (IRES). Each cassette also includes a polyA sequence (eg, HBB, bGH, or SPAActB). An exemplary nucleic acid having the cassette of FIG. 1A is SEQ ID NO: 23. [Figure 1B]

[0059] Figure 1B shows the coagulation cassette under the control of the mmEF1α1 promoter containing TFPI and THBD, the complement control cassette under the control of the hEF1α1 (designated hsEF1α1) promoter containing the CD46_LL (designated CD46) and CD59 cistrons, and the B2M HLA -E fusion protein and an exemplary nucleic acid comprising an innate immunity cassette under the control of a CAG promoter comprising a nucleic acid encoding a CD47 cistron. The genes in each cassette are separated by a nucleic acid sequence encoding a 2A peptide (P2A or F2A) or an IRES. Each cassette also includes a polyA sequence (eg HBB, btGH, or SPAActB). An exemplary nucleic acid having the cassette of FIG. 1B is SEQ ID NO: 25. [Figure 1C]

[0060] Figure 1C shows the coagulation cassette under the control of the mmEF1α1 (designated mEF1α1) promoter containing the TFPI and THBD cistrons, the complement control cassette under the control of the hEF1α1 promoter containing the CD46 and CD59 cistrons, and the B2M HLA-E fusion protein and 1 illustrates exemplary nucleic acids including innate immunity and inflammation and apoptosis cassettes under the control of a CAG promoter including nucleic acids encoding CD47, A20, and HO1 cistrons. The genes in each cassette are separated by nucleic acid sequences encoding 2A peptides (E2A, T2A, F2A, P2A) or IRES. Each cassette also includes a polyA sequence (eg, HBB, bGH, or SPAActB). An exemplary nucleic acid having the cassette of Figure 1C is SEQ ID NO:26. [Figure 1D]

[0061] Figure 1D shows the coagulation cassette under the control of the mmEF1α1 promoter containing the TFPI and THBD cistrons, the complement control cassette under the control of the hEF1α1 (designated hsEF1α1) promoter containing the CD46 and CD59 cistrons, and the B2M HLA-E fusion protein and 1 illustrates an exemplary nucleic acid comprising an innate immunity cassette under the control of a CAG promoter comprising a nucleic acid encoding a CD47 cistron. The genes in each cassette are separated by nucleic acid sequences encoding 2A peptides (E2A, T2A, F2A, P2A) or IRES. Each cassette also includes a polyA sequence (eg HBB, btGH, or SPAActB). An exemplary nucleic acid having the cassette of FIG. ID is SEQ ID NO:24. [Figure 2A]

[0062] Figure 2A shows the coagulation cassette under the control of the mmEF1α1 promoter containing TFPI, THBD, and CD39 cistrons, the complement control cassette under the control of the ssEF1α1 promoter containing CD46i, CD59, and CD55 cistrons, and the B2M HLA-E fusion protein and 1 illustrates exemplary nucleic acids including innate immune and inflammation and apoptosis cassettes under the control of a CAG promoter including nucleic acids encoding CD47, A20, HO1, and PD-L1 cistrons. The genes in each cassette are separated by nucleic acid sequences encoding 2A peptides (E2A, T2A, F2A, P2A) or IRES. Each cassette also includes a polyA sequence (eg HBB, btGH, or SPA / hsActB). An exemplary nucleic acid having the cassette of FIG. 2A is SEQ ID NO:27. [Figure 2B]

[0063] Figure 2B shows the coagulation cassette under the control of the ssUBC promoter containing TFPI, THBD, and CD39, the complement control cassette under the control of the ssEF1α1 promoter containing the CD46i, CD59, and CD55 cistrons, and the B2M HLA-E fusion protein and CD47. , A20, HO1, and PD-L1 cistron. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, T2A, F2A, P2A). Each cassette also includes a polyA sequence (eg HBB, btGH, or SPA / hsActB). An exemplary nucleic acid having the cassette of Figure 2B is SEQ ID NO:28. [Figure 2C]

[0064] Figure 2C shows the coagulation cassette under the control of the mmEF1α1 promoter containing TFPI and THBD, the complement control cassette under the control of the hEF1α1 (designated hsEF1α1) promoter containing CD46_LL (designated CD46) and CD59, and the B2M HLA- FIG. 4 illustrates an exemplary nucleic acid comprising an E fusion protein and an innate immunity cassette under the control of a CAG promoter containing CD47. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, T2A, F2A, P2A). Each cassette also includes a polyA sequence (eg hsHBB, btGH, or SPAActB). An exemplary nucleic acid having the cassette of Figure 2C is SEQ ID NO:29. [Figure 2D]

[0065] Figure 2D shows the coagulation cassette under the control of the ssUBC promoter containing PROCR and THBD, the inflammation and apoptosis cassette under the control of the ssEF1α1 promoter containing A20 and HO1, and the complement under the control of the CAG promoter containing CD46i, CD55, and CD47. 1 illustrates exemplary nucleic acids including body control and innate immunity cassettes. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, T2A, F2A, P2A). Each cassette also includes a polyA sequence (eg hsHBB, btGH, or SPA hsActB). An exemplary nucleic acid having the cassette of FIG. 2D is SEQ ID NO:30. [Figure 2E]

[0066] Figure 2E shows the coagulation cassette under the control of the ssUBC promoter containing TFPI, PROCR, and THBD (designated THBDda), the B2M HLA-E fusion protein and the control of the ssHSPA8 (designated ssHSPA8(ATACseq)) promoter containing CD47. An exemplary nucleic acid comprising the innate immunity cassette below and a complement control cassette under the control of a CAG promoter containing CD46da1 (designated CD46da) and CD55 is illustrated. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, T2A, F2A, P2A). Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 2E is SEQ ID NO:31. [Figure 2F]

[0067] Figure 2F shows the innate immune cassette under the control of the ssUBC promoter containing the B2M HLA-E fusion protein and CD47, the coagulation cassette under the control of the ssHSPA8 promoter containing TFPI, PROCR, and THBDda, and CD46da1 (denoted as CD46da). 2 illustrates an exemplary nucleic acid comprising a complement control cassette under the control of a CAG promoter comprising CD55 and CD55. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, T2A, F2A, P2A). Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 2F is SEQ ID NO: 32. [Figure 2G]

[0068] Figure 2G shows the innate immune cassette under the control of the ssUBC promoter containing the B2M HLA-E fusion protein and CD47, the coagulation cassette under the control of the ssHSPA8 promoter containing TFPI, PROCR, and THBDda, and CD46da1 (denoted as CD46da). 2 illustrates an exemplary nucleic acid comprising a complement control cassette under the control of a CAG promoter comprising CD55 and CD55. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, T2A, F2A, P2A). Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 2G is SEQ ID NO: 33. [Figure 2H]

[0069] Figure 2H shows the coagulation cassette under the control of the ssUBC promoter containing TFPI, PROCR, and THBDda, the innate immunity cassette under the control of the ssEF1α1 (designated as ssEEF1α1(ATACseq)) promoter containing B2M HLA-E fusion protein and CD47. , and a complement control cassette under the control of a CAG promoter including CD46da1 (designated CD46da) and CD55. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, T2A, F2A, P2A). Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of Figure 2H is SEQ ID NO:34. [Figure 2I]

[0070] Figure 2I shows coagulation under the control of the ssUBC promoter containing CD47-2, PROCR, and THBDda and apoptosis under the control of the ssHSPA8 promoter (denoted as “ssHSPA8(ATACseq)”) containing ssA20 and ssHO1. and a cellular immunity cassette, and an exemplary nucleic acid comprising a complement control cassette under the control of a CAG promoter including CD46da and CD55. The genes in each cassette are separated by nucleic acid sequences encoding 2A peptides (P2A, P2A*) or IRESs (eg IRES(FMDV) or IRES(EMCV)). Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 2I is SEQ ID NO: 174. [Figure 2J]

[0071] Figure 2J shows the coagulation and innate immunity cassette under the control of the ssUBC promoter containing CD47-2, PROCR, and THBDda, the ssHSPA8 promoter containing ssA20 and LEA29Y (denoted as "LEA29Y-Ig") ('ssHSPA8(ATACseq) 2 illustrates an exemplary nucleic acid comprising an apoptosis and cellular immunity cassette under the control of a CAG promoter containing CD46da and CD55; The genes in each cassette are separated by nucleic acid sequences encoding 2A peptides (P2A, P2A*) or IRESs (eg IRES(FMDV) or IRES(EMCV)). Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of Figure 2J is SEQ ID NO: 175. [Figure 3A]

[0072] Figure 3A shows the B2M HLA-E fusion protein and the innate immune cassette under the control of the mmEF1α1 (denoted mEF1α1) promoter containing CD47, the coagulation cassette under the control of the hEF1α1 promoter containing TFPI, THBD, and CD39, and CD46i. 1 depicts an exemplary nucleic acid comprising complement regulation and inflammation and apoptosis cassettes under the control of the CAG promoter, including , CD55, CD59, A20, HO1, and PD-L1 (designated PDL1). The genes in each cassette are separated by a nucleic acid sequence encoding a 2A peptide (P2A, P2Amut1, E2A, F2A, P2Amut2, P2Amut3, T2A) or an IRES. Each cassette also includes a polyA sequence (eg hsHBB, btGH, or SPAActB). An exemplary nucleic acid having the cassette of Figure 3A is SEQ ID NO:35. [Figure 3B]

[0073] Figure 3B contains a coagulation cassette under the control of the mmEF1α1 promoter containing TFPI and THBD, a complement control cassette under the control of the hEF1α1 (designated hsEF1α1) promoter containing CD46i and CD55, B2M HLA-E fusion protein and CD47. 1 illustrates an exemplary nucleic acid comprising an innate immunity cassette under the control of a CAG promoter. The genes in each cassette are separated by nucleic acids encoding 2A peptides (T2A, F2A, P2A). Each cassette also includes a polyA sequence (eg hsHBB, btGH, or SPAActB). An exemplary nucleic acid having the cassette of FIG. 3B is SEQ ID NO:36. [Figure 3C]

[0074] Figure 3C shows a coagulation cassette under the control of the mmEF1α1 promoter containing PROCR and THBD, a complement control cassette under the control of hEF1α1 (designated hsEF1α1) containing CD46i and CD55, B2M HLA-E fusion protein, CD47, A20, and HO1, and HO1. The genes in each cassette are separated by nucleic acid sequences encoding 2A peptides (P2A, T2A, F2A) or IRES. Each cassette also includes a polyA sequence (eg hsHBB, btGH, or SPAActB). An exemplary nucleic acid having the cassette of Figure 3C is SEQ ID NO:37. [Figure 4A]

[0075] Figure 4A shows the innate immune cassette under the control of the ssUBC promoter containing the B2M HLA-E fusion protein and CD47, the coagulation cassette under the control of the hsHSPA8 promoter containing TFPI, THBD, and CD39, and CD46da1 (denoted as CD46da). , illustrates exemplary nucleic acids comprising complement regulation and inflammation and apoptosis cassettes under the control of the CAG promoter, including CD55, CD59, A20, HO1, and PD-L1. The genes in each cassette are separated by nucleic acid sequences encoding 2A peptides (E2A, P2A, P2Amut1, P2Amut2, P2Amut3, T2A, F2A) or IRES. Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 4A is SEQ ID NO:38. [Figure 4B]

[0076] Figure 4B shows the innate immune cassette under the control of the ssUBC promoter containing the B2M HLA-E fusion protein and CD47, the coagulation cassette under the control of the hsHSPA8 promoter containing TFPI, THBD, and CD39, and CD46da2 (denoted as CD46da). , illustrates exemplary nucleic acids comprising complement regulation and inflammation and apoptosis cassettes under the control of the CAG promoter, including CD55, CD59, A20, HO1, and PD-L1. The genes in each cassette are separated by nucleic acid sequences encoding 2A peptides (E2A, P2A, P2Amut1, P2Amut2, P2Amut3, T2A, F2A) or IRES. Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of Figure 4B is SEQ ID NO:39. [Figure 4C]

[0077] Figure 4C shows the innate immune cassette under the control of the ssUBC containing B2M HLA-E fusion protein and CD47, the coagulation cassette under the control of the hsHSPA8 promoter containing TFPI and THBD, and the CAG promoter containing CD46i and CD55. 1 illustrates an exemplary nucleic acid containing a complement control cassette. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, P2A, F2A). Each cassette also includes a polyA sequence (eg hsHBB, btGH, or SPA / ACTB). An exemplary nucleic acid having the cassette of Figure 4C is SEQ ID NO:40. [Figure 4D]

[0078] Figure 4D shows the innate immune cassette under the control of the ssUBC promoter containing the B2M HLA-E fusion protein and CD47, the coagulation cassette under the control of the hsHSPA8 promoter containing TFPI and THBD, and CD46da1 (denoted as CD46da), CD55, FIG. 3 illustrates exemplary nucleic acids containing complement control and inflammation and apoptosis cassettes under the control of the CAG promoter, including A20, and HO1. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, P2A, P2Amut1, F2A). Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of Figure 4D is SEQ ID NO:41. [Figure 4E]

[0079] Figure 4E shows the innate immune cassette under the control of the ssUBC promoter containing the B2M HLA-E fusion protein and CD47, the coagulation cassette under the control of the hsHSPA8 promoter containing TFPI and THBD, and CD46da2 (denoted as CD46da), CD55, FIG. 3 illustrates exemplary nucleic acids containing complement control and inflammation and apoptosis cassettes under the control of the CAG promoter, including A20, and HO1. The genes in each cassette are separated by nucleic acid sequences encoding 2A peptides (E2A, P2A, P2Amut1, F2A) or IRES. Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 4E is SEQ ID NO: 42. [Figure 4F]

[0080] Figure 4F shows the B2M HLA-E fusion protein and the innate immune cassette under the control of the ssUBC promoter containing CD47 (denoted as CD47_2), the coagulation cassette under the control of the ssHSPA8 promoter containing TFPI, THBD, and CD39, and CD46da2. FIG. 4 illustrates an exemplary nucleic acid comprising complement regulation and inflammation and apoptosis cassettes under the control of the CAG promoter including (designated CD46da), CD55, CD59, A20, HO1, and PD-L1. The genes in each cassette are separated by a nucleic acid or IRES encoding a 2A peptide (P2A, P2Amut1, E2A, F2A, P2Amut2, PTAmut3, T2A). Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of Figure 4F is SEQ ID NO: 173. [Figure 4G]

[0081] Figure 4G shows the coagulation cassette under the control of the ssUBC promoter containing TFPI (denoted as “TFPI*”) and THBDda, the ssHSPA8 promoter containing B2M HLA-E fusion protein and CD47-2 (denoted as “ssHSPA8(ATAC seq)”). FIG. 2 illustrates an exemplary nucleic acid comprising an innate immunity cassette under the control of a cassette (indicated) and a complement control cassette under the control of a CAG promoter including CD46da and CD55. The genes in each cassette are separated by a nucleic acid encoding a 2A peptide (P2A) or an IRES (eg, IRES(FMDV) or IRES(EMCV)). Each cassette also includes a polyA sequence (eg, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 4G is SEQ ID NO: 176. [Figure 4H]

[0082] Figure 4H shows the coagulation cassette under the control of the ssUBC promoter containing TFPI (TFPI*) and THBDda, the control of the ssHSPA8 promoter (denoted as “ssHSPA8(ATAC seq)”) containing B2M HLA-E fusion protein and CD47-2. Illustrated below is an exemplary nucleic acid comprising an innate immune cassette, a complement control cassette under the control of a CAG promoter containing CD46da and CD55, and an inflammation and apoptosis cassette under the control of the ssEF1α1 promoter (designated ssEEF1A1). The genes in each cassette are separated by nucleic acids encoding 2A peptides (P2A, P2A*) or IRESs (e.g. IRES(FMDV) or IRES(EMCV)). Each cassette also contains polyA An exemplary nucleic acid having the cassette of FIG. 4H is SEQ ID NO: 177. [Figure 5A]

[0083] Figure 5A shows the coagulation cassette under the control of the ssHSPA8 promoter containing TFPI (ΔP-Sel) and THBDda, the innate immunity cassette under the control of the ssUBC promoter containing B2M HLA-E fusion protein and CD47, CTLA-4 (e.g. LEA29Y ) and CD39, and a complement control cassette under the control of the CAG promoter, including CD46da1 (designated CD46da (BC1)) and CD55. do. This nucleic acid further includes GFP (labeled d2GFP) on the 5' side of the coagulation cassette. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, P2A, P2Amut1, F2A). Each cassette also includes a polyA sequence (eg SPA / PTCH2 pA, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 5A is SEQ ID NO: 43. [Figure 5B]

[0084] Figure 5B shows the coagulation cassette under the control of the ssHSPA8 promoter containing TFPI (ΔP-Sel) and THBDda, the innate immunity cassette under the control of the ssUBC promoter containing B2M HLA-E fusion protein and CD47, A20 and PD-L1. 1 depicts an exemplary nucleic acid comprising an inflammation and apoptosis cassette under the control of the ssEF1α1 promoter, including an inflammatory and apoptosis cassette, and a complement control cassette under the control of the CAG promoter, including CD46da1 (designated CD46da (BC1)) and CD55. This nucleic acid further includes GFP (labeled d2GFP) on the 5' side of the coagulation cassette. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, P2A, P2Amut1, F2A). Each cassette also includes a polyA sequence (eg SPA / PTCH2, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of Figure 5B is SEQ ID NO:44. [Figure 5C]

[0085] Figure 5C shows the coagulation cassette under the control of the ssHSPA8 promoter containing TFPI (ΔP-Sel) and THBDda, the innate immunity cassette under the control of the ssUBC promoter containing B2M HLA-E fusion protein and CD47, ssEF1α1 containing XIAP and CD39. 1 illustrates an exemplary nucleic acid comprising an apoptosis and coagulation cassette under the control of a promoter and a complement control cassette under the control of a CAG promoter including CD46da1 (designated CD46da (BC1)) and CD55. This nucleic acid further includes GFP (labeled d2GFP) on the 5' side of the coagulation cassette. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, P2A, P2Amut1, F2A). Each cassette also includes a polyA sequence (eg SPA / PTCH2, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of Figure 5C is SEQ ID NO: 45. [Figure 5D]

[0086] Figure 5D shows the coagulation cassette under the control of the ssHSPA8 promoter containing TFPI (ΔP-Sel) and THBDda, the innate immunity cassette under the control of the ssUBC promoter containing B2M HLA-E fusion protein and CD47, CTLA-4 (e.g. LEA29Y ) and A20, an apoptotic and cellular immunity cassette under the control of the ssEF1α1 promoter, and a complement control cassette under the control of the CAG promoter, including CD46da1 (designated CD46da (BC1)) and CD55. do. This nucleic acid further includes GFP (labeled d2GFP) on the 5' side of the coagulation cassette. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, P2A, P2Amut1, F2A). Each cassette also includes a polyA sequence (eg SPA / PTCH2, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 5D is SEQ ID NO: 46. [Figure 5E]

[0087] Figure 5E shows the coagulation cassette under the control of the ssHSPA8 promoter containing TFPI (ΔP-Sel) and THBDda, the innate immunity cassette under the control of the ssUBC promoter containing B2M HLA-E fusion protein and CD47, ssEF1α1 containing LEA29Y and CD39. 1 illustrates an exemplary nucleic acid comprising a cellular immunity and coagulation cassette under the control of a promoter and a complement control cassette under the control of a CAG promoter containing CD46da1 (designated CD46da (BC1)) and CD55. This nucleic acid further includes GFP (labeled d2GFP) on the 5' side of the coagulation cassette. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, P2A, P2Amut1, F2A). Each cassette also includes a polyA sequence (eg SPA / PTCH2 pA, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 5A is SEQ ID NO: 43. [Figure 5F]

[0088] Figure 5F shows the coagulation cassette under the control of the ssHSPA8 promoter containing TFPI (ΔP-Sel) and THBDda, the innate immunity cassette under the control of the ssUBC promoter containing B2M HLA-E fusion protein and CD47, ssEF1α1 containing LEA29Y and A20. 1 illustrates an exemplary nucleic acid comprising an apoptosis and cellular immunity cassette under the control of a promoter and a complement control cassette under the control of a CAG promoter including CD46da1 (designated CD46da (BC1)) and CD55. This nucleic acid further includes GFP (labeled d2GFP) on the 5' side of the coagulation cassette. The genes in each cassette are separated by nucleic acids encoding 2A peptides (E2A, P2A, P2Amut1, F2A). Each cassette also includes a polyA sequence (eg SPA / PTCH2, hsHBB, btGH, or hsGH). An exemplary nucleic acid having the cassette of FIG. 5D is SEQ ID NO: 46. [Figure 6]

[0089] Figure 6 shows the B2M HLA-E fusion protein and the innate immune cassette under the control of the ssUBC promoter containing CD47 (denoted as CD47-2), the inflammation under the control of the hsHSPA8 promoter containing A20, HO1, and PD-L1. and the complement control cassette under the control of the CAG promoter containing the apoptosis cassette, CD46da2 (denoted as CD46da(BC2)), CD55, and CD59, and the ssICAM2 promoter containing TFPI (denoted as *TFPI), CD39, and THBDda. 2 illustrates an exemplary nucleic acid comprising a coagulation cassette under the control of a coagulation cassette. The genes in each cassette are separated by nucleic acids encoding 2A peptides (P2A, P2Amut3, T2A, F2A, P2Amut2, P2Amut1, and E2A). Each cassette also contains polyA sequences (eg, hsHBB, btGH (labeled "btGH"), btHBB, and hsGH). An exemplary nucleic acid having the cassette of FIG. 6 is SEQ ID NO: 172. [Figure 7A]

[0090] Figure 7A shows arteries and portal veins in pig liver xenografts containing the polycistronic cassette-containing nucleic acid of Figure 2D treated with or without anti-GPIb fragmented mouse antibody and the GPIIb / IIIa inhibitor eptifibatide (ab / eptifibatide). shows the total flow rate. [Figure 7B]

[0091] Figure 7B shows lactate clearance in pig liver xenografts containing the polycistronic cassette-containing nucleic acid of Figure 2D treated with or without anti-GPIb fragmentation mouse antibody and the GPIIb / IIIa inhibitor eptifibatide (ab / eptifibatide). show. [Figure 8A]

[0092] Figure 8A shows platelet counts measured by hemocytometer over time in pig liver xenografts treated with or without anti-GPIb fragmented mouse antibody and the GPIIb / IIIa inhibitor eptifibatide (ab / eptifibatide). [Figure 8B]

[0093] Figure 8B shows platelet counts over time as measured by flow cytometry in pig liver xenografts treated with or without anti-GPIb fragmented mouse antibody and the GPIIb / IIIa inhibitor eptifibatide (ab / eptifibatide). [Figure 9A]

[0094] Figure 9A shows an image of a pig liver xenograft. The suprahepatic inferior vena cava (IVC) and portal vein are shown in the image. [Figure 9B]

[0095] Figure 9B shows lactate clearance in pig liver xenografts during ex vivo normothermic perfusion of the xenografts. [Figure 10A]

[0096] Figure 10A shows the mean troponin I concentration (ng / mL) over time in cardiac xenografts stored in cold storage solution (CS) or perfused with oxygenated Steen's solution containing red blood cells (IM). show. The following cardiac xenografts were studied. (a) Heart xenografts (“TKO”) containing knockouts of GGTA1, CMAH, and B4GALNT2 and with variable expression of human complement and platelet regulatory genes; (b) Hearts containing knockouts of GGTA1 and expression of CD55. xenograft (“GTKO.hDAF”), and (c) wild-type heart xenograft “WT”. [Figure 10B]

[0097] Figure 10B shows mean troponin I concentrations (ng / mL) over 1 hour in cardiac xenografts stored in cold preservation solution (CS) or perfused with oxygenated Steen's solution containing red blood cells (IM). show. The following cardiac xenografts were studied. (a) Heart xenografts (“TKO”) containing knockouts of GGTA1, CMAH, and B4GALNT2 and with variable expression of human complement and platelet regulatory genes; (b) Hearts containing knockouts of GGTA1 and expression of CD55. xenograft (“GTKO.hDAF”), and (c) wild-type heart xenograft “WT”. [Figure 10C]

[0098] Figure 10C shows the concentration of troponin I at 1 hour and the final time point (ng / mL). [Figure 11A]

[0099] FIG. 11A is a graph showing cardiac output over time in (CS) TKO heart xenografts stored in cold storage solution. [Figure 11B]

[0100] FIG. 11B is a graph showing cardiac output over time in TKO heart xenografts perfused (IM) with oxygenated Steen fluid containing red blood cells. [Figure 11C]

[0101] FIG. 11C is a graph showing cardiac output over time in (CS) TKO heart xenografts stored in cold storage solution. [Figure 11D]

[0102] FIG. 11D is a graph showing cardiac output over time in TKO heart xenografts perfused (IM) with oxygenated Steen fluid containing red blood cells. [Figure 12A]

[0103] Figure 12A shows an exemplary polyA (pA) sequence, an untranslated region (UTR), an intron, an IRES, a 2A peptide, and three cistrons (labeled "1," "2," and "3"). It is a polycistronic cassette. [Figure 12B]

[0104] FIG. 12B is an exemplary nucleic acid comprising multiple polycistronic cassettes (referred to as "transcription unit 1," "transcription unit 2," "transcription unit 3," and "transcription unit 4"). Each transcription unit consists of a promoter, a polyA (pA) sequence, and a cistron (“1”, “2”, “3”, “4”, “5”, “6”, “7”, “8”, and labeled "9"). The nucleic acid also includes an insulator sequence (labeled "INS"), a first loxP site (labeled "loxP") and a second loxP site (labeled "lox66"). A ubiquitous chromatin opening element (UCOE) separates the second and third polycistronic cassettes. [Figure 13A]

[0105] FIG. 13A shows flow cytometric expression of a nucleic acid containing the polycistronic cassette of FIG. 2D in donor cells, fetal pig cells, and adult pig cells. The circled cell contains the polycistronic cassette of Figure 2D. Figure 13B shows immunohistochemical expression of the nucleic acid containing the polycistronic cassette of Figure 2D in donor cells, fetal pig cells, and adult pig cells. [Figure 13B] FIG. 13A shows flow cytometric expression of a nucleic acid containing the polycistronic cassette of FIG. 2D in donor cells, fetal pig cells, and adult pig cells. The circled cell contains the polycistronic cassette of Figure 2D. Figure 13B shows immunohistochemical expression of the nucleic acid containing the polycistronic cassette of Figure 2D in donor cells, fetal pig cells, and adult pig cells. [Figure 14]

[0106] Figure 14 shows that earpunch-derived cells (EPDCs) containing the polycistronic cassette of Figure 2D express CD46 and CD55. [Figure 15A]

[0107] Figure 15A shows the expression of human CD46 and CD55 surface proteins in cells (EPDCs) or isotype control stained cells from ear punches of PL15S pigs or GGTA1 and B4GALNT2 double knockout (DKO) pigs as a control. Figure 15B assesses complement activation in PL15S or DKO pigs. PL15S pigs express the polycistronic cassette of Figure 2D. [Figure 15B] Figure 15A shows the expression of human CD46 and CD55 surface proteins in cells (EPDCs) or isotype control stained cells from ear punches of PL15S pigs or GGTA1 and B4GALNT2 double knockout (DKO) pigs as a control. Figure 15B assesses complement activation in PL15S or DKO pigs. PL15S pigs express the polycistronic cassette of Figure 2D. [Figure 16A]

[0108] Figures 16A-C show that the nucleic acids described herein provide protection from complement deposition in islet cells. Figure 16A shows that cells containing the polycistronic cassette-containing nucleic acid of Figure 2D provide protection from complement deposition in islet cells in the absence of anti-CD46 and / or anti-CD55 blocking antibodies. shows. In the absence of anti-CD46 and / or anti-CD55 blocking antibodies, cells containing the polycistronic cassette-containing nucleic acid of Figure 4D showed a reduction in the percentage of C3b (Figure 16C) and a reduction in the mean fluorescence intensity of C3b (Figure 16B). ) provides protection from complement deposition in islet cells. [Figure 16B] Figures 16A-C show that the nucleic acids described herein provide protection from complement deposition in islet cells. Figure 16A shows that cells containing the polycistronic cassette-containing nucleic acid of Figure 2D provide protection from complement deposition in islet cells in the absence of anti-CD46 and / or anti-CD55 blocking antibodies. shows. In the absence of anti-CD46 and / or anti-CD55 blocking antibodies, cells containing the polycistronic cassette-containing nucleic acid of Figure 4D showed a reduction in the percentage of C3b (Figure 16C) and a reduction in the mean fluorescence intensity of C3b (Figure 16B). ) provides protection from complement deposition in islet cells. [Figure 16C]Figures 16A-C show that the nucleic acids described herein provide protection from complement deposition in islet cells. Figure 16A shows that cells containing the polycistronic cassette-containing nucleic acid of Figure 2D provide protection from complement deposition in islet cells in the absence of anti-CD46 and / or anti-CD55 blocking antibodies. shows. In the absence of anti-CD46 and / or anti-CD55 blocking antibodies, cells containing the polycistronic cassette-containing nucleic acid of Figure 4D showed a reduction in the percentage of C3b (Figure 16C) and a reduction in the mean fluorescence intensity of C3b (Figure 16B). ) provides protection from complement deposition in islet cells. [Figure 17A]

[0109] Figures 17A-B show the expression of CD55 and CD46 in KCDC cells transfected with a nucleic acid containing CD46da, a nucleic acid containing CD55, or a nucleic acid containing CD46da and CD55 linked by an F2A peptide. Figure 17A shows that CD55 is expressed when linked to the 2A peptide. Figure 17B shows that CD46da (labeled "CD46") is expressed when linked to the 2A peptide. Figure 17C shows that nucleic acids containing CD46da ("CD46") and CD55 reduce complement deposition. [Figure 17B] Figures 17A-B show the expression of CD55 and CD46 in KCDC cells transfected with a nucleic acid containing CD46da, a nucleic acid containing CD55, or a nucleic acid containing CD46da and CD55 linked by an F2A peptide. Figure 17A shows that CD55 is expressed when linked to the 2A peptide. Figure 17B shows that CD46da (labeled "CD46") is expressed when linked to the 2A peptide. Figure 17C shows that nucleic acids containing CD46da ("CD46") and CD55 reduce complement deposition. [Figure 17C] Figures 17A-B show the expression of CD55 and CD46 in KCDC cells transfected with a nucleic acid containing CD46da, a nucleic acid containing CD55, or a nucleic acid containing CD46da and CD55 linked by an F2A peptide. Figure 17A shows that CD55 is expressed when linked to the 2A peptide. Figure 17B shows that CD46da (labeled "CD46") is expressed when linked to the 2A peptide. Figure 17C shows that nucleic acids containing CD46da ("CD46") and CD55 reduce complement deposition. [Figure 18A]

[0110] Figures 18A-C show the following nucleic acids: (i) hsCD46da2; (ii) hsCD55; (iii) hsCD59; (iv) hsCD46da2-F2A-hsCD55; (v) hsCD46da2-F2A-hsCD59; (vi) hsCD55-P2A- Expression of CD46, CD55, and CD59 in KCDC cells transfected with one of hsCD59; or (viii) hsCD46da2-F2A-hsCD55-P2A-hsCD59. Figures 18A-C show the expression of CD46 (Figure 18A), CD55 (Figure 18B), and CD59 (Figure 18C), respectively. Figure 18D shows that expression of each of these nucleic acids reduces complement deposition. In each of FIGS. 18A to 18D, CD46da2 is labeled "46," CD55 is labeled "55," and CD59 is labeled "59." [Figure 18B] Figures 18A-C show the following nucleic acids: (i) hsCD46da2; (ii) hsCD55; (iii) hsCD59; (iv) hsCD46da2-F2A-hsCD55; (v) hsCD46da2-F2A-hsCD59; (vi) hsCD55-P2A- Expression of CD46, CD55, and CD59 in KCDC cells transfected with one of hsCD59; or (viii) hsCD46da2-F2A-hsCD55-P2A-hsCD59. Figures 18A-C show the expression of CD46 (Figure 18A), CD55 (Figure 18B), and CD59 (Figure 18C), respectively. Figure 18D shows that expression of each of these nucleic acids reduces complement deposition. In each of FIGS. 18A to 18D, CD46da2 is labeled "46," CD55 is labeled "55," and CD59 is labeled "59." [Figure 18C] Figures 18A-C show the following nucleic acids: (i) hsCD46da2; (ii) hsCD55; (iii) hsCD59; (iv) hsCD46da2-F2A-hsCD55; (v) hsCD46da2-F2A-hsCD59; (vi) hsCD55-P2A- Expression of CD46, CD55, and CD59 in KCDC cells transfected with one of hsCD59; or (viii) hsCD46da2-F2A-hsCD55-P2A-hsCD59. Figures 18A-C show the expression of CD46 (Figure 18A), CD55 (Figure 18B), and CD59 (Figure 18C), respectively. Figure 18D shows that expression of each of these nucleic acids reduces complement deposition. In each of FIGS. 18A to 18D, CD46da2 is labeled "46," CD55 is labeled "55," and CD59 is labeled "59." [Figure 18D] Figures 18A-C show the following nucleic acids: (i) hsCD46da2; (ii) hsCD55; (iii) hsCD59; (iv) hsCD46da2-F2A-hsCD55; (v) hsCD46da2-F2A-hsCD59; (vi) hsCD55-P2A- Expression of CD46, CD55, and CD59 in KCDC cells transfected with one of hsCD59; or (viii) hsCD46da2-F2A-hsCD55-P2A-hsCD59. Figures 18A-C show the expression of CD46 (Figure 18A), CD55 (Figure 18B), and CD59 (Figure 18C), respectively. Figure 18D shows that expression of each of these nucleic acids reduces complement deposition. In each of FIGS. 18A to 18D, CD46da2 is labeled "46," CD55 is labeled "55," and CD59 is labeled "59." [Figure 19A]

[0111] Figure 19A shows the expression of CD46 isoforms BC-Cyt1 ("SG_BC1"), Bc-Cy2 ("SG_BC2"), and ABC1 ("SG_ABC1"). FIG. 19B shows the ability of each of the CD46 isoforms BC-Cyt1 (“SG_BC1”), Bc-Cy2 (“SG_BC2”), and ABC1 (“SG_ABC1”) to reduce complement deposition. Expression of a nucleic acid containing the polycistronic cassette of Figure 2D also reduces complement deposition. [Figure 19B] Figure 19A shows the expression of CD46 isoforms BC-Cyt1 ("SG_BC1"), Bc-Cy2 ("SG_BC2"), and ABC1 ("SG_ABC1"). FIG. 19B shows the ability of each of the CD46 isoforms BC-Cyt1 (“SG_BC1”), Bc-Cy2 (“SG_BC2”), and ABC1 (“SG_ABC1”) to reduce complement deposition. Expression of a nucleic acid containing the polycistronic cassette of Figure 2D also reduces complement deposition. [Figure 20A]

[0112] Figure 20A shows that AEC, KEC, PUVEC, and HUVEC cells transfected with the nucleic acid containing the polycistronic cassette of Figure 2D express CD46 and CD55 (Figure 20A). Figure 20B shows that AEC, KEC, PUVEC, and HUVEC cells transfected with the nucleic acid containing the polycistronic cassette of Figure 4C express CD46 and CD55 (Figure 20B). FIG. 20C shows that AEC, KEC, and PUVEC cells containing a nucleic acid comprising the polycistronic cassette of FIG. 2D reduces complement deposition in AEC, KEC, and PUVEC cells. FIG. 20D shows that AEC, KEC, and PUVEC cells containing a nucleic acid comprising the polycistronic cassette of FIG. 4C reduces complement deposition in AEC, KEC, and PUVEC cells. [Figure 20B] Figure 20A shows that AEC, KEC, PUVEC, and HUVEC cells transfected with the nucleic acid containing the polycistronic cassette of Figure 2D express CD46 and CD55 (Figure 20A). Figure 20B shows that AEC, KEC, PUVEC, and HUVEC cells transfected with the nucleic acid containing the polycistronic cassette of Figure 4C express CD46 and CD55 (Figure 20B). FIG. 20C shows that AEC, KEC, and PUVEC cells containing a nucleic acid comprising the polycistronic cassette of FIG. 2D reduces complement deposition in AEC, KEC, and PUVEC cells. FIG. 20D shows that AEC, KEC, and PUVEC cells containing a nucleic acid comprising the polycistronic cassette of FIG. 4C reduces complement deposition in AEC, KEC, and PUVEC cells. [Figure 20C] Figure 20A shows that AEC, KEC, PUVEC, and HUVEC cells transfected with the nucleic acid containing the polycistronic cassette of Figure 2D express CD46 and CD55 (Figure 20A). Figure 20B shows that AEC, KEC, PUVEC, and HUVEC cells transfected with the nucleic acid containing the polycistronic cassette of Figure 4C express CD46 and CD55 (Figure 20B). FIG. 20C shows that AEC, KEC, and PUVEC cells containing a nucleic acid comprising the polycistronic cassette of FIG. 2D reduces complement deposition in AEC, KEC, and PUVEC cells. FIG. 20D shows that AEC, KEC, and PUVEC cells containing a nucleic acid comprising the polycistronic cassette of FIG. 4C reduces complement deposition in AEC, KEC, and PUVEC cells. [Figure 20D]Figure 20A shows that AEC, KEC, PUVEC, and HUVEC cells transfected with the nucleic acid containing the polycistronic cassette of Figure 2D express CD46 and CD55 (Figure 20A). Figure 20B shows that AEC, KEC, PUVEC, and HUVEC cells transfected with the nucleic acid containing the polycistronic cassette of Figure 4C express CD46 and CD55 (Figure 20B). FIG. 20C shows that AEC, KEC, and PUVEC cells containing a nucleic acid comprising the polycistronic cassette of FIG. 2D reduces complement deposition in AEC, KEC, and PUVEC cells. FIG. 20D shows that AEC, KEC, and PUVEC cells containing a nucleic acid comprising the polycistronic cassette of FIG. 4C reduces complement deposition in AEC, KEC, and PUVEC cells. [Figure 21A]

[0113] Figure 21A shows that expression of a nucleic acid comprising the polycistronic cassette ("15S") of Figure 2D reduces complement deposition even in the presence of donor-specific alloantibodies (DSA). Figure 21B shows the concentration of DSA after implantation. "POD" means days post-transplant. [Figure 21B] Figure 21A shows that expression of a nucleic acid comprising the polycistronic cassette ("15S") of Figure 2D reduces complement deposition even in the presence of donor-specific alloantibodies (DSA). Figure 21B shows the concentration of DSA after implantation. "POD" means days post-transplant. [Figure 22]

[0114] FIG. 22 shows the experimental timeline of Example 1. [Figure 23]

[0115] Figure 23 shows the expression of CD46, CD55, CD59, HLA-E, CD47, and PD-L1 in TKO-A and TKO-B xenografts compared to wild-type xenografts in animals of Example 1A. Show the image. [Figure 24]

[0116] Figure 24 shows images of the expression of CD46, CD55, CD47, EPCR, THBD, A20, and HO1 in the TKO-C animals of Example 1A. [Figure 25]

[0117] Figure 25 shows images of the expression of CD46, CD55, B2M, CD47, TFPI, and THBD in the TKO-D animals of Example 1A. [Figure 26]

[0118] Figure 26 shows the serum creatinine concentration (labeled Cr) up to 313 days after transplantation in the animals of Example 1A. [Figure 27]

[0119] Figure 27 shows images of renal tissue stained with either hematoxylin and eosin or complement component C4d at 217 days (“POD217”), 230 days (“POD230”), or 105 days (“POD105”) after transplantation. show. Animal B6 received a TKO-B xenograft. Animal C9 received a TKO-F xenograft. Animal D2 received a TKO-G xenograft. [Figure 28A]

[0120] FIG. 28A shows an exemplary landing pad. The landing pad contains an insulator sequence (HS4), a loxP site (lox71 and lox2272), a polyA sequence (SPAAct1 pA and hsHBB pA), a CAG promoter, and a marker gene (d2BFP). Figure 28B shows integration of the 15S5 payload of Figure 2I at a genomic safe harbor locus. FIG. 28C shows an exemplary landing pad. The landing pad contains a loxP site (loxP and lox2272), hsEF1α1, a polyA sequence (SPAC2 pA), and blue fluorescent protein (BFP). The landing pad is integrated between exon 1 and exon 2 in the AAVS1 genomic safe harbor. [Figure 28B] FIG. 28A shows an exemplary landing pad. The landing pad contains an insulator sequence (HS4), a loxP site (lox71 and lox2272), a polyA sequence (SPAAct1 pA and hsHBB pA), a CAG promoter, and a marker gene (d2BFP). Figure 28B shows integration of the 15S5 payload of Figure 2I at a genomic safe harbor locus. FIG. 28C shows an exemplary landing pad. The landing pad contains a loxP site (loxP and lox2272), hsEF1α1, a polyA sequence (SPAC2 pA), and blue fluorescent protein (BFP). The landing pad is integrated between exon 1 and exon 2 in the AAVS1 genomic safe harbor. [Figure 28C] FIG. 28A shows an exemplary landing pad. The landing pad contains an insulator sequence (HS4), a loxP site (lox71 and lox2272), a polyA sequence (SPAAct1 pA and hsHBB pA), a CAG promoter, and a marker gene (d2BFP). Figure 28B shows integration of the 15S5 payload of Figure 2I at a genomic safe harbor locus. FIG. 28C shows an exemplary landing pad. The landing pad contains a loxP site (loxP and lox2272), hsEF1α1, a polyA sequence (SPAC2 pA), and blue fluorescent protein (BFP). The landing pad is integrated between exon 1 and exon 2 in the AAVS1 genomic safe harbor. [Figure 29A]

[0121] Figures 29A-E are graphs showing blood urea nitrogen (BUN) and creatinine for five monkeys containing TKO-F xenografts. [Figure 29B] Figures 29A-E are graphs showing blood urea nitrogen (BUN) and creatinine for five monkeys containing TKO-F xenografts. [Figure 29C] Figures 29A-E are graphs showing blood urea nitrogen (BUN) and creatinine for five monkeys containing TKO-F xenografts. [Figure 29D] Figures 29A-E are graphs showing blood urea nitrogen (BUN) and creatinine for five monkeys containing TKO-F xenografts. [Figure 29E] Figures 29A-E are graphs showing blood urea nitrogen (BUN) and creatinine for five monkeys containing TKO-F xenografts. [Figure 30A]

[0122] Figures 30A-B are graphs showing BUN and creatinine levels for two monkeys containing TKO-G xenografts. [Figure 30B] Figures 30A-B are graphs showing BUN and creatinine levels for two monkeys containing TKO-G xenografts. [Figure 31]

[0123] Figures 31 and 32 are graphs showing BUN and creatinine levels for two monkeys containing xenografts containing the polycistronic cassette of Figure 2H. [Figure 32] Figures 31 and 32 are graphs showing BUN and creatinine levels for two monkeys containing xenografts containing the polycistronic cassette of Figure 2H. [Figure 33]

[0124] Figure 33 shows the expression of a nucleic acid comprising the polycistronic cassette of Figure 2E in fibroblasts from Yorkshire pigs. [Figure 34]

[0125] Figure 34 (see circled cells) shows expression of the nucleic acid containing the polycistronic cassette of Figure 2E in fibroblasts from Yucatan pigs. [Figure 35]

[0126] Figure 35 shows the expression of a nucleic acid comprising the polycistronic cassette of Figure 2D in fibroblasts from Yucatan pigs. [Figure 36]

[0127] Figure 36 (see circled cells) shows expression of a nucleic acid containing the polycistronic cassette of Figure 2D in fibroblasts containing a PERV knockout from Yucatan pigs. [Figure 37A]

[0128] Figure 37A shows expression of A20 in islet cells containing the polycistronic cassette of Figure 4A. Figure 37B shows that expression of A20 in islet cells containing the polycistronic cassette of Figure 4B protects cells from TNFα-mediated apoptosis. [Figure 37B] Figure 37A shows expression of A20 in islet cells containing the polycistronic cassette of Figure 4A. Figure 37B shows that expression of A20 in islet cells containing the polycistronic cassette of Figure 4B protects cells from TNFα-mediated apoptosis. [Figure 38A]

[0129] Figures 38A-C show expression of the transgene of the TKO-F xenograft of Example 1A in tissues, glomeruli, and tubules. [Figure 38B] Figures 38A-C show expression of the transgene of the TKO-F xenograft of Example 1A in tissues, glomeruli, and tubules. [Figure 38C] Figures 38A-C show expression of the transgene of the TKO-F xenograft of Example 1A in tissues, glomeruli, and tubules. [Figure 39]

[0130] Figure 39 shows expression of the 15S4 transgene in monkey tissues, glomeruli, and renal tubules containing the nucleic acid containing the polycistronic cassette of Figure 2H. [Figure 40]

[0131] Figure 40 shows an immunohistochemical image of monkey transgene expression containing a nucleic acid containing the polycistronic cassette of Figure 2H. [Figure 41A]

[0132] Figures 41A-D show a comparison of the expression of the polycistronic cassette of Figure 2H ("15S4") or Figure 2E ("15S1") in monkeys containing renal xenografts. Figure 41A shows transgene expression by immunohistochemistry. Figures 41B-D show transgene expression in whole tissues (Figure 41B), glomeruli (Figure 41C), and renal tubules (Figure 41D). [Figure 41B] Figures 41A-D show a comparison of the expression of the polycistronic cassette of Figure 2H ("15S4") or Figure 2E ("15S1") in monkeys containing renal xenografts. Figure 41A shows transgene expression by immunohistochemistry. Figures 41B-D show transgene expression in whole tissues (Figure 41B), glomeruli (Figure 41C), and renal tubules (Figure 41D). [Figure 41C] Figures 41A-D show a comparison of the expression of the polycistronic cassette of Figure 2H ("15S4") or Figure 2E ("15S1") in monkeys containing renal xenografts. Figure 41A shows transgene expression by immunohistochemistry. Figures 41B-D show transgene expression in whole tissues (Figure 41B), glomeruli (Figure 41C), and renal tubules (Figure 41D). [Figure 41D] Figures 41A-D show a comparison of the expression of the polycistronic cassette of Figure 2H ("15S4") or Figure 2E ("15S1") in monkeys containing renal xenografts. Figure 41A shows transgene expression by immunohistochemistry. Figures 41B-D show transgene expression in whole tissues (Figure 41B), glomeruli (Figure 41C), and renal tubules (Figure 41D). [Figure 42A]

[0133] Figure 42A shows expression of the 15S1 transgene in fetal pig kidney relative to expression in wild type Yucatan pigs. Figure 42B shows expression of the 15S1 transgene in neonatal pig kidneys relative to expression in wild type Yucatan pigs. Figure 42C shows expression of the 15S1 transgene in adult pig kidney relative to expression in wild type Yucatan pigs. [Figure 42B] Figure 42A shows expression of the 15S1 transgene in fetal pig kidney relative to expression in wild type Yucatan pigs. Figure 42B shows expression of the 15S1 transgene in neonatal pig kidneys relative to expression in wild type Yucatan pigs. Figure 42C shows expression of the 15S1 transgene in adult pig kidney relative to expression in wild type Yucatan pigs. [Figure 42C] Figure 42A shows expression of the 15S1 transgene in fetal pig kidney relative to expression in wild type Yucatan pigs. Figure 42B shows expression of the 15S1 transgene in neonatal pig kidneys relative to expression in wild type Yucatan pigs. Figure 42C shows expression of the 15S1 transgene in adult pig kidney relative to expression in wild type Yucatan pigs. [Figure 43A]

[0134] Figure 43A shows expression of the 15S1 transgenes TFPI, EPCR, and THBD in fetal, neonatal, and adult pig kidney tissue. Figure 43B shows expression of 15S1 transgene B2M HLA-E fusion protein and CD47 in fetal, neonatal, and adult pig kidney tissue. Figure 43C shows expression of the 15S1 transgenes CD46 and CD55 in fetal, neonatal, and adult pig kidney tissue. Figure 43D shows the respective expression of the 15S1 transgene in two different fetal pig kidney tissues. [Figure 43B] Figure 43A shows expression of the 15S1 transgenes TFPI, EPCR, and THBD in fetal, neonatal, and adult pig kidney tissue. Figure 43B shows expression of 15S1 transgene B2M HLA-E fusion protein and CD47 in fetal, neonatal, and adult pig kidney tissue. Figure 43C shows expression of the 15S1 transgenes CD46 and CD55 in fetal, neonatal, and adult pig kidney tissue. Figure 43D shows the respective expression of the 15S1 transgene in two different fetal pig kidney tissues. [Figure 43C] Figure 43A shows expression of the 15S1 transgenes TFPI, EPCR, and THBD in fetal, neonatal, and adult pig kidney tissue. Figure 43B shows expression of 15S1 transgene B2M HLA-E fusion protein and CD47 in fetal, neonatal, and adult pig kidney tissue. Figure 43C shows expression of the 15S1 transgenes CD46 and CD55 in fetal, neonatal, and adult pig kidney tissue. Figure 43D shows the respective expression of the 15S1 transgene in two different fetal pig kidney tissues. [Figure 43D] Figure 43A shows expression of the 15S1 transgenes TFPI, EPCR, and THBD in fetal, neonatal, and adult pig kidney tissue. Figure 43B shows expression of 15S1 transgene B2M HLA-E fusion protein and CD47 in fetal, neonatal, and adult pig kidney tissue. Figure 43C shows expression of the 15S1 transgenes CD46 and CD55 in fetal, neonatal, and adult pig kidney tissue. Figure 43D shows the respective expression of the 15S1 transgene in two different fetal pig kidney tissues. [Figure 44]

[0135] Figure 44 shows expression of CD47 by islet cells containing a nucleic acid comprising the polycistronic cassette of Figure 2H ("15S4") or Figure 4A ("17M1"). [Figure 45]

[0136] Figure 45 shows that dissociated islet cells containing the polycistronic cassette of Figure 2H ("15S4") are superior to islet cells containing the polycistronic cassette of Figure 4A ("17M1") in protection from phagocytosis. Indicates that there is a [Figure 46]

[0137] FIG. 46 provides an example of a method of producing a transgenic pig containing the nucleic acids described herein. [Figure 47A]

[0138] Figure 47A is an illustration of a standard promoter. Figure 47B is an illustration of a promoter containing a CpG island. [Figure 47B] Figure 47A is an illustration of a standard promoter. Figure 47B is an illustration of a promoter containing a CpG island. [Figure 48A]

[0139] Figures 48A-C show expression of CD47 cistrons using promoters containing or lacking CpG islands in fibroblasts (Figure 48A), beta islet cells (Figure 48B), and pAEC-SV40 cells (Figure 48C). Figures 48D-F show expression of CD46 in fibroblasts (Figure 48D), beta islet cells (Figure 48E), and pAEC-SV40 cells (Figure 48F) using promoters containing or lacking CpG islands. The x-axis of each of the graphs in Figures 48A-F indicates the sequence number of the promoter used to express the cistron. [Figure 48B] Figures 48A-C show expression of CD47 cistrons using promoters containing or lacking CpG islands in fibroblasts (Figure 48A), beta islet cells (Figure 48B), and pAEC-SV40 cells (Figure 48C). Figures 48D-F show expression of CD46 in fibroblasts (Figure 48D), beta islet cells (Figure 48E), and pAEC-SV40 cells (Figure 48F) using promoters containing or lacking CpG islands. The x-axis of each of the graphs in Figures 48A-F indicates the sequence number of the promoter used to express the cistron. [Figure 48C] Figures 48A-C show expression of CD47 cistrons using promoters containing or lacking CpG islands in fibroblasts (Figure 48A), beta islet cells (Figure 48B), and pAEC-SV40 cells (Figure 48C). Figures 48D-F show expression of CD46 in fibroblasts (Figure 48D), beta islet cells (Figure 48E), and pAEC-SV40 cells (Figure 48F) using promoters containing or lacking CpG islands. The x-axis of each of the graphs in Figures 48A-F indicates the sequence number of the promoter used to express the cistron. [Figure 48D] Figures 48A-C show expression of CD47 cistrons using promoters containing or lacking CpG islands in fibroblasts (Figure 48A), beta islet cells (Figure 48B), and pAEC-SV40 cells (Figure 48C). Figures 48D-F show expression of CD46 in fibroblasts (Figure 48D), beta islet cells (Figure 48E), and pAEC-SV40 cells (Figure 48F) using promoters containing or lacking CpG islands. The x-axis of each of the graphs in Figures 48A-F indicates the sequence number of the promoter used to express the cistron. [Figure 48E] Figures 48A-C show expression of CD47 cistrons using promoters containing or lacking CpG islands in fibroblasts (Figure 48A), beta islet cells (Figure 48B), and pAEC-SV40 cells (Figure 48C). Figures 48D-F show expression of CD46 in fibroblasts (Figure 48D), beta islet cells (Figure 48E), and pAEC-SV40 cells (Figure 48F) using promoters containing or lacking CpG islands. The x-axis of each of the graphs in Figures 48A-F indicates the sequence number of the promoter used to express the cistron. [Figure 48F] Figures 48A-C show expression of CD47 cistron in fibroblasts (Figure 48A), beta islet cells (Figure 48B), and pAEC-SV40 cells (Figure 48C) using promoters containing or lacking CpG islands. Figures 48D-F show expression of CD46 in fibroblasts (Figure 48D), beta islet cells (Figure 48E), and pAEC-SV40 cells (Figure 48F) using promoters containing or lacking CpG islands. The x-axis of each of the graphs in Figures 48A-F indicates the sequence number of the promoter used to express the cistron. [Figure 49]

[0140] Figure 49 shows an immunohistochemical image of islet cells containing the nucleic acid containing the polycistronic cassette of Figure 4A transplanted into diabetic mice. Images show staining for insulin, glucagon, and nucleus in individual mice. [Figure 50]

[0141] FIG. 50 shows the experimental design for the experiment of Example 16. [Figure 51]

[0142] FIG. 51 shows blood glucose levels in NSG mice that received transplants of neonatal porcine islet cells containing the nucleic acid containing the polycistronic cassette of FIG. 4A. [Figure 52A]

[0143] Figures 52A-B show fasting blood glucose levels, total insulin, and porcine C-peptide in two cynomolgus monkeys that received transplants of neonatal porcine islet cells containing the polycistronic cassette-containing nucleic acid of Figure 4A. [Figure 52B] Figures 52A-B show fasting blood glucose levels, total insulin, and porcine C-peptide in two cynomolgus monkeys that received transplants of neonatal porcine islet cells containing the polycistronic cassette-containing nucleic acid of Figure 4A. [Figure 53A]

[0144] Figure 53A shows that cells expressing 14P nucleic acid are protected from NK cell-mediated cytolysis. Figure 53B shows that cells expressing 14P and 14S nucleic acids are protected from NK cell-mediated cytolysis compared to wild type (WT) cells or K562 cancer cells that do not express 14P and 14S nucleic acids. [Figure 53B] Figure 53A shows that cells expressing 14P nucleic acid are protected from NK cell-mediated cytolysis. Figure 53B shows that cells expressing 14P and 14S nucleic acids are protected from NK cell-mediated cytolysis compared to wild type (WT) cells or K562 cancer cells that do not express 14P and 14S nucleic acids. [Figure 54A]

[0145] In Figure 54A, wild type (WT) aorta-derived cells (AECs), GGTA1, B4GALNT2, and CMAH triple knockout (TKO) aorta-derived cells (AECs), human umbilical cord-derived endothelial cells (Hu UVECs), and umbilical cord ( Surface expression of human EPCR and THBD proteins in payload 15S porcine endothelial cells derived from porcine UVEC), aorta, or kidney (KEC) is shown in the histogram graph on the left. Payload 15S cells contain a nucleic acid containing the polycistronic cassette of Figure 2D. Figure 54B shows that various cells expressing the nucleic acid containing the polycistronic cassette ("15S") of Figure 2D are functional, as shown by increased concentrations of activated protein C compared to cells that do not express 15S. THBD and PROCR. The following cell types were evaluated: alveolar epithelial cells (AECs), renal epithelial cells (KECs), human umbilical vein endothelial cells (“Hu UVECs”), porcine umbilical vein endothelial cells (“porcine UVECs”), and extracardiac cells. Membrane-derived cells (EPDCs). [Figure 54B] In Figure 54A, wild type (WT) aorta-derived cells (AECs), GGTA1, B4GALNT2, and CMAH triple knockout (TKO) aorta-derived cells (AECs), human umbilical cord-derived endothelial cells (Hu UVECs), and umbilical cord ( Surface expression of human EPCR and THBD proteins in payload 15S porcine endothelial cells derived from porcine UVEC), aorta, or kidney (KEC) is shown in the histogram graph on the left. Payload 15S cells contain a nucleic acid containing the polycistronic cassette of Figure 2D. Figure 54B shows that various cells expressing the nucleic acid containing the polycistronic cassette ("15S") of Figure 2D are functional, as shown by increased concentrations of activated protein C compared to cells that do not express 15S. THBD and PROCR. The following cell types were evaluated: alveolar epithelial cells (AECs), renal epithelial cells (KECs), human umbilical vein endothelial cells (“Hu UVECs”), porcine umbilical vein endothelial cells (“porcine UVECs”), and extracardiac cells. Membrane-derived cells (EPDCs). [Figure 55]

[0146] FIG. 55 is a diagram illustrating an exemplary method of preparing a genetically modified animal containing the nucleic acids described herein. In the first step (round 1), CRISPR-Cas9-mediated non-homologous end joining (NHEJ) and homologous recombination repair is performed to knock out ( (eg, TKO) to introduce a landing pad into the cell at a genomic safe harbor site (eg, in intron 1 of the genomic safe harbor AAVS1 site or in the 3' flanking region of the AAVS1 site). By introducing the landing pad, a loxP site is introduced into the genome of the cell. In the second step (round 2), recombinase-mediated cassette exchange is used to introduce the nucleic acid containing the polycistronic cassette (e.g. payload KI). The third step (round 3) uses CRISPR-Cas9 NHEJ to knock out the porcine endogenous retroviral element (PERV). [Figure 56A]

[0147] Figure 56A shows the expression of human CD47 protein in wild type (WT) and GGTA1 plus B4GALNT2 double knockout (DKO) ear punch-derived cells (EPDCs) and fetal fibroblasts (FF) from PL15S pigs. Figure 56B shows reduced phagocytosis by PL15S pigs. The phagocytosis index is determined by the formula: total phagocytosis signal divided by the sum of total phagocytosis signal and non-phagocytosed signal. Figure 56C shows that PL15S cells are protected from phagocytosis. PL15S pigs express the polycistronic cassette of Figure 2D. [Figure 56B] Figure 56A shows the expression of human CD47 protein in wild type (WT) and GGTA1 plus B4GALNT2 double knockout (DKO) ear punch-derived cells (EPDCs) and fetal fibroblasts (FF) from PL15S pigs. Figure 56B shows reduced phagocytosis by PL15S pigs. The phagocytosis index is determined by the formula: total phagocytosis signal divided by the sum of total phagocytosis signal and non-phagocytosed signal. Figure 56C shows that PL15S cells are protected from phagocytosis. PL15S pigs express the polycistronic cassette of Figure 2D. [Figure 56C] Figure 56A shows the expression of human CD47 protein in wild type (WT) and GGTA1 plus B4GALNT2 double knockout (DKO) ear punch-derived cells (EPDCs) and fetal fibroblasts (FF) from PL15S pigs. Figure 56B shows reduced phagocytosis by PL15S pigs. The phagocytosis index is determined by the formula: total phagocytosis signal divided by the sum of total phagocytosis signal and non-phagocytosed signal. Figure 56C shows that PL15S cells are protected from phagocytosis. PL15S pigs express the polycistronic cassette of Figure 2D. [Form for carrying out the invention]

[0058] detailed description I. Definition

[0148] The terms "pig," "swine," and "porcine" are used interchangeably herein and refer to various breeds of domestic pigs, the species Sus scrofa. It means anything.

[0059]

[0149] The term "biologically active" when used to refer to a fragment or derivative of a protein or polypeptide means that the fragment or derivative has at least one measurable and / or or possess detectable biological activity. For example, biologically active fragments or derivatives of CRISPR / Cas9 proteins bind gRNAs, sometimes referred to herein as single guide RNAs (sgRNAs), and when complexed with guide RNAs bind to target DNA sequences. can bind and / or cleave one or more DNA strands.

[0060]

[0150] When used in the context of a disease, injury, or disorder, terms such as "treatment," "treat," and "alleviation" generally refer to the desired pharmacological and / or physiological effect. used to mean obtaining and can also be used to refer to ameliorating, alleviating, and / or reducing the severity of one or more symptoms of the condition being treated. The effect may be preventive in that it completely or partially delays the onset or recurrence of the disease, condition, or symptoms thereof, and / or prevents the disease, condition, and / or harm caused by the disease, condition, or condition. It may be therapeutic in terms of partial or complete cure of the effect. "Treatment" as used herein encompasses any treatment of a disease or condition in a mammal, particularly a human, who (a) may be suffering from the disease or condition but is not yet suffering from the disease or condition; prevent a disease or condition from occurring in a subject who has not been diagnosed with the disease; (b) suppress the disease or condition (e.g., prevent its onset); or (c) alleviate the disease or condition. (e.g., causing regression of a disease or condition, providing amelioration of one or more symptoms).

[0061]

[0151] The term "simultaneously" is used herein to refer to an event that occurs simultaneously with another event, such as within seconds, milliseconds, microseconds, or less than the occurrence of the other event. used.

[0062]

[0152] The term "knockout" ("KO") or "knockout" as used herein refers to the deletion, inactivation, or removal of a gene in a pig or other animal, or in any cell of a pig or other animal. , or used to refer to a defective gene. KO as used herein may also refer to a method of performing or having performed deletion, inactivation or removal of a gene or part thereof.

[0063]

[0153] The term "knock-in" ("KI") or "knocking in" as used herein refers to the addition of nucleotide(s) of a gene in a pig or other animal, or in any cell of a pig or other animal; Used to refer to substitutions or mutations. KI as used herein may also refer to a method of performing or having performed the addition, substitution, or mutation of nucleotide(s) of a gene or part thereof.

[0064]

[0154] The term "PERV-free" with respect to a porcine tissue, organ, or cell refers to a tissue, organ, or cell that has at least 75% inactive porcine endogenous retroviral (PERV) elements. The PERV element can be a gag gene, a pol gene, or an env gene. In embodiments, the porcine tissue, organ, or cell has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% PERV Does not include.

[0065]

[0155] The term "percent identity" in the context of two or more nucleic acid or polypeptide sequences refers to two or more sequences or subsequences that have a specified percentage of nucleotide or amino acid residues that are the same when compared. . Percentage identity can be calculated using the tool CLUSTALW2, available online. The following parameters can be used for CLUSTALW2 pairwise alignment: Protein Weight Matrix=Gonnet;Gap Open=10;Gap Extension=0.1.

[0066]

[0156] The term "conservative substitution" refers to the exchange of one amino acid for another among the following groups of amino acids: (i) aliphatic amino acids (alanine, valine, leucine, and isoleucine); (ii) Amino acids with hydroxyl groups (serine and threonine); (iii) acidic amino acids (glutamic acid and aspartic acid); (iv) amino acids with amide side chains (asparagine and glutamine); (v) basic amino acids (lysine and arginine); (vii) Amino acids with aromatic side chains (phenylalanine, tyrosine, tryptophan). In embodiments, provided herein are nucleic acids encoding proteins that include conservative substitutions. For example, a protein may have a conservative substitution of valine for alanine. In embodiments, the number of amino acid changes to the encoded protein can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids.

[0067]

[0157] The term "polycistronic cassette" as used herein refers to a nucleic acid containing two or more "cistrons" or genes under the control of a single promoter and polyA sequence. The term "polycistronic cassette" is used herein interchangeably with "transcription unit." In embodiments, the polycistronic cassette includes cDNA. In embodiments, the polycistronic cassette comprises DNA. In embodiments, the polycistronic cassette includes one or more introns. An exemplary polycistronic cassette is shown in Figure 12A. An exemplary nucleic acid containing multiple polycistronic cassettes is shown in Figure 12B.

[0068]

[0158] The term "regulatory element" as used herein refers to a nucleic acid sequence that regulates the expression of a cistron. Exemplary regulatory elements include promoters, enhancers, polyA signals, and terminators. A cistron whose expression is controlled by a regulatory element is said to be operably regulated by the regulatory element.

[0069]

[0159] For example, the term "isolated" as used herein with respect to a nucleic acid or cell refers to a nucleic acid or cell that has been purified such that it is isolated from other components. For example, an isolated nucleic acid can be purified from bacterial cells used to produce the nucleic acid, or the cells can be isolated from an animal for use in therapeutic purposes. obtain.

[0070]

[0160] The term "heterologous" as used herein refers to controlled expression of a nucleic acid as a result of recombinant DNA manipulation in the organism, rather than expression of the endogenous nucleic acid of the host organism. Typically, the cistron and / or the regulatory element or elements controlling the expression of the cistron are either artificial or derived from a different species than the host organism. In embodiments, the cistron and regulatory elements may be derived from the same species as the host organism, but may be introduced by recombinant approaches that alter the regulation and expression of the cistron as compared to an equivalent native cistron.

[0071] II. Nucleic acids containing one or more polycistronic cassettes

[0161] Porcine xenografts are broadly compatible with human organ size and physiology and are ethically acceptable to the general public in the United States. However, xenografted pig tissue suffers from hyperacute rejection due to the presence of preformed antibodies against pig antigens, increased complement activation and coagulability, and congenital and adaptive reactions due to molecular incompatibility. It triggers a complex series of events that result in graft rejection, including an increased immune response. The present disclosure uses genetic engineering approaches to address the current drawbacks of xenotransplantation.

[0072]

[0162] The present disclosure provides nucleic acids containing one or more polycistronic cassettes for genetic manipulation of cells, organs, tissues, and animals.

[0163] In embodiments, provided herein are nucleic acids comprising about 1 to about 10 polycistronic cassettes. For example, the nucleic acid may contain about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 polycistronic cassettes. Each polycistronic cassette is from the group CD46, CD55, CD59, THBD, TFPI, PROCR, CD39, B2M, HLA-E, CD47, A20, PD-L1, HO1, CTLA-4 (e.g. LEA29Y), XIAP. Including two or more selected cistrons and combinations thereof. In embodiments, the polycistronic cassette is flanked by insulator sequences, loxP sites, or a combination thereof.

[0073]

[0164] In embodiments, each cistron of the polycistronic cassette is separated by a nucleic acid encoding a 2A polypeptide or a sequence containing an internal ribosome entry site (IRES). In embodiments, one, two, three, four, or five polycistronic cassettes do not include a nucleic acid encoding a 2A polypeptide. Each polycistronic cassette is under the control of a promoter. Exemplary promoters are listed in Table B. Each polycistronic cassette also includes one or more poly A (also referred to as "poly A") and / or terminator sequences. Exemplary polyA and / or terminator sequences are provided in Table C.

[0074]

[0165] When the name of a cistron, promoter, or polyA sequence includes a lowercase letter before the name of the cistron, promoter, or polyA sequence, the lowercase letter refers to the genus and species from which the cistron was isolated. For example, ssA20 means A20 from Sus scrofa, hsCD46 means CD46 from Homo sapiens, mmA20 means A20 from Mus musculus, and btA20 means A20 from Bos taurus. When a lowercase "s" is used before the name of a cistron, promoter, or polyA sequence, the s means Sus scrofa. When a lowercase "h" is used before the name of a cistron, promoter, or polyA sequence, h means Homo sapiens. When a lowercase "m" is used before the name of a cistron, promoter, or polyA sequence, m means Mus musculus.

[0075]

[0166] In embodiments, cistron nucleic acid sequences are provided in Table A. The NCBI reference sequences, gene IDs, and protein IDs in Table A are incorporated herein by reference. In embodiments, the cistron is a porcine cistron. In embodiments, the cistron is a human cistron. In embodiments, the cistron is a mouse cistron.

[0076] [Table 1-1]

[0077] [Table 1-2]

[0078] [Table 1-3]

[0079]

[0167] In embodiments, the polycistronic cassette includes a nucleic acid encoding beta-2 microglobulin (B2M) protein. The B2M gene encodes a serum protein found in association with major histocompatibility complex (MHC) class I heavy chains on the surface of almost all nucleated cells. In embodiments, the polycistronic cassette comprises a nucleic acid encoding a major histocompatibility complex class 1, E (HLA-E) protein. HLA-E protein belongs to HLA class I heavy chain paralogs. This class I molecule is a heterodimer (beta-2 microglobulin) containing a heavy and a light chain. In embodiments, the polycistronic cassette includes nucleic acids encoding both B2M and HLA-E proteins. In embodiments, the polycistronic cassette comprises a nucleic acid encoding a fusion of B2M and HLA-E proteins, referred to as a "B2M HLA-E fusion protein." In embodiments, the B2M HLA-E fusion protein has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least a sequence selected from the group consisting of SEQ ID NOs: 62, 66, and 105. Encoded by nucleic acid sequences that are 97%, at least 98%, at least 99%, or 100% identical. In embodiments, the B2M HLA-E fusion protein includes a peptide epitope. In embodiments, the peptide epitope is encoded by a nucleic acid having the sequence SEQ ID NO: 260 or SEQ ID NO: 261. B2M HLA-E fusion proteins containing peptide epitopes are referred to herein as "single chain trimers." In embodiments, the amino acid sequence of the epitope is VMAPRTLIL (SEQ ID NO: 197) or VMAPRTLFL (SEQ ID NO: 198). In embodiments, the amino acid sequence of the epitope is MAPRTLIL (SEQ ID NO: 251) or MAPRTLFL (SEQ ID NO: 252). In embodiments, the epitope is located at the N-terminus of the B2M-HLA-E fusion protein. A nucleic acid having a sequence represented by SEQ ID NO: 23, 24, 26, 201, 202, and 204 encodes a B2M HLA-E fusion protein comprising a peptide epitope having an amino acid sequence represented by SEQ ID NO: 251. SEQ ID NOs: 31, 32, 33, 34, 39, 30, 41, 42, 43, 44, 45, 46, 172, 173, 176, 177, 209-212, 216, 217, 219-226, 229, and 230 A nucleic acid having the sequence represented by encodes a B2M HLA-E fusion protein comprising a peptide epitope having the amino acid sequence represented by SEQ ID NO: 198. Nucleic acids having sequences represented by SEQ ID NOs: 25, 27-29, 35-37, 40, 203, 205-207, 213-215, and 218 have a peptide epitope having an amino acid sequence represented by SEQ ID NO: 197. encodes a B2M HLA-E fusion protein containing.

[0080]

[0168] In embodiments, the polycistronic cassette comprises a nucleic acid encoding a heme oxygenase-1 (HO1) protein. HO1 is an essential enzyme in heme metabolism that cleaves heme to form biliverdin and carbon monoxide, a putative neurotransmitter, which is subsequently converted to bilirubin by biliverdin reductase. Heme oxygenase activity is induced by its substrate heme and various non-heme substances. In embodiments, the nucleic acid encoding HO1 is isolated from Sus scrofa. In embodiments, HO1 is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% with a sequence selected from the group consisting of SEQ ID NOs: 63, 109, 165, 183, and 189. %, at least 98%, at least 99%, or 100% identical.

[0081]

[0169] In embodiments, the polycistronic cassette includes a nucleic acid encoding an A20 protein. A20 protein is a zinc finger protein and ubiquitin editing enzyme that has been shown to inhibit NF-kappaB activation and TNF-mediated apoptosis. The A20 protein has both ubiquitin ligase and deubiquitinase activities and is involved in cytokine-mediated immune and inflammatory responses. In embodiments, the nucleic acid encoding the A20 protein is isolated from Sus scrofa. In embodiments, the A20 protein has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least a sequence selected from the group consisting of SEQ ID NOS: 64-65, 104, 182, and 188. Encoded by nucleic acids having sequences that are 97%, at least 98%, at least 99%, or 100% identical.

[0082]

[0170] In embodiments, the polycistronic cassette comprises a nucleic acid encoding cluster of differentiation 39 (CD39) protein. The protein encoded by this gene is a plasma membrane protein that hydrolyzes extracellular ATP and ADP to AMP. In embodiments, CD39 has at least 80%, at least 85%, at least 90%, at least 95%, at least 96 sequences selected from the group consisting of SEQ ID NOs: 67-70, 106, 253-258, and 262-264. %, at least 97%, at least 98%, at least 99%, or 100% identical.

[0083]

[0171] In embodiments, the polycistronic cassette comprises a nucleic acid encoding cluster of differentiation 46 (CD46) protein. The protein encoded by this gene is a type I membrane protein and is a regulatory part of the complement system. The encoded protein has cofactor activity for the inactivation of complement components C3b and C4b by serum factor I, thereby protecting host cells from complement damage. In embodiments, CD46 is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% with a sequence selected from the group consisting of SEQ ID NOS: 71-76 and 185. , encoded by nucleic acids having sequences that are at least 99%, or 100% identical. In embodiments, CD46 comprises a splice site mutation in which the acceptor and donor sites have been removed. CD46_LL (SEQ ID NO: 71 or 258 or 254), CD46da1 (SEQ ID NO: 72), CD46da2 (SEQ ID NO: 73), CD46da (SEQ ID NO: 72, 73, 185, 200, or 256), and CD46i (SEQ ID NO: 74-75, SEQ ID NO: 255) means a CD46 protein with a splice site mutation. In embodiments, the polycistronic cassette comprising a gene encoding a CD46 protein encodes a CD46 isoform selected from CD46 C1, CD46 C2, CD46 BC1, CD46 BC2, and CD46 ABC1. The cistron encoding the CD46 BC1 protein isoform has the nucleic acid sequence of SEQ ID NO: 263. The cistron encoding the CD46 BC2 protein isoform has the nucleic acid sequence of SEQ ID NO: 264. These isoforms are described in the following references, which are incorporated herein in their entirety. Human Genetics volume 136, pages 421-435 (2017).

[0084]

[0172] In embodiments, the polycistronic cassette comprises a nucleic acid encoding cluster of differentiation 47 (CD47) protein. The CD47 protein is a membrane protein that is involved in the increase in intracellular calcium concentration that occurs upon attachment of cells to the extracellular matrix. The CD47 protein is also a receptor for the C-terminal cell-binding domain of thrombospondin and may play a role in membrane trafficking and signal transduction. The CD47 protein contains an IgV domain, a transmembrane domain, and a C-terminal domain. There are four isoforms in the C-terminal domain of the CD47 protein: isoform 1, isoform 2, isoform 3, and isoform 4. Isoform 1 is 4 amino acids long and is expressed in epithelial and endothelial cells. Isoform 2 is 16 amino acids long and is the most abundantly expressed isoform of CD47. Isoform 2 is expressed in hematopoietic, endothelial, and epithelial cells. Isoform 3 is 23 amino acids long and isoform 4 is 36 amino acids long. Isoforms 3 and 4 are expressed in neurons, intestine, and testis. In embodiments, CD47 has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least a sequence selected from the group consisting of SEQ ID NOS: 77-83, 180, and 259. Encoded by nucleic acids having sequences that are 98%, at least 99%, or 100% identical. In embodiments, CD47 is isoform 1, 2, 3, or 4. In embodiments, CD47 is CD47 isoform 2 (CD47-2). In embodiments, CD47-2 is encoded by a nucleic acid having a sequence selected from any one of SEQ ID NOs: 78, 80, 83, and 180. In embodiments, CD47 is CD47 isoform 1 (CD47-1). In embodiments, CD47-1 is encoded by a nucleic acid having the sequence SEQ ID NO: 259. In embodiments, the polycistronic cassette comprises a nucleic acid encoding a CD47 protein having an S64A mutation, a S79A mutation, or a combination thereof compared to SEQ ID NO: 201. The following papers describe the S64A and S79A mutations and are incorporated herein by reference in their entirety. J Biol Chem. 2011 Apr 29;286(17):14991-5002.

[0085]

[0173] In embodiments, the polycistronic cassette includes a nucleic acid encoding cluster of differentiation 55 (CD55) protein. This gene encodes a glycoprotein involved in the regulation of the complement cascade. Binding of the encoded protein to the complement protein accelerates the decay of the complement protein, thereby interfering with the cascade and preventing damage to the host cell. In embodiments, the CD55 protein is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, with a sequence selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184. Encoded by nucleic acids having sequences that are at least 98%, at least 99%, or 100% identical.

[0086]

[0174] In embodiments, the polycistronic cassette comprises a nucleic acid encoding cluster of differentiation 59 (CD59) protein. CD59 protein is a cell surface glycoprotein that controls complement-mediated cell lysis and is involved in signal transduction in lymphocytes. The CD59 protein is a potent inhibitor of the complement membrane attack complex and binds complement C8 and / or C9 during the assembly of this complex, thereby providing the necessary C9 for pore formation by osmotic lysis. inhibits the incorporation of multiple copies of into the complex. In embodiments, CD59 is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, with a sequence selected from the group consisting of SEQ ID NO: 86 and SEQ ID NO: 108. Encoded by nucleic acids having sequences that are at least 99%, or 100% identical.

[0087]

[0175] In embodiments, the polycistronic cassette includes a nucleic acid encoding a CTLA-4 protein. In embodiments, the nucleic acid encodes the extracellular domain of CTLA-4 protein. In embodiments, the extracellular domain of the CTLA-4 protein comprises an L104E mutation, an A29Y mutation, or both relative to SEQ ID NO: 199. In embodiments, the nucleic acid encoding CTLA-4 includes a nucleic acid encoding an immunoglobulin or fragment thereof. In embodiments, the fragment of the immunoglobulin is a kappa light chain or a lambda light chain. In embodiments, the fragment is an immunoglobulin heavy chain. In embodiments, the fragment is a CH1, CH2, CH3, or CH4 domain of an immunoglobulin globulin heavy chain. In embodiments, the fragment is an immunoglobulin variable heavy or light domain. In embodiments, the nucleic acid encoding the CLTA-4 protein or fragment thereof and the immunoglobulin or fragment thereof is LEA29Y. In embodiments, the nucleic acid encoding the CLTA-4 protein or fragment thereof and the immunoglobulin or fragment thereof comprises the extracellular domain of CTLA-4 (SEQ ID NO: 199) having an L104E mutation and an A29Y mutation relative to SEQ ID NO: 199. Contains proteins and the hinge, CH2, and CH3 domains of human immunoglobulin 1. The nucleic acid sequence of LEA29Y is as follows: VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 196). LEA29Y binds with high affinity to human B7.1 / CD80 and B7.2 / CD86 and is therefore a potent inhibitor of T cell costimulation through this pathway. The following references describe LEA29Y and are incorporated herein by reference in their entirety. WO 2001 / 092337 and Wolf-van Buerck et al. Scientific Reports. 7: 3572 (2017). In embodiments, the CTLA-4 protein is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, with a sequence selected from the group consisting of SEQ ID NO: 87, SEQ ID NO: 88, and SEQ ID NO: 186. Encoded by nucleic acids having sequences that are at least 97%, at least 98%, at least 99%, or 100% identical.

[0088]

[0176] In embodiments, the polycistronic cassette comprises a nucleic acid encoding programmed cell death 1 ligand 1 (PD-L1) protein. PD-L1 protein is an immunoinhibitory receptor ligand expressed by hematopoietic cells and non-hematopoietic cells such as T cells and B cells, as well as various types of tumor cells. PD-L1 protein is a type I transmembrane protein with immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T cell activation and cytokine production. In embodiments, the PD-L1 protein has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% with a sequence selected from the group consisting of SEQ ID NOS: 89-91. %, at least 99%, or 100% identity.

[0089]

[0177] In embodiments, the polycistronic cassette comprises a nucleic acid encoding an endothelial cell protein C receptor (EPCR) protein. The gene encoding EPCR is called PROCR. EPCR binds to activated protein C. In embodiments, the EPCR is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% with a sequence selected from the group consisting of SEQ ID NOs: 92, 93, and 181. , encoded by nucleic acids with at least 99%, or 100% identity.

[0090]

[0178] In embodiments, the polycistronic cassette includes a nucleic acid encoding a tissue factor pathway inhibitor (TFPI) protein. The protein encoded by TFPI inhibits factor X and inhibits the activity of VIIa / tissue factor. In embodiments, the TFPI has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least a sequence selected from the group consisting of SEQ ID NOS: 94-96, 103, and 187. Encoded by nucleic acids with 98%, at least 99%, or 100% identity. In embodiments, TFPI is a fusion between TFPI, the CD4 transmembrane domain (NM_000616) or a fragment thereof, and the cytoplasmic tail of P-selectin (NM_003005) or a fragment thereof. In embodiments, TFPI lacks the P-selectin tail and is referred to herein as TFPI (ΔP-Sel). In an embodiment, the transmembrane domain of CD4 comprises amino acids 166-435 of CD4 and an NCBI RefSeq ID of NM_000616. In an embodiment, the cytoplasmic tail of P-selectin comprises amino acids 797-830 of P-selectin and the NCBI RefSeq ID of NM_003005.

[0091]

[0179] In embodiments, the polycistronic cassette includes a nucleic acid encoding thrombomodulin (THBD) protein. The THBD protein is an endothelial cell-specific type I membrane receptor that binds thrombin. This binding results in activation of protein C, which degrades clotting factors Va and VIIIa and reduces the amount of thrombin produced. In embodiments, the THBD protein has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% with a sequence selected from the group consisting of SEQ ID NOS: 97-102, 166, 265-266. , encoded by nucleic acids having at least 98%, at least 99%, or 100% identity. In embodiments, the gene encoding the THBD protein is "THBDda." THBDda is a cistron encoding THBD containing a splice site mutation. In embodiments, the THBDda cistron has at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% with a sequence selected from the group consisting of SEQ ID NOS: 99-102, 166, and 266. , have sequences that are at least 98%, at least 99%, or 100% identical.

[0092]

[0180] In embodiments, the polycistronic cassette comprises a nucleic acid encoding an X-linked inhibitor of apoptosis (XIAP) protein. In embodiments, the XIAP is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence of SEQ ID NO: 110. encoded by a nucleic acid having This gene encodes a protein that belongs to the family of apoptosis suppressor proteins.

[0093]

[0181] In embodiments, any cistron described herein includes a start codon or a stop codon. Polycistronic cassettes are organized so that transcription proceeds from the 5' prime end to the 3' end of the cassette to facilitate expression of each cistron. To facilitate polycistronic expression, start or stop codons may be added or removed from individual cistrons.

[0094]

[0182] In embodiments, a polycistronic cassette includes two or more cistrons that share a function, such as genes involved in complement regulation, coagulation, innate immunity, inflammation and apoptosis, and cellular immunity. In embodiments, a polycistronic cassette includes two or more cistrons with different functions.

[0095]

[0183] In embodiments, the nucleic acids described herein are coagulation cassettes, complement regulation cassettes, complement regulation and inflammation and apoptosis cassettes, innate immunity cassettes, innate immunity and inflammation and apoptosis cassettes, inflammation and apoptosis cassettes, one or more polycistronic cassettes selected from the group consisting of body regulatory and innate immunity cassettes, cellular immunity and coagulation cassettes, apoptosis and coagulation cassettes, and apoptosis and cellular immunity cassettes.

[0096]

[0184] In embodiments, the coagulation cassette includes one or more cistrons selected from the group consisting of THBD, TFPI, CD39, and PROCR. In embodiments, the coagulation cassette includes one or more cistrons selected from THBD and TFPI. In embodiments, the coagulation cassette includes one or more cistrons selected from THBD, TFPI, and CD39. In embodiments, the coagulation cassette includes one or more cistrons selected from PROCR and THBD. In embodiments, the coagulation cassette includes one or more cistrons selected from TFPI, PROCR, and THBD.

[0097]

[0185] In embodiments, the complement control cassette comprises one or more cistrons selected from the group consisting of CD46, C59, and CD55. In embodiments, the complement control cassette comprises one or more cistrons selected from CD46 and CD59. In embodiments, the complement control cassette comprises one or more cistrons selected from CD46 and CD55. In embodiments, the complement control cassette comprises one or more cistrons selected from CD46, CD55, and CD59. In embodiments, the complement control cassette comprises one or more cistrons selected from CD55 and CD59. In embodiments, a nucleic acid comprising a complement control cassette prevents complement deposition. For example, FIG. 18D shows that expression of a nucleic acid containing cistron CD46, CD55, CD59, or a combination thereof reduces deposition of complement protein C3b compared to expression of a nucleic acid lacking cistron CD46, CD55, and CD59. It is shown that.

[0098]

[0186] In embodiments, the complement regulation and inflammation and apoptosis cassette comprises one or more cistrons selected from the group consisting of CD46, CD55, CD59, A20, HO1, and PD-L1. In embodiments, the complement control and inflammation and apoptosis cassette comprises one or more cistrons selected from CD46, CD55, CD59, A20, HO1, and PD-L1. In embodiments, the complement regulation and inflammation and apoptosis cassette comprises one or more cistrons selected from CD46, CD55, A20, and HO1.

[0099]

[0187] In embodiments, the innate immunity cassette comprises one or more cistrons selected from the group consisting of B2M, HLA-E, B2M HLA-E fusion protein, CD47, and combinations thereof. In embodiments, the innate immunity cassette includes a cistron encoding a B2M HLA-E fusion protein and a CD47 cistron.

[0100]

[0188] In embodiments, the innate immunity and inflammation and apoptosis cassette is one selected from the group consisting of B2M, HLA-E, B2M HLA-E fusion protein, CD47, A20, HO1, PD-L1, and combinations thereof. or contain multiple cistrons. In embodiments, the innate immune and inflammation and apoptosis cassette is one of the following: B2M cistron, HLA-E cistron, cistron encoding a B2M HLA-E fusion protein, CD47 cistron, A20 cistron, HO1 cistron, and PD-L1 cistron or more than one. In embodiments, the innate immunity and inflammation and apoptosis cassette comprises one or more cistrons selected from B2M, HLA-E, B2M HLA-E fusion protein, CD47, A20, and HO1. In embodiments, the innate immunity and inflammation and apoptosis cassette comprises one or more cistrons selected from cistrons encoding B2M HLA-E fusion protein, CD47, A20, and HO1.

[0101]

[0189] In embodiments, the inflammation and apoptosis cassette comprises one or more cistrons selected from the group consisting of A20, HO1, and PD-L1. In embodiments, the inflammation and apoptosis cassette comprises one or more cistrons selected from A20 and HO1. In embodiments, the inflammation and apoptosis cassette comprises one or more cistrons selected from A20 and PD-L1.

[0102]

[0190] In embodiments, the complement control and innate immunity cassette comprises one or more cistrons selected from CD46, CD55, CD47, B2M, HLA-E, B2M HLA-E fusion protein, and combinations thereof. In embodiments, the complement control and innate immunity cassette comprises one or more cistrons selected from CD46, CD55, and CD47.

[0103]

[0191] In embodiments, the cellular immunity and coagulation cassette comprises one or more cistrons selected from LEA29Y, CD39, TFPI, THBD, and PROCR. In embodiments, the cellular immunity and coagulation cassette includes a CTLA-4 (eg, LEA29Y) cistron and a CD39 cistron.

[0104]

[0192] In embodiments, the apoptosis and coagulation cassette comprises one or more cistrons selected from the group consisting of THBD, TFPI, CD39, PROCR, and XIAP. In embodiments, the apoptosis and coagulation cassette includes a XIAP cistron and a CD39 cistron.

[0105]

[0193] In embodiments, the apoptosis and cellular immunity cassette comprises one or more cistrons selected from the group consisting of A20, PD-L1, HO1, and CTLA-4 (eg, LEA29Y). In embodiments, the apoptosis and cellular immunity cassette includes A20 and CTLA-4 (eg, LEA29Y) cistrons. In embodiments, the apoptosis and cellular immunity cassette includes the A20 and HO1 cistrons. In embodiments, the A20 cistron, the HO1 cistron, or both are derived from Sus scrofa.

[0106]

[0194] In embodiments, the coagulation and innate immunity cassette is from the group consisting of a THBD cistron, a TFPI cistron, a CD39 cistron, a PROCR cistron, a B2M cistron, an HLA-E cistron, a cistron encoding a B2M HLA-E fusion protein, and a CD47 cistron. Contains one or more selected cistrons. In embodiments, the coagulation and innate immunity cassette includes a THBD cistron, a CD47 cistron, and a PROCR cistron.

[0107]

[0195] In embodiments, the nucleic acid comprises a first polycistronic cassette, a second polycistronic cassette, and a third polycistronic cassette, the first polycistronic cassette being 5 of the second polycistronic cassette. The second polycistronic cassette is located 5' of the third polycistronic cassette. In embodiments, the coagulation cassette is a first, second, or third polycistronic cassette. In embodiments, the complement control cassette is a first, second, or third polycistronic cassette. In embodiments, the complement control and inflammation and apoptosis cassette is the first, second, or third polycistronic cassette. In embodiments, the innate immunity cassette is a first, second, or third polycistronic cassette. In embodiments, the innate immunity and inflammation and apoptosis cassette is the first, second, or third polycistronic cassette. In embodiments, the inflammation and apoptosis cassette is a first, second, or third polycistronic cassette. In embodiments, the complement control and innate immunity cassette is a first, second, or third polycistronic cassette. In embodiments, the cellular immunity and coagulation cassette is a first, second, or third polycistronic cassette. In embodiments, the apoptosis and coagulation cassette is a first, second, or third polycistronic cassette. In embodiments, the apoptosis and cellular immunity cassette is a first, second, or third polycistronic cassette. In embodiments, the coagulation and innate immunity cassette is a first, second, or third polycistronic cassette.

[0108]

[0196] In embodiments, the nucleic acid comprises a first polycistronic cassette, a second polycistronic cassette, a third polycistronic cassette, and a fourth polycistronic cassette, wherein the first polycistronic cassette The second polycistronic cassette is located 5' to the third polycistronic cassette, and the third polycistronic cassette is located 5' to the fourth polycistronic cassette. Located on the 5' side of the sex cassette. In embodiments, the coagulation cassette is a first, second, third, or fourth polycistronic cassette. In embodiments, the complement control cassette is a first, second, third, or fourth polycistronic cassette. In embodiments, the complement control and inflammation and apoptosis cassette is a first, second, third, or fourth polycistronic cassette. In embodiments, the innate immunity cassette is a first, second, third, or fourth polycistronic cassette. In embodiments, the innate immunity and inflammation and apoptosis cassette is the first, second, third, or fourth polycistronic cassette. In embodiments, the inflammation and apoptosis cassette is a first, second, third, or fourth polycistronic cassette. In embodiments, the complement control and innate immunity cassette is a first, second, third, or fourth polycistronic cassette. In embodiments, the cellular immunity and coagulation cassette is a first, second, third, or fourth polycistronic cassette. In embodiments, the apoptosis and coagulation cassette is a first, second, third, or fourth polycistronic cassette. In embodiments, the apoptosis and cellular immunity cassette is a first, second, third, or fourth polycistronic cassette. In embodiments, the coagulation and innate immunity cassette is a first, second, third, or fourth polycistronic cassette.

[0109]

[0197] In embodiments, nucleic acids comprising multiple polycistronic cassettes include a coagulation cassette, a complement control cassette, and an innate immunity cassette. In embodiments, the coagulation cassette is located 5' to the complement control cassette. In embodiments, the complement control cassette is located 5' to the innate immunity cassette. In embodiments, the coagulation cassette is located 5' to the complement control cassette, and the complement control cassette is located 5' to the innate immunity cassette. In embodiments, the coagulation cassette is located 5' to the innate immunity cassette, and the innate immunity cassette is located 5' to the complement control cassette. In embodiments, the innate immunity cassette is located 5' to the coagulation cassette, and the coagulation cassette is located 5' to the complement control cassette.

[0110]

[0198] In embodiments, nucleic acids comprising multiple polycistronic cassettes include coagulation cassettes, complement control cassettes, and innate immunity and inflammation and apoptosis cassettes. In embodiments, the coagulation cassette is located 5' to the complement control cassette, and the complement control cassette is located 5' to the innate immunity and apoptosis cassette. In embodiments, the complement control cassette is located 5' to the innate immunity and apoptosis cassette. In embodiments, the coagulation cassette is located 5' to the complement control cassette.

[0111]

[0199] In embodiments, nucleic acids comprising multiple polycistronic cassettes include coagulation cassettes, inflammation and apoptosis cassettes, and complement regulation and innate immunity cassettes. In embodiments, the coagulation cassette is located 5' to the inflammation and apoptosis cassette, and the inflammation and apoptosis cassette is located 5' to the complement control and innate immunity cassette. In embodiments, the coagulation cassette is located 5' to the inflammation and apoptosis cassette. In embodiments, the inflammation and apoptosis cassette is located 5' to the complement control and innate immunity cassette.

[0112]

[0200] In embodiments, nucleic acids comprising multiple polycistronic cassettes include coagulation cassettes, complement control and inflammation and apoptosis cassettes, and innate immunity cassettes. In embodiments, the innate immunity is located 5' to the coagulation cassette, and the coagulation cassette is located 5' to the complement control and inflammation and apoptosis cassettes.

[0113]

[0201] In embodiments, nucleic acids comprising multiple polycistronic cassettes include coagulation cassettes, complement control cassettes, innate immunity cassettes, and cellular immunity and coagulation cassettes. In embodiments, the coagulation cassette is located 5' to the innate immunity cassette. In embodiments, the innate immunity cassette is located 5' to the cellular immunity and coagulation cassette. In embodiments, the cellular immunity and coagulation cassette is located 5' to the complement control cassette. In embodiments, the coagulation cassette is located 5' to the innate immunity cassette, the innate immunity cassette is located 5' to the cellular immunity and coagulation cassette, and the cellular immunity and coagulation cassette is 5' to the complement control cassette. Located on the side.

[0114]

[0202] In embodiments, nucleic acids comprising multiple polycistronic cassettes include coagulation cassettes, complement control cassettes, innate immunity cassettes, and apoptosis and inflammation cassettes. In embodiments, the coagulation cassette is located 5' to the innate immunity cassette, the innate immunity cassette is located 5' to the apoptosis and inflammation cassette, and the apoptosis and inflammation cassette is located 5' to the complement control cassette. positioned. In embodiments, the coagulation cassette is located 5' to the innate immunity cassette, the innate immunity cassette is located 5' to the complement control cassette, and the complement control cassette is located 5' to the apoptosis and inflammation cassette. positioned.

[0115]

[0203] In embodiments, nucleic acids comprising multiple polycistronic cassettes include coagulation cassettes, complement control cassettes, innate immunity cassettes, and apoptosis and coagulation cassettes. In embodiments, the coagulation cassette is located 5' to the innate immunity cassette, the innate immunity cassette is located 5' to the apoptosis and coagulation cassette, and the cellular immunity and coagulation cassette is located 5' to the complement control cassette. It is located in

[0116]

[0204] In embodiments, nucleic acids comprising multiple polycistronic cassettes include coagulation cassettes, complement control cassettes, innate immunity cassettes, and apoptosis and cellular immunity cassettes. In embodiments, the coagulation cassette is located 5' to the innate immunity cassette, the innate immunity cassette is located 5' to the apoptotic and cellular immunity cassette, and the apoptotic and cellular immunity cassette is 5' to the complement control cassette. Located on the side.

[0117]

[0205] In embodiments, nucleic acids comprising multiple polycistronic cassettes include coagulation and innate immunity cassettes, apoptosis and cellular immunity cassettes, and complement control cassettes. In embodiments, the coagulation and innate immunity cassette is located 5' to the apoptosis and cellular immunity cassette, and the apoptosis and cellular immunity cassette is located 5' to the complement control cassette.

[0118]

[0206] In embodiments, the nucleic acid comprising at least one polycistronic cassette is linked to one or more promoters, such as about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 , 14, 15, 16, 17, or 18 promoters. In embodiments, the nucleic acid comprising at least one polycistronic cassette comprises a different promoter for each polycistronic cassette. A promoter is a DNA sequence that defines where transcription of a polycistronic cassette by RNA polymerase begins. In embodiments, the promoter is derived from a pig gene. In embodiments, the promoter is derived from a mouse gene. In embodiments, the promoter is derived from a human gene. In embodiments, the promoter is the eukaryotic translation elongation factor 1 alpha 1 (abbreviated as "EF1α1" or "EEF1α1") promoter. The EF1α1 promoter is a constitutive promoter. In embodiments, the promoter is a CAG promoter. The CAG promoter contains a cytomegalovirus enhancer fused to the chicken beta actin promoter and the splice acceptor of the rabbit beta globin gene. In embodiments, the promoter is the actin gamma 1 (ACTG1) promoter. In embodiments, the promoter is the heat shock protein family A member 8 (HSPA8) promoter. In embodiments, the promoter is the ubiquitin C (UBC) promoter. In embodiments, the promoter is the intracellular adhesion molecule 2 (ICAM2) promoter. In embodiments, the promoter includes the EF1α1, CAG, ACTG1, HSPA8, UBC, or ICAM2 promoter. In embodiments, the promoter includes an extension at the 5' or 3' end. In embodiments, the extension is an intron or a fragment thereof. Introns may be inherited from endogenous promoter genes (eg, EF1α1, CAG, ACTG1, HSPA8, UBC, or ICAM2) or may be provided from another source.

[0119]

[0207] In embodiments, the promoter includes a CpG island. CpG islands are regions with high GC content and high density of CpG dinucleotides. In embodiments, the CpG island is located 5' to the exonic sequences of the promoter. In embodiments, the CpG island has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% GC Contains content. In embodiments, the CpG island comprises about 500 base pairs (bp) to about 3 kilobase pairs (kb). In embodiments, the CpG island comprises about 500 bp to about 5 kb. In embodiments, the CpG island comprises about 1 kb to about 3 kb. For example, a CpG island can be at least about 500 bp, at least about 1 kb, at least about 1.5 kb, at least about 2 kb, at least about 2.5 kb, at least about 3 kb, at least about 3.5 kb, at least about 4 kb, at least about 4.5 kb, or at least about 5 kb. may include. In contrast, standard promoters are approximately 100-200 base pairs in length. In embodiments, the CpG island comprises a ratio of observed to expected number of CpG dinucleotides greater than 0.60. In embodiments, the CpG island comprises unmethylated CpG dinucleotides. In embodiments, the CpG islands include methylated CpG dinucleotides. The following references describe CpG islands. J Mol Bio. 1987 Jul 20;196(2):261-82; Nat Rev Mol Cell Biol. 2018 Oct; 19(10): 621-637; Biochem Biophys Res Commun. 2009 May 15; 382(4): 643 -645. Each of these references is incorporated herein in its entirety.

[0120]

[0208] Non-limiting examples of promoters included within the nucleic acids or polycistronic cassettes described herein are shown in Table B. In embodiments, the promoter is at least 80%, at least 85%, at least 90%, Includes nucleic acid sequences having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity.

[0121] [Table 2]

[0122]

[0209] In embodiments, each promoter within the nucleic acid is distinct. In embodiments, the first promoter and second promoter in the nucleic acid are the same. In embodiments, each polycistronic cassette of nucleic acids includes a different promoter. In embodiments, the promoter is a forward promoter and is located on the sense strand. In embodiments, the promoter is a reverse promoter and is located on the antisense strand.

[0123]

[0210] In Figures 1A-D, 2A-J, 3A-3C, 4A-4H, 5A-5F, and 6, forward promoters are represented by forward-pointing arrows, and reverse promoters are represented by reverse-pointing arrows.

[0124]

[0211] In embodiments, any of the cassettes described herein may include any promoter of Table B. Exemplary arrangements of promoters and polycistronic cassettes are found in FIGS. 1A-D, 2A-J, 3A-3C, 4A-4H, 5A-5F, and 6.

[0125]

[0212] In embodiments, provided herein are nucleic acids that include, 5' to 3', a first polycistronic cassette, a second polycistronic cassette, and a third polycistronic cassette. In embodiments, the first polycistronic cassette and the second polycistronic cassette are under the control of promoters that initiate cassette transcription on different strands. For example, a first polycistronic cassette may contain a forward promoter and a second polycistronic cassette may contain a reverse promoter. Alternatively, the first polycistronic cassette may contain a reverse promoter and the second polycistronic cassette may contain a forward promoter. In embodiments, the second polycistronic cassette and the third polycistronic cassette are under the control of promoters that initiate cassette transcription on different strands. For example, the second polycistronic cassette may contain a forward promoter and the third polycistronic cassette may contain a reverse promoter. Alternatively, the second polycistronic cassette may contain a reverse promoter and the third polycistronic cassette may contain a forward promoter. In embodiments, the first polycistronic cassette is under the control of a forward promoter, the second polycistronic cassette is under the control of a reverse promoter, and the third polycistronic cassette is under the control of a forward promoter. be. In embodiments, the first polycistronic cassette is under the control of a reverse promoter, the second polycistronic cassette is under the control of a forward promoter, and the third polycistronic cassette is under the control of a reverse promoter. be.

[0126]

[0213] In embodiments, the nucleic acids herein include, 5' to 3', a first polycistronic cassette, a second polycistronic cassette, a third polycistronic cassette, and a fourth polycistronic cassette. provided by. In embodiments, the first polycistronic cassette and the second polycistronic cassette are under the control of promoters that initiate cassette transcription on different strands. For example, a first polycistronic cassette may contain a forward promoter and a second polycistronic cassette may contain a reverse promoter. Alternatively, the first polycistronic cassette may contain a reverse promoter and the second polycistronic cassette may contain a forward promoter. In embodiments, the second polycistronic cassette and the third polycistronic cassette are under the control of promoters that initiate cassette transcription on different strands. For example, the second polycistronic cassette may contain a forward promoter and the third polycistronic cassette may contain a reverse promoter. Alternatively, the second polycistronic cassette may contain a reverse promoter and the third polycistronic cassette may contain a forward promoter. In embodiments, the third polycistronic cassette and the fourth polycistronic cassette are under the control of promoters that initiate cassette transcription on different strands. For example, the third polycistronic cassette may contain a forward promoter and the fourth polycistronic cassette may contain a reverse promoter. Alternatively, the third polycistronic cassette may contain a reverse promoter and the fourth polycistronic cassette may contain a forward promoter. In embodiments, the first polycistronic cassette is under the control of a reverse promoter, the second polycistronic cassette is under the control of a forward promoter, and the third polycistronic cassette is under the control of a reverse promoter. and a fourth polycistronic cassette is under the control of a forward promoter. In embodiments, the first polycistronic cassette is under the control of a forward promoter, the second polycistronic cassette is under the control of a reverse promoter, and the third polycistronic cassette is under the control of a forward promoter. A fourth polycistronic cassette is under the control of a reverse promoter.

[0127]

[0214] In embodiments, the nucleic acid comprising at least one polycistronic cassette comprises one or more polyA sequences. In embodiments, the polyA sequence is derived from the human growth hormone (GH) gene. In embodiments, the polyA sequence is derived from the beta globin (HBB) gene. In embodiments, polyA is derived from the SV40 virus. In embodiments, the poly A sequence is synthetic poly A (pA). Exemplary polyA sequences are found in Table C. In embodiments, any of the cassettes described herein may include any polyA sequence of Table C. In embodiments, the polyA sequence has at least 80%, at least 85%, at least 90%, at least 95 %, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity.

[0128]

[0215] Exemplary arrangements of polyA sequences within polycistronic cassettes are found in FIGS. 1A-D, 2A-J, 3A-3C, 4A-4H, 5A-5F, and 6. In embodiments, the nucleic acids described herein include one or more polyA sequences of Table C located on the 5' side of the polycistronic cassette. In embodiments, the polyA sequence includes a terminator. In embodiments, the nucleic acids described herein include one or more polyA sequences of Table C located on the 3' side of the polycistronic cassette.

[0129] [Table 3]

[0130]

[0216] In embodiments, the polyA sequence comprises synthetic pA (SEQ ID NO: 117 or SEQ ID NO: 125) and the transcription terminator ACTB (SEQ ID NO: 158). In embodiments, the polyA sequence includes a synthetic pA and a transcription terminator. In embodiments, the transcription terminator is ACTB. In embodiments, ACTB has the nucleic acid sequence of SEQ ID NO: 118. In embodiments, the presence of a polyA sequence and a terminator sequence terminates transcription of the polycistronic cassette. In embodiments, transcription of a polycistronic cassette is more effectively stopped when the polycistronic cassette includes both a polyA sequence and a terminator, as compared to when the polycistronic cassette includes only a polyA sequence. be done. In embodiments, the terminator is selected from any terminator sequence described in the following documents, which are incorporated herein by reference in their entirety: Nojima et al. Cell Reports 3, 1080-1092 (2013).

[0131]

[0217] In embodiments, the nucleic acid comprises a polyA sequence and a transcription terminator (eg, ACTB) on the 5' or 3' side of the first or last polycistronic cassette in the nucleic acid. Inclusion of a transcription terminator on the 5' or 3' side of the first or last polycistronic cassette terminates transcription mediated by the upstream genomic promoter. Therefore, only that polycistronic cassette is transcribed.

[0132]

[0218] In embodiments, the cistrons in a polycistronic cassette are separated by nucleic acids encoding 2A polypeptides (also referred to herein as "2A peptides"). The term "2A polypeptide" refers to a self-cleaving peptide that induces ribosome skipping during translation of proteins within cells. In embodiments, the polycistronic cassette comprises one or more 2A polypeptides selected from the group consisting of E2A, F2A, P2A, and T2A polypeptides. In embodiments, the polycistronic cassette encodes an E2A polypeptide derived from a nucleic acid sequence selected from SEQ ID NOs: 1 and 9. In embodiments, the polycistronic cassette comprises a F2A polypeptide encoded by a nucleic acid having a sequence selected from SEQ ID NOs: 2 and 10. In embodiments, the polycistronic cassette comprises a P2A polypeptide encoded by a nucleic acid having a sequence selected from SEQ ID NOs: 3-6, 12-14, and 169. In embodiments, the polycistronic cassette includes a T2A polypeptide encoded by a nucleic acid having SEQ ID NO:11. Liu et al. describe additional 2A polypeptides and are incorporated herein by reference in their entirety. Liu et al. Scientific Reports, volume 7, article 2193 (2017). In embodiments, each nucleic acid encoding a 2A polypeptide among the nucleic acids described herein encodes a different amino acid sequence.

[0133]

[0219] In embodiments, when a polycistronic cassette containing cistrons separated by 2A peptides is expressed, the expressed cistrons have an N-terminal proline, a C-terminal fusion of the 2A peptide or fragment thereof, or a combination thereof. may be included. In embodiments, the expressed cistron comprises a C-terminal fusion of the 2A peptide, where the 2A peptide lacks the C-terminal proline.

[0134]

[0220] In embodiments, when a cistron located at the 5' end of the 2A peptide is expressed, the expressed cistron comprises a C-terminal fusion of the 2A peptide, and the 2A peptide lacks the C-terminal proline. In embodiments, when a cistron located at the 3' end of the 2A peptide is expressed, the expressed cistron includes an N-terminal proline. In embodiments, when the cistron is located at the 5' end of the first 2A peptide and at the 3' end of the second 2A peptide, the expressed cistron contains a fusion of the N-terminal proline and the C-terminus of the 2A peptide. The C-terminal fusion of the 2A peptide lacks the C-terminal proline of the 2A peptide.

[0135]

[0221] In embodiments, the cistrons in a polycistronic cassette are separated by internal ribosome entry sites (IRES). In embodiments, a nucleic acid described herein comprises one or more IRES having a nucleic acid sequence of any one of SEQ ID NOs: 11, 194, and 195. In embodiments, when a polycistronic cassette containing cistrons separated by IRES is expressed, the cistrons expressed are wild-type proteins.

[0136]

[0222] In embodiments, the nucleic acids provided herein include a first insulator sequence 5' to a 5' polycistronic cassette and a second insulator sequence 3' to a 3' polycistronic cassette. Contains Slater array. In embodiments, the insulator is HS4. In embodiments, HS4 has a sequence selected from any one of SEQ ID NOs: 49-58, 163, and 164. In embodiments, HS4 prevents interference with transcription by promoters at genomic integration sites.

[0137]

[0223] In embodiments, the nucleic acids provided herein comprise a first inverted terminal repeat (ITR) located 5' to the 5' polycistronic cassette and having the sequence of SEQ ID NO: 17 or 18; '3' to the polycistronic cassette and comprises a second ITR having the sequence SEQ ID NO: 15 or 16. Inclusion of ITRs in the nucleic acids provided herein allows for integration of the nucleic acids into a genome (eg, a pig genome) via piggyback transposon-mediated gene transfer.

[0138]

[0224] In embodiments, the nucleic acids provided herein have a first loxP site located 5' to the 5' polycistronic cassette and a second loxP site located 3' to the 3' polycistronic cassette. Contains the loxP site. LoxP sites are nucleic acid sequences that mediate mitotic recombination by recombinases. Inclusion of a loxP site in the nucleic acids provided herein allows integration of the nucleic acid into a genome (eg, a pig genome) via recombinases. Maizels et al. describe genome engineering with loxP and recombinases and are incorporated herein by reference in their entirety. Maizels et al. J Immunol. 2013; 191(1). In embodiments, the first or second loxP site has a nucleic acid sequence selected from SEQ ID NOs: 146-150 and 244. In embodiments, the region between the first loxP and second loxP sites of the nucleic acids described herein is inserted into the genome by recombination.

[0139]

[0225] In embodiments, the nucleic acids provided herein include 5' and 3' guide RNA (gRNA) target sequences (eg, FOS_sg1 or AAVS_sg3 of FIGS. 5A-F). The gRNA target sequence is recognized by a guide RNA and a nuclease (eg, Cas9). The region between the 5' guide RNA target sequence and the 3' gRNA sequence is cleaved by the guide RNA and nuclease. In embodiments, a portion of a nucleic acid comprising a multiple polycistronic cassette described herein between a 5' and 3' gRNA target sequence is integrated into a cell, tissue, organ, or animal. In embodiments, the nucleic acid sequence located between the 5'gRNA target sequence and the 3'gRNA target sequence is cloned into a cell, tissue, organ, or animal by homology independent target integration (HITI). Suzuki et al. describe in vivo genome editing using HITI and are incorporated herein by reference in their entirety. Suzuki et al. Nature. 2016 Dec 1; 540(7631): 144-149. In embodiments, the nucleic acid sequence located between the 5' and 3' gRNA target sequences is cloned into a cell, tissue, organ, or animal by CRISPR-mediated homologous recombination repair (HDR). Hsu et al. describe in vivo genome editing using CRISPR-mediated HDR, and is incorporated herein by reference in its entirety. Hsu et al. Cell 157, 1262-1278 (2014). In embodiments, the 5'gRNA target sequence is FOS (SEQ ID NO: 47) or AAVS (SEQ ID NO: 48). In embodiments, the 3'gRNA target sequence is FOS (SEQ ID NO: 47) or AAVS (SEQ ID NO: 48).

[0140]

[0226] Exemplary arrangements of loxP sites, insulator sequences, guide RNA target sequences, and polycistronic cassettes are presented in Table D.

[0141] [Table 4-1]

[0142] [Table 4-2]

[0143]

[0227] In embodiments, the nucleic acids described herein further include an initiation codon. In embodiments, the nucleic acids described herein further include a stop codon. In embodiments, a stop codon is found at the 3' end of each polycistronic cassette. In embodiments, a nucleic acid described herein comprises a Kozak sequence. In embodiments, the Kozak sequence is the nucleic acid of SEQ ID NO: 59 or 61.

[0144]

[0228] In embodiments, the nucleic acids described herein include one or more ubiquitous chromatin opening elements (UCOE). Neville et al. describe UCOE, which is incorporated herein by reference in its entirety. Neville et al. Biotechnology Advances 35 (2017) 557-564. In embodiments, polycistronic cassettes of the nucleic acids described herein are separated by UCOEs. In embodiments, UCOE Can 6-3, A2CBX3, CBX3, CBX3 * , and SRF1. In embodiments, UCOE comprises any one of the sequences defined by SEQ ID NOs: 19-22, 157, and 193.

[0145]

[0229] In embodiments, the nucleic acids provided herein include fluorescent proteins. In embodiments, the fluorescent protein is located 5' to the 5' polycistronic cassette. In embodiments, the fluorescent protein is located 3' to the 3' polycistronic cassette. In embodiments, the fluorescent protein is located 5' to the ITR, gRNA target sequence, loxP site, or a combination thereof. In embodiments, fluorescent proteins are used for negative selection. In embodiments, the fluorescent protein is green fluorescent protein. In embodiments, the fluorescent protein is GFP having the nucleic acid sequence of SEQ ID NO: 111. In embodiments, the fluorescent protein is BFP having the nucleic acid sequence of SEQ ID NO: 242 or SEQ ID NO: 246.

[0146]

[0230] In embodiments, any one of the nucleic acids described herein or a fragment thereof is integrated into a chromosome. In embodiments, the fragment is a contiguous portion of a nucleic acid described herein, e.g., the fragment comprises about 20%, about 25%, about 30%, Approximately 35%, approximately 40%, approximately 45%, approximately 50%, approximately 55%, approximately 60%, approximately 65%, approximately 70%, approximately 75%, approximately 80%, approximately 85%, approximately 90%, approximately 95 %, about 97%, about 99%, or about 100%. In embodiments, the fragment comprises at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, of the nucleotides of any of the nucleic acids described herein. at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96 %, at least 97%, at least 98%, at least 99%, or at least 100%.

[0147]

[0231] In embodiments, fragments containing individual components of the nucleic acids described herein are amplified or synthesized from genomic DNA by polymerase chain reaction. Adjacent fragments overlap by at least 50 base pairs at their 5' or 3' ends. The fragments are assembled into full-length nucleic acids by yeast homologous recombination. The plasmid containing the nucleic acid inside is transformed into Escherichia coli and amplified therein. exemplary nucleic acids

[0232] Exemplary nucleic acids containing multiple polycistronic cassettes are presented in FIGS. 1A-D, 2A-J, 3A-C, 4A-H, 5A-F, and FIG. 6. In embodiments, the nucleic acid comprising multiple polycistronic cassettes has a sequence selected from any one of SEQ ID NOs: 23-46, 172-177.

[0148]

[0233] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a mouse EF1α1 promoter selected from SEQ ID NOs: 134-135; and SEQ ID NOs: 114-114. (b) a complement control cassette comprising an hsHBB polyA ("hsHBB pA" or "HBB pA") sequence selected from 116, and combinations thereof; (b) a complement control cassette, wherein the CD46 nucleic acid sequence is SEQ ID NO: 71 to The first cistron encoding CD59 is selected from the group consisting of SEQ ID NO: 86, 185, 200, and 253-258, and the first cistron encoding CD59 is selected from the group consisting of SEQ ID NO: 86, 108. 2 cistron, a human EF1α1 promoter selected from SEQ ID NOs: 130-132, a btGH pA sequence selected from any one of SEQ ID NOs: 112, 120-122, 159, and 190, and combinations thereof. a control cassette, and a first innate immunity cassette encoding a B2M HLA-E fusion protein, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105. a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259, a CAG promoter selected from SEQ ID NOs: 126-128, and SEQ ID NOs: Provided herein are nucleic acids comprising innate immunity cassettes comprising SPAActB polyA sequences selected from 123-125 and 154-156, and combinations thereof. In embodiments, CD46 is CD46_LL comprising the nucleic acid sequence of SEQ ID NO:71. In embodiments, a UCOE separates the complement control cassette and the innate immunity cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20.

[0149]

[0234] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a mouse EF1α1 promoter selected from SEQ ID NOs: 134-135; and SEQ ID NOs: 114-114. (b) a complement control cassette comprising an hsHBB polyA ("hsHBB pA" or "HBB pA") sequence selected from 116, and combinations thereof, wherein the CD46 nucleic acid sequence is SEQ ID NO: 71-76; , 185, 200, and 253-258, the second cistron encoding CD59, whose nucleic acid sequence for CD59 is selected from the group consisting of SEQ ID NOs: 86, 108. cistron, a human EF1α1 promoter selected from SEQ ID NOs: 130-132, a btGH pA sequence selected from any one of SEQ ID NOs: 112, 120-122, 159, and 190, and combinations thereof. cassette, and an innate immunity cassette, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105. a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; a CAG promoter selected from SEQ ID NOs: 126-128; and SEQ ID NO: 123. Provided herein are nucleic acids comprising innate immunity cassettes comprising SPAActB polyA sequences selected from ~125 and 154-156, and combinations thereof. In embodiments, a UCOE separates the complement control cassette and the innate immunity cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20.

[0150]

[0235] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a mouse EF1α1 promoter selected from SEQ ID NOs: 134-135; and SEQ ID NOs: 114-114. (b) a complement control cassette comprising an hsHBB polyA ("hsHBB pA" or "HBB pA") sequence selected from 116, and combinations thereof, wherein the CD46 nucleic acid sequence is SEQ ID NO: 71- The first cistron encoding CD46 is selected from the group consisting of 76, 185, 200, and 253-258, and the first cistron encoding CD59 is selected from the group consisting of SEQ ID NO: 86, 108. 2 cistron, a human EF1α1 promoter selected from SEQ ID NOs: 130-132, a btGH pA sequence selected from any one of SEQ ID NOs: 112, 120-122, 159, and 190, and combinations thereof. a B2M HLA-E fusion protein, a regulatory cassette, and an innate immune and inflammation and apoptosis cassette, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105. The first cistron encoding CD47 has a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; the second cistron encoding CD47 has a nucleic acid sequence of A20 SEQ ID NOs: 64-65; 104, 182, and 188, the nucleic acid sequence of HO1 encoding A20 is selected from the group consisting of SEQ ID NOs: 63, 109, 165, 183, and 189. innate immunity and inflammation, including a fourth cistron encoding a CAG promoter selected from SEQ ID NOs: 126-128, and SPAActB polyA sequences selected from SEQ ID NOs: 123-125 and 154-156, and combinations thereof; Provided herein are nucleic acids that include apoptosis cassettes. In embodiments, an IRES (SEQ ID NO: 11) separates the second and third cistrons of the innate immune and inflammation and apoptosis cassette. In embodiments, the UCOE separates the complement control cassette from the innate immunity and inflammation and apoptosis cassettes. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20.

[0151]

[0236] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; the nucleic acid sequence of CD39 is selected from the group consisting of SEQ ID NOs: 67-70 and SEQ ID NO: 106; a third cistron encoding CD39 selected, a mouse EF1α1 promoter selected from SEQ ID NOs: 134-135, and hsHBB polyA (“hsHBB pA” or “HBB pA”) selected from SEQ ID NOs: 114-116. (b) a complement control cassette, wherein the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258; The first cistron, encoding CD59, has a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 86 and 108; the second cistron, encoding CD59, has a nucleic acid sequence of SEQ ID NOs: 84, 85, 107, and 184. a third cistron encoding CD55 selected from the group consisting of; a human EF1α1 promoter selected from SEQ ID NOs: 130-132; a complement control cassette comprising the btGH pA sequence, and a combination thereof, and an innate immune and inflammation and apoptosis cassette, wherein the nucleic acid sequence encoding a B2M HLA-E fusion protein consists of SEQ ID NOs: 62, 66, 105. a first cistron encoding a B2M HLA-E fusion protein selected from the group; a second cistron encoding CD47, the nucleic acid sequence of CD47 being selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; The nucleic acid sequence of the third cistron, HO1 encoding A20, is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; , and a fifth cistron encoding HO1, the nucleic acid sequence of PD-L1 being selected from the group consisting of SEQ ID NOs: 89 to 91. , a CAG promoter selected from SEQ ID NOs: 126-128, and a SPAActB polyA sequence selected from SEQ ID NOs: 123-125 and 154-156, and combinations thereof. provided herein. In embodiments, an IRES (SEQ ID NO: 11) separates the second and third cistrons of the innate immune and inflammation and apoptosis cassette. In embodiments, the UCOE separates the complement control cassette from the innate immunity and inflammation and apoptosis cassettes. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20.

[0152]

[0237] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a mouse EF1α1 promoter selected from SEQ ID NOs: 134-135; and SEQ ID NOs: 114-114. (b) a complement control cassette comprising an hsHBB polyA ("hsHBB pA" or "HBB pA") sequence selected from 116, and combinations thereof; (b) a complement control cassette, wherein the CD46 nucleic acid sequence is SEQ ID NO: 71 to The first cistron encoding CD59 is selected from the group consisting of SEQ ID NO: 86, 185, 200, and 253-258, and the first cistron encoding CD59 is selected from the group consisting of SEQ ID NO: 86, 108. 2 cistron, a human EF1α1 promoter selected from SEQ ID NOs: 130-132, a btGH pA sequence selected from any one of SEQ ID NOs: 112, 120-122, 159, and 190, and combinations thereof. a control cassette, and a first innate immunity cassette encoding a B2M HLA-E fusion protein, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105. a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259, a CAG promoter selected from SEQ ID NOs: 126-128, and SEQ ID NOs: Provided herein are nucleic acids comprising innate immunity cassettes comprising SPAActB polyA sequences selected from 123-125 and 154-156, and combinations thereof. In embodiments, CD46 is CD46_LL comprising the nucleic acid sequence of SEQ ID NO:71. In embodiments, a UCOE separates the complement control cassette and the innate immunity cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22, 157, and 193 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22, 157, and 193 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE located on the 5' or 3' side of the coagulation cassette is an SRF having the sequence SEQ ID NO:22.

[0153]

[0238] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; the nucleic acid sequence of CD39 is selected from the group consisting of SEQ ID NOs: 67-70 and SEQ ID NO: 106; a third cistron encoding CD39 selected, a mouse EF1α1 promoter selected from SEQ ID NOs: 134-135, and hsHBB polyA (“hsHBB pA” or “HBB pA”) selected from SEQ ID NOs: 114-116. (b) a complement control cassette, wherein the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258; The first cistron encoding CD59 has a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 86, 108, the second cistron encoding CD59 has a nucleic acid sequence of SEQ ID NOs: 84, 85, 107, and 184. a third cistron encoding CD55 selected from the group consisting of a ssEF1α1 promoter selected from SEQ ID NOs: 136-138, selected from any one of SEQ ID NOs: 112, 120-122, 159, and 190 Complement control cassettes comprising btGH pA sequences, and combinations thereof, and innate immunity and inflammation and apoptosis cassettes, wherein the nucleic acid sequence encoding a B2M HLA-E fusion protein consists of SEQ ID NO: 62, 66, 105 a first cistron encoding a B2M HLA-E fusion protein selected from; a second cistron encoding CD47, the nucleic acid sequence of CD47 being selected from the group consisting of SEQ ID NOs: 77-83, 180, 259; A third cistron encoding A20, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; A fourth cistron encoding HO1, the nucleic acid sequence of PD-L1, selected from the group consisting of SEQ ID NOs: 89 to 91; Nucleic acids comprising an innate immunity and inflammation and apoptosis cassette comprising a CAG promoter selected from SEQ ID NOS: 126-128 and a SPAActB polyA sequence selected from SEQ ID NOS: 123-125 and 154-156, and combinations thereof, are provided herein. Provided in book form. In embodiments, an IRES (SEQ ID NO: 11) separates the second and third cistrons of the innate immune and inflammation and apoptosis cassette. In embodiments, the UCOE separates the complement control cassette from the innate immunity and inflammation and apoptosis cassettes. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is a CBX3 UCOE having the sequence SEQ ID NO:21. In embodiments, the UCOE is located on the 5' or 3' side of the coagulation cassette. In an embodiment, the UCOE located on the 5' or 3' side of the coagulation cassette is a Can 6-3 UCOE having the sequence SEQ ID NO: 19. In embodiments, the CD46 is CD46i having a nucleic acid sequence selected from SEQ ID NO: 74 or SEQ ID NO: 75.

[0154]

[0239] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; the nucleic acid sequence of CD39 is selected from the group consisting of SEQ ID NOs: 67-70 and SEQ ID NO: 106; a third cistron encoding CD39, an ssUBC promoter having the sequence of SEQ ID NO: 141, and an hsHBB polyA ("hsHBB pA" or " (b) a complement control cassette, wherein the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258. The first cistron encoding CD46, the nucleic acid sequence of CD59 is selected from the group consisting of SEQ ID NOs: 86, 108, the second cistron encoding CD59, the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, a third cistron encoding CD55 selected from the group consisting of 107, and 184; a ssEF1α1 promoter selected from SEQ ID NOs: 136-138; a complement control cassette comprising a pA sequence, and a combination thereof, and an innate immune and inflammation and apoptosis cassette, wherein the nucleic acid sequence encoding a B2M HLA-E fusion protein is from the group consisting of SEQ ID NO: 62, 66, 105. a first cistron encoding a B2M HLA-E fusion protein selected, a second cistron encoding CD47, the nucleic acid sequence of CD47 being selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; A third cistron encoding A20, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; A fourth cistron encoding HO1, the nucleic acid sequence of PD-L1, selected from the group consisting of SEQ ID NOs: 89 to 91; Nucleic acids comprising an innate immunity and inflammation and apoptosis cassette comprising a CAG promoter selected from SEQ ID NOS: 126-128 and a SPAActB polyA sequence selected from SEQ ID NOS: 123-125 and 154-156, and combinations thereof, are provided herein. Provided in book form. In embodiments, an IRES (SEQ ID NO: 11) separates the second and third cistrons of the innate immune and inflammation and apoptosis cassette. In embodiments, the UCOE separates the complement control cassette from the innate immunity and inflammation and apoptosis cassettes. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is a CBX3 UCOE having the sequence SEQ ID NO:21. In embodiments, the CD46 is CD46i having a nucleic acid sequence selected from SEQ ID NO: 74 or SEQ ID NO: 75.

[0155]

[0240] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding PROCR, in which the nucleic acid sequence of PROCR is selected from the group consisting of SEQ ID NOs: 92, 93, and 181; a ssUBC promoter having a sequence of SEQ ID NOs: 19-22, 157, or 193; (b) an inflammation and apoptosis cassette comprising an hsHBB polyA ("hsHBB pA" or "HBB pA") sequence selected from any one of 114-116 and 191, or a combination thereof; The first cistron encoding A20, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188, and the nucleic acid sequence of HO1 is selected from the group consisting of SEQ ID NOs: 63, 109, 165, 183, and a second cistron encoding HO1 selected from the group consisting of 189; a ssEF1α1 promoter selected from SEQ ID NOs: 136-138 and 179; a btGH pA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190. , and combinations thereof, and complement regulation and innate immunity cassettes, wherein the nucleic acid sequence of CD46 is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258. the first cistron encoding CD46, the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259, the second cistron encoding CD47, the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259 a third cistron encoding CD55 selected from the group consisting of 84, 85, 107, and 184; a CAG promoter selected from SEQ ID NOs: 126-128; and a CAG promoter selected from SEQ ID NOs: 123-125 and 154-156. Provided herein are nucleic acids comprising complement control and innate immunity cassettes comprising SPAActB polyA sequences, and combinations thereof. In embodiments, the UCOE separates the inflammation and apoptosis cassette from the complement control and innate immunity cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is a CBX3 UCOE having the sequence SEQ ID NO:21. In embodiments, the CD46 is CD46i having a nucleic acid sequence selected from SEQ ID NO: 74 or SEQ ID NO: 75.

[0156]

[0241] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding PROCR, in which the nucleic acid sequence of PROCR is selected from the group consisting of SEQ ID NOs: 92, 93, and 181; the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a third cistron encoding TFPI, an ssUBC promoter having the sequence of SEQ ID NO: 141, and an hsHBB polyA (“hsHBB pA” or “HBB (b) an innate immunity cassette, wherein the nucleic acid sequence encoding a B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NOs: 62, 66, 105; a first cistron encoding a B2M HLA-E fusion protein; a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; an innate immunity cassette comprising an ssHSPA8 promoter selected from 139-140, and a btGH pA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190, and combinations thereof, and (c) a complement control cassette. the first cistron encoding CD46, wherein the nucleic acid sequence of CD46 is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258; the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and a second cistron encoding CD55 selected from the group consisting of 184, a CAG promoter selected from SEQ ID NO: 126 to 128, and a complement control comprising an hsGH polyA sequence having the sequence of SEQ ID NO: 113. Provided herein are nucleic acids that include cassettes. In embodiments, a UCOE separates the innate immunity cassette from the complement control cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is a CBX3 UCOE having the sequence SEQ ID NO:21. In embodiments, poly A is located on the 5' or 3' side of the coagulation cassette. In an embodiment, polyA is SV40 pA having the sequence SEQ ID NO: 119. In embodiments, CD46 is CD46da having the sequence SEQ ID NO: 73 or SEQ ID NO: 72. In embodiments, THBD is THBDda having a sequence selected from SEQ ID NOs: 99-102. In embodiments, the B2M HLA-E fusion protein includes an HLA-G epitope. In embodiments, CD47 is CD47-2 (eg, NM_198793) having a sequence of SEQ ID NO: 80, 81, or 83. In embodiments, polyA is located on the 5' or 3' side of the complement control cassette. In an embodiment, the polyA located on the 5' or 3' side of the complement control cassette is SPAActB pA having the sequence of SEQ ID NO: 118.

[0157]

[0242] In some embodiments, (a) a B2M HLA-E fusion cassette, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; a ssUBC promoter having a second cistron encoding CD47, the nucleic acid sequence of CD47 encoding a protein selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; , and an hsHBB polyA (“hsHBB pA” or “HBB pA”) sequence selected from any one of SEQ ID NOS: 114-116 and 191, and a combination thereof, (b) a coagulation cassette The first cistron encoding THBD, the nucleic acid sequence of PROCR is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266, and the nucleic acid sequence of PROCR is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266. a second cistron encoding PROCR selected from the group consisting of 181; a third cistron encoding TFPI, the nucleic acid sequence of TFPI being selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a coagulation cassette comprising an hsHSPA8 promoter having the sequence of SEQ ID NO: 133, and a btGH pA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190, and combinations thereof; and (c) a complement control cassette, comprising: , the first cistron encoding CD46, wherein the nucleic acid sequence of CD46 is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258, the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and a second cistron encoding CD55 selected from the group consisting of: Provided herein are nucleic acids that include complement control cassettes. In embodiments, a UCOE separates the innate immunity cassette from the complement control cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20. In embodiments, polyA is located on the 5' or 3' side of the innate immunity cassette. In an embodiment, polyA is SV40 pA having the sequence SEQ ID NO: 119. In embodiments, CD46 is CD46da having the sequence SEQ ID NO: 73 or SEQ ID NO: 72. In embodiments, THBD is THBDda having a sequence selected from SEQ ID NOs: 99-102. In embodiments, the B2M HLA-E fusion protein has an HLA-G epitope. In embodiments, CD47 is CD47-2 (eg, NM_198793) having a sequence of SEQ ID NO: 80, 81, or 83. In embodiments, polyA is located on the 5' or 3' side of the complement control cassette. In an embodiment, the polyA located on the 5' or 3' side of the complement control cassette is SPAActB pA having the sequence of SEQ ID NO: 118. In embodiments, the nucleic acid comprises a gRNA target sequence selected from SEQ ID NOs: 47-48.

[0158]

[0243] In some embodiments, (a) a B2M HLA-E fusion cassette, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; a ssUBC promoter having a protein-encoding first cistron, CD47, whose nucleic acid sequence is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; a second cistron encoding CD47, having the sequence of SEQ ID NO: 141; , and an hsHBB polyA (“hsHBB pA” or “HBB pA”) sequence selected from any one of SEQ ID NOs: 114-116 and 191, and combinations thereof; (b) a coagulation cassette; the first cistron encoding THBD, wherein the nucleic acid sequence of THBD is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266, and the nucleic acid sequence of PROCR is selected from the group consisting of SEQ ID NOs: 92, 93, and 265-266. a second cistron encoding PROCR selected from the group consisting of 181; a third cistron encoding TFPI, the nucleic acid sequence of TFPI being selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a coagulation cassette comprising an hsHSPA8 promoter having the sequence of SEQ ID NO: 133, and a btGH pA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190, and combinations thereof; and (c) a complement control cassette, comprising: , the first cistron encoding CD46, wherein the nucleic acid sequence of CD46 is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258, the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and a second cistron encoding CD55 selected from the group consisting of: Provided herein are nucleic acids that include complement control cassettes. In embodiments, a UCOE separates the innate immunity cassette from the complement control cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22 and 157. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20. In embodiments, polyA is located on the 5' or 3' side of the innate immunity cassette. In an embodiment, polyA is SV40 pA having the sequence SEQ ID NO: 119. In embodiments, CD46 is CD46da having the sequence SEQ ID NO: 73 or SEQ ID NO: 72. In embodiments, THBD is THBDda having a sequence selected from SEQ ID NOs: 99-102. In embodiments, the B2M HLA-E fusion protein has an HLA-G epitope. In embodiments, CD47 is CD47-2 (eg, NM_198793) having a sequence of SEQ ID NO: 80, 81, or 83. In embodiments, polyA is located on the 5' or 3' side of the complement control cassette. In an embodiment, the polyA located on the 5' or 3' side of the complement control cassette is SPAActB pA having the sequence of SEQ ID NO: 118. In embodiments, the nucleic acid comprises a gRNA target sequence selected from SEQ ID NOs: 47-48.

[0159]

[0244] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding PROCR, in which the nucleic acid sequence of PROCR is selected from the group consisting of SEQ ID NOs: 92, 93, and 181; the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a third cistron encoding TFPI, an ssUBC promoter having the sequence of SEQ ID NO: 141, and an hsHBB polyA (“hsHBB pA” or “HBB (b) an innate immunity cassette, wherein the nucleic acid sequence encoding a B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105. a first cistron encoding a B2M HLA-E fusion protein; a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; an innate immunity cassette comprising an ssEF1α1 promoter selected from 136-138, and 179, and a btGH pA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190, and combinations thereof, and (c) complement. a control cassette, the first cistron encoding CD46, the nucleic acid sequence of CD55 being selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258; , a second cistron encoding CD55 selected from the group consisting of , 85, 107, and 184, a CAG promoter selected from SEQ ID NOs: 126-128, and a CAG promoter selected from SEQ ID NOs: 123-125 and 154-156. Provided herein are nucleic acids comprising complement control cassettes comprising SPAActB polyA sequences, and combinations thereof. In embodiments, a UCOE separates the innate immunity cassette from the complement control cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is a CBX3 UCOE having the sequence SEQ ID NO:21. In embodiments, poly A is located on the 5' or 3' side of the coagulation cassette. In an embodiment, polyA is SV40 pA having the sequence SEQ ID NO: 119. In embodiments, CD46 is CD46da having the sequence SEQ ID NO: 73 or SEQ ID NO: 72. In embodiments, THBD is THBDda having a sequence selected from SEQ ID NOs: 99-102. In embodiments, the B2M HLA-E fusion protein has an HLA-G epitope. In embodiments, CD47 is CD47-2 (eg, NM_198793) having a sequence of SEQ ID NO: 80, 81, or 83. In embodiments, polyA is located on the 5' or 3' side of the complement control cassette. In an embodiment, the polyA located on the 5' or 3' side of the complement control cassette is SPAActB pA having the sequence of SEQ ID NO: 118. In embodiments, the nucleic acid comprises a gRNA target sequence selected from SEQ ID NOs: 47-48.

[0160]

[0245] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, wherein the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a mouse EF1α1 promoter selected from SEQ ID NOs: 134-135; and SEQ ID NOs: 114-114. (b) a coagulation cassette comprising an hsHBB polyA (“hsHBB pA” or “HBB pA”) sequence selected from any one of 116 and 191, and combinations thereof; (b) a complement control cassette comprising: the first cistron encoding CD46, the nucleic acid sequence of CD55 being selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258; a second cistron encoding CD55 selected from the group consisting of: a human EF1α1 promoter selected from SEQ ID NOs: 130-132; a btGH pA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190; and an innate immunity cassette comprising a combination of B2M HLA-E fusions, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NOs: 62, 66, 105. The first cistron encoding a protein, the nucleic acid sequence of CD47, is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; The second cistron encoding CD47 is selected from SEQ ID NOs: 126-128. Provided herein are nucleic acids comprising an innate immunity cassette comprising a CAG promoter and a SPAActB polyA sequence selected from SEQ ID NOs: 123-125 and 154-156, and combinations thereof. In embodiments, a UCOE separates the complement control cassette and the innate immunity cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22, 157, and 193 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22, 157, and 193 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE located on the 5' or 3' side of the coagulation cassette is an SRF having the sequence SEQ ID NO:22. In embodiments, the CD46 is CD46i having a nucleic acid sequence selected from SEQ ID NO: 74 or SEQ ID NO: 75.

[0161]

[0246] In some embodiments, (a) the coagulation cassette comprises a first cistron encoding a THBD, wherein the THBD nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding PROCR, in which the nucleic acid sequence of PROCR is selected from the group consisting of SEQ ID NOs: 92, 93, and 181; a mouse EF1α1 promoter selected from SEQ ID NOs: 134-135; and a mouse EF1α1 promoter selected from SEQ ID NOs: 114-116 and a coagulation cassette comprising an hsHBB polyA (“hsHBB pA” or “HBB pA”) sequence selected from any one of 191, and combinations thereof; (b) a complement control cassette, the nucleic acid sequence of CD46; is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258, the first cistron encoding CD46, and the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184. a second cistron encoding CD55 selected from; a human EF1α1 promoter selected from SEQ ID NOs: 130-132; a btGH pA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190, and combinations thereof. and (c) an innate immune and inflammation and apoptosis cassette, wherein the nucleic acid sequence encoding a B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105. The nucleic acid sequence of the second cistron, A20, encoding a B2M HLA-E fusion protein, wherein the nucleic acid sequence of the first cistron, CD47, is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259. is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; a fourth cistron encoding HO1 selected from HO1, a CAG promoter selected from SEQ ID NOs: 126-128, and a SPAActB polyA sequence selected from SEQ ID NOs: 123-125 and 154-156, and combinations thereof. Provided herein are nucleic acids comprising innate immunity and inflammation and apoptosis cassettes comprising. In embodiments, an IRES having the sequence SEQ ID NO: 11 separates the B2M HLA-E fusion protein and CD47 from A20 and HO1. In some embodiments, a UCOE separates the complement control cassette and the innate immunity cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22 and 157. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22, 157, and 193 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22 and 157 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE located on the 5' or 3' side of the coagulation cassette is an SRF having the sequence SEQ ID NO:22. In embodiments, the CD46 is CD46i having a nucleic acid sequence selected from SEQ ID NO: 74 or SEQ ID NO: 75.

[0162]

[0247] In some embodiments, (a) a B2M HLA-E fusion cassette, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; A first cistron encoding a protein, the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; a second cistron encoding CD47, selected from SEQ ID NOs: 134-135. an innate immunity cassette comprising a mouse EF1α1 promoter and an hsHBB polyA (“hsHBB pA” or “HBB pA”) sequence selected from any one of SEQ ID NOs: 114-116 and 191, and combinations thereof, (b ) A coagulation cassette, wherein the nucleic acid sequence of the first cistron encoding THBD, TFPI, is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266, and the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266. a second cistron encoding TFPI selected from the group consisting of 96, 103, and 187; 3 cistron, a human EF1α1 promoter selected from SEQ ID NOs: 130-132, a btGH pA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190, and combinations thereof, and (c) a coagulation cassette comprising body regulatory and inflammation and apoptosis cassette, the first cistron encoding CD46, the nucleic acid of CD59, wherein the nucleic acid sequence of CD46 is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258. a second cistron encoding CD59, the sequence of which is selected from the group consisting of SEQ ID NO: 86, 108; The nucleic acid sequence of the fourth cistron, HO1 encoding A20, is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; a fifth cistron encoding HO1 selected from the group consisting of , 165, 183, and 189; the nucleic acid sequence of PD-L1 encoding PD-L1 selected from the group consisting of SEQ ID NOs: 89 to 91; Complement control and inflammation and apoptosis cassette comprising a sixth cistron, a CAG promoter selected from SEQ ID NO: 126-128, and a SPAActB polyA sequence selected from SEQ ID NO: 123-125 and 154-156, and combinations thereof. Provided herein are nucleic acids comprising. In embodiments, an IRES having the sequence SEQ ID NO: 11 separates CD46, CD55, and CD59 from A20, HO1, and PD-L1. In some embodiments, a UCOE separates the complement control cassette and the innate immunity cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22 and 157. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22, 157, and 193 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22 and 157 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE located on the 5' or 3' side of the coagulation cassette is an SRF having the sequence SEQ ID NO:22. In embodiments, the CD46 is CD46i having a nucleic acid sequence selected from SEQ ID NO: 74 or SEQ ID NO: 75.

[0163]

[0248] In some embodiments, (a) a B2M HLA-E fusion cassette, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; a ssUBC promoter having a second cistron encoding CD47, the nucleic acid sequence of CD47 encoding a protein selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; , and an hsHBB polyA (“hsHBB pA” or “HBB pA”) sequence selected from any one of SEQ ID NOs: 114-116 and 191, and combinations thereof; (b) a coagulation cassette; The first cistron encoding THBD, the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266, and the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266. , and a second cistron encoding TFPI selected from the group consisting of , and 187, a hsHSPA8 promoter selected from SEQ ID NO: 133, a btGH pA sequence selected from SEQ ID NO: 112, 120-122, 159, 190, and and (c) a complement control cassette encoding CD46, wherein the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258. a first cistron encoding CD55, the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184, a second cistron encoding CD55, a CAG promoter selected from SEQ ID NOs: 126 to 128; and a SPAActB polyA sequence selected from SEQ ID NOS: 123-125 and 154-156, and combinations thereof. In embodiments, a UCOE separates the complement control cassette and the coagulation cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22, 157, and 193 is located on the 5' or 3' side of the innate immunity cassette. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22, 157, and 193 is located on the 5' or 3' side of the innate immunity cassette. In an embodiment, the UCOE located on the 5' or 3' side of the innate immunity cassette is an SRF having the sequence of SEQ ID NO:22. In embodiments, the CD46 is CD46i having a nucleic acid sequence selected from SEQ ID NO: 74 or SEQ ID NO: 75.

[0164]

[0249] In some embodiments, (a) a B2M HLA-E fusion cassette, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; a ssUBC promoter having a second cistron encoding CD47, the nucleic acid sequence of CD47 encoding a protein selected from the group consisting of SEQ ID NOs: 77-83, 180, and 259; , and an hsHBB polyA (“hsHBB pA” or “HBB pA”) sequence selected from any one of SEQ ID NOs: 114-116 and 191, and combinations thereof; (b) a coagulation cassette; The first cistron encoding THBD, the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266, and the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266. , and a second cistron encoding TFPI selected from the group consisting of , and 187, a hsHSPA8 promoter selected from SEQ ID NO: 133, a btGH pA sequence selected from SEQ ID NO: 112, 120-122, 159, 190, and a coagulation cassette comprising a combination thereof, and (c) a complement regulation and inflammation and apoptosis cassette, wherein the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258. , the first cistron encoding CD46, the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NO: 84, 85, 107, and 184, the second cistron encoding CD55, the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NO: 64 The nucleic acid sequence of the third cistron, HO1, encoding A20 is selected from the group consisting of ~65, 104, 182, and 188 is selected from the group consisting of SEQ ID NO: 63, 109, 165, 183, and 189 , a fourth cistron encoding HO1, a CAG promoter selected from SEQ ID NOs: 126-128, and a complement control and inflammation and apoptosis cassette comprising an hsGH polyA sequence having the sequence of SEQ ID NO: 113. Provided in book form. In embodiments, an IRES having the sequence SEQ ID NO: 11 separates CD46 and CD55 from A20 and HO1. In embodiments, a UCOE separates the complement control cassette and the coagulation cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20. In embodiments, the UCOE having a sequence selected from SEQ ID NOS: 19-22, 157, and 193 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE having a sequence selected from SEQ ID NOS: 19-22, 157, and 193 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE located on the 5' or 3' side of the coagulation cassette is an SRF having the sequence SEQ ID NO:22. In embodiments, the CD46 is CD46da having a nucleic acid sequence selected from SEQ ID NO: 72 or SEQ ID NO: 73.

[0165]

[0250] In embodiments, (a) the innate immunity cassette encodes a B2M HLA-E fusion protein, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; a first cistron encoding CD47, a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259, an ssUBC promoter having the sequence of SEQ ID NO: 141; an innate immunity cassette comprising an hsHBB polyA ("hsHBB pA" or "HBB pA") sequence selected from any one of numbers 114 to 116 and 191, and a combination thereof; (b) a coagulation cassette, comprising: , the nucleic acid sequence of THBD is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a second cistron encoding TFPI, the nucleic acid sequence of CD39 is selected from the group consisting of SEQ ID NO: 67-70 and SEQ ID NO: 106, a third cistron encoding CD39, SEQ ID NO: a coagulation cassette comprising an hsHSPA8 promoter selected from 133, a btGH pA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190, and combinations thereof; and (c) a complement regulation and inflammation and apoptosis cassette. The first cistron encoding CD46 has a nucleic acid sequence of CD46 selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258, and the nucleic acid sequence of CD55 has SEQ ID NOs: 84, 85, 107. , and the nucleic acid sequence of the third cistron encoding CD59, A20, wherein the nucleic acid sequence of the second cistron encoding CD55, CD59 is selected from the group consisting of SEQ ID NO: 86 and SEQ ID NO: 108. is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188, and the nucleic acid sequence of HO1, the fourth cistron encoding A20, is selected from the group consisting of SEQ ID NOs: 63, 109, 165, 183, and 189. The fifth cistron encoding HO1 is selected from SEQ ID NOs: 89-91; the sixth cistron encoding PD-L1 is selected from SEQ ID NOs: 126-128; Provided herein are nucleic acids comprising a CAG promoter comprising a CAG promoter, and a complement control and inflammation and apoptosis cassette comprising an hsGH polyA sequence having the sequence of SEQ ID NO: 113. In embodiments, an IRES having the sequence SEQ ID NO: 11 separates CD46, CD55, and CD59 from A20, HO1, and PD-L1. In embodiments, a UCOE separates the complement control cassette and the coagulation cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In an embodiment, the UCOE is an A2CBX3 UCOE having the sequence SEQ ID NO:20. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22 and 157 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE having a sequence selected from SEQ ID NOs: 19-22 and 157 is located on the 5' or 3' side of the coagulation cassette. In embodiments, the UCOE located on the 5' or 3' side of the coagulation cassette is an SRF having the sequence SEQ ID NO:22. In embodiments, CD46 is CD46da having a sequence selected from SEQ ID NO: 72 or SEQ ID NO: 73.

[0166]

[0251] In embodiments, (a) the innate immunity cassette encodes a B2M HLA-E fusion protein, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; a first cistron encoding CD47, a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259, an ssUBC promoter having the sequence of SEQ ID NO: 141; an innate immunity cassette comprising an hsHBB polyA ("hsHBB pA" or "HBB pA") sequence selected from any one of numbers 114 to 116 and 191, and a combination thereof; (b) a coagulation cassette, comprising: , the nucleic acid sequence of THBD is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a second cistron encoding TFPI, the nucleic acid sequence of CD39 is selected from the group consisting of SEQ ID NO: 67-70 and SEQ ID NO: 106, a third cistron encoding CD39, SEQ ID NO: a coagulation cassette comprising a ssHSPA8 promoter selected from 142-145, a btGH pA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190, and combinations thereof, and (c) a complement regulation and inflammation and apoptosis cassette. the first cistron encoding CD46, wherein the nucleic acid sequence of CD46 is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258; , 107, and 184; the third cistron encoding CD59, the nucleic acid sequence of CD59 being selected from SEQ ID NO: 86 and SEQ ID NO: 108; The nucleic acid sequence of the fourth cistron, HO1 encoding A20, is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188, and the nucleic acid sequence is selected from SEQ ID NOs: 63, 109, 165, 183, and 189. The fifth cistron encoding HO1 is selected from the group consisting of: the nucleic acid sequence of PD-L1 is selected from the group consisting of SEQ ID NOs: 89 to 91; the sixth cistron encoding PD-L1 is selected from SEQ ID NOs: 126 to 128; Provided herein are nucleic acids comprising a selected CAG promoter and a complement control and inflammation and apoptosis cassette comprising an hsGH polyA sequence having the sequence of SEQ ID NO: 113. In embodiments, an IRES having the sequence SEQ ID NO: 11 separates CD46, CD55, and CD59 from A20, HO1, and PD-L1. In embodiments, a UCOE separates the complement control cassette and the coagulation cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In embodiments, UCOE is CBX3 having the sequence SEQ ID NO: 21 * It is UCOE. In embodiments, the nucleic acid comprises a polyA sequence located 5' or 3' to all of the polycistronic cassette. In embodiments, the polyA sequence located 5' or 3' to all of the polycistronic cassettes is SV40 pA having the nucleic acid sequence of SEQ ID NO: 119 or SEQ ID NO: 162.

[0167]

[0252] In an embodiment, (a) the coagulation cassette comprises a nucleic acid of a first cistron, TFPI, encoding a THBD, wherein the nucleic acid sequence of the THBD is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, the sequence of which is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a ssHSPA8 promoter selected from SEQ ID NOs: 142-145; SPA PTCH2 having the sequence of SEQ ID NO: 124; a coagulation cassette comprising a pA sequence; (b) an innate immunity cassette, wherein the nucleic acid sequence encoding a B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NOs: 62, 66, 105; a ssUBC promoter having a protein-encoding first cistron, CD47, whose nucleic acid sequence is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; a second cistron encoding CD47, having the sequence of SEQ ID NO: 141; , and an innate immunity cassette comprising an hsHBB polyA (“hsHBB pA” or “HBB pA”) sequence selected from any one of SEQ ID NOs: 114-116 and 191, and combinations thereof; (c) cellular immunity; and a coagulation cassette, wherein the nucleic acid sequence of a first cistron, CD39, encoding CTLA-4 (e.g., LEA29Y) is selected from the group consisting of SEQ ID NOs: 87-88 and 186. a second cistron encoding CD39 selected from the group consisting of numbers 67-70 and SEQ ID NO: 106, a ssEF1α1 promoter selected from SEQ ID NOs: 136-138 and 179, and SEQ ID NOs: 112, 120-122, 159, and (d) a complement control cassette, wherein the CD46 nucleic acid sequence is from SEQ ID NOs: 71-76, 185, 200, and 253-258. a first cistron encoding CD46 selected from the group consisting of; a second cistron encoding CD55, the nucleic acid sequence of CD55 being selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; Provided herein are nucleic acids comprising a CAG promoter selected from 126-128, and a complement control cassette comprising an hsGH polyA sequence having the sequence of SEQ ID NO: 113. In embodiments, the nucleic acid comprises a polyA sequence located 5' or 3' to all of the polycistronic cassette. In an embodiment, the polyA sequence located 5' or 3' to all of the polycistronic cassettes is SV40 pA having the nucleic acid sequence of SEQ ID NO: 119. In embodiments, the nucleic acid comprises a fluorescent protein located 5' or 3' to all of the polycistronic cassette. In an embodiment, the fluorescent protein located 5' or 3' to all of the polycistronic cassettes is a green fluorescent protein having the sequence SEQ ID NO: 111. In embodiments, CD46 is CD46da having the nucleic acid sequence of SEQ ID NO:72. In embodiments, THBD is THBDda having a sequence selected from SEQ ID NOs: 99-102. In embodiments, TFPI comprises TFPI and CD4 transmembrane domains. In an embodiment, TFPI has the sequence SEQ ID NO:94. In embodiments, the UCOE separates the complement control cassette from the cellular immunity and coagulation cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In embodiments, UCOE is CBX3 having the sequence SEQ ID NO: 21 *It is UCOE.

[0168]

[0253] In an embodiment, (a) the coagulation cassette comprises a nucleic acid of a first cistron, TFPI, encoding a THBD, wherein the nucleic acid sequence of the THBD is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, the sequence of which is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a ssHSPA8 promoter selected from SEQ ID NOs: 142-145; SPA PTCH2 having the sequence of SEQ ID NO: 124; a coagulation cassette comprising a pA sequence; (b) an innate immunity cassette, wherein the nucleic acid sequence encoding a B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NOs: 62, 66, 105; a ssUBC promoter having a protein-encoding first cistron, CD47, whose nucleic acid sequence is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; a second cistron encoding CD47, having the sequence of SEQ ID NO: 141; , and an innate immune cassette comprising an hsHBB poly("hsHBB pA" or "HBB pA") sequence selected from any one of SEQ ID NOs: 114-116 and 191, and combinations thereof; (c) inflammation and apoptosis; a cassette, wherein the nucleic acid sequence of the first cistron encoding A20, PD-L1, is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188; a second cistron encoding PD-L1 selected from the group consisting of: an inflammation and apoptosis cassette comprising a btGH polyA sequence; and (d) a complement control cassette, wherein the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258. The first cistron encoding CD46, the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NOs: 84, 85, 107, and 184; The second cistron encoding CD55 is selected from SEQ ID NOs: 126-128. Provided herein is a nucleic acid comprising a CAG promoter and a complement control cassette comprising a hsGH polyA sequence having the sequence of SEQ ID NO: 113. In embodiments, the nucleic acid comprises a polyA sequence located 5' or 3' to all of the polycistronic cassette. In an embodiment, the polyA sequence located either 5' or 3' to all of the polycistronic cassettes is SV40 pA having the sequence of SEQ ID NO: 119. In embodiments, the nucleic acid comprises a fluorescent protein located 5' or 3' to all of the polycistronic cassette. In an embodiment, the fluorescent protein located 5' or 3' to all of the polycistronic cassettes is a green fluorescent protein having the sequence SEQ ID NO: 111. In embodiments, CD46 is CD46da having the nucleic acid sequence of SEQ ID NO:72. In embodiments, THBD is THBDda having a sequence selected from SEQ ID NOs: 99-102. In embodiments, TFPI comprises TFPI and CD4 transmembrane domains. In an embodiment, TFPI has the sequence SEQ ID NO:94. In embodiments, a UCOE separates the complement control cassette from the inflammation and apoptosis cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In embodiments, UCOE is CBX3 having the sequence SEQ ID NO: 21 * It is UCOE.

[0169]

[0254] In an embodiment, (a) the coagulation cassette comprises a nucleic acid of a first cistron, TFPI, encoding a THBD, wherein the nucleic acid sequence of the THBD is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, the sequence of which is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a ssHSPA8 promoter selected from SEQ ID NOs: 142-145; SPA PTCH2 having the sequence of SEQ ID NO: 124; a coagulation cassette comprising a pA sequence; (b) an innate immunity cassette, wherein the nucleic acid sequence encoding a B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NOs: 62, 66, 105; a ssUBC promoter having a protein-encoding first cistron, CD47, whose nucleic acid sequence is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; a second cistron encoding CD47, having the sequence of SEQ ID NO: 141; , and an innate immune cassette comprising an hsHBB polyA (“hsHBB pA” or “HBB pA”) sequence selected from any one of SEQ ID NOS: 114-116 and 191, or a combination thereof; (c) apoptosis and a first cistron encoding XIAP, wherein the nucleic acid sequence of XIAP is selected from the group consisting of SEQ ID NO: 110; (ii) the nucleic acid sequence of CD39 is selected from the group consisting of SEQ ID NO: 106; Apoptosis comprising a second cistron encoding CD39, an ssEF1α1 promoter selected from SEQ ID NOs: 136-138 and 179, and a btGH polyA sequence having a sequence of any one of SEQ ID NOs: 112, 120-122, 159, 190 and (d) a complement control cassette, wherein the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258. a second cistron encoding CD55, wherein the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NO: 84, 85, 107, and 184, a CAG promoter selected from SEQ ID NO: 126-128, and SEQ ID NO: 113. Provided herein are nucleic acids comprising a complement control cassette comprising an hsGH polyA sequence having a sequence of . In embodiments, the nucleic acid comprises a polyA sequence located 5' or 3' to all of the polycistronic cassette. In an embodiment, the polyA sequence located 5' or 3' to all of the polycistronic cassettes is SV40 pA having the nucleic acid sequence of SEQ ID NO: 119. In embodiments, the nucleic acid comprises a fluorescent protein located 5' or 3' to all of the polycistronic cassette. In an embodiment, the fluorescent protein located 5' or 3' to all of the polycistronic cassettes is a green fluorescent protein having the sequence SEQ ID NO: 111. In embodiments, CD46 is CD46da having the nucleic acid sequence of SEQ ID NO:72. In embodiments, THBD is THBDda having a sequence selected from SEQ ID NOs: 99-102. In embodiments, TFPI comprises TFPI and CD4 transmembrane domains. In an embodiment, TFPI has the sequence SEQ ID NO:94. In embodiments, a UCOE separates the complement control cassette from the apoptosis and coagulation cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In embodiments, UCOE is CBX3 having the sequence SEQ ID NO: 21 * It is UCOE.

[0170]

[0255] In an embodiment, (a) the coagulation cassette comprises a nucleic acid of a first cistron, TFPI, encoding a THBD, wherein the nucleic acid sequence of the THBD is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a second cistron encoding TFPI, the sequence of which is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187; a ssHSPA8 promoter selected from SEQ ID NOs: 142-145; SPA PTCH2 having the sequence of SEQ ID NO: 124; a coagulation cassette comprising a pA sequence; (b) an innate immunity cassette, wherein the nucleic acid sequence encoding a B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NOs: 62, 66, 105; a ssUBC promoter having a protein-encoding first cistron, CD47, whose nucleic acid sequence is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259; a second cistron encoding CD47, having the sequence of SEQ ID NO: 141; , and an innate immune cassette comprising an hsHBB polyA (“hsHBB pA” or “HBB pA”) sequence selected from any one of SEQ ID NOs: 114-116 and 191, and combinations thereof, (c) apoptosis and A cellular immunity cassette, wherein the nucleic acid sequence of A20 is selected from the group consisting of SEQ ID NO: 64-65, 104, 182, and 188, wherein the nucleic acid sequence of CTLA-4, the first cistron encoding A20, is selected from the group consisting of SEQ ID NO: 64-65, 104, 182, and 188. a second cistron encoding CTLA-4 (e.g. LEA29Y) selected from the group consisting of 87-88 and 186, an ssEF1α1 promoter selected from SEQ ID NOs: 136-138 and 179, and SEQ ID NOs: 112, 120-122 , 159, and 190, and (d) a complement control cassette, wherein the CD46 nucleic acid sequence is SEQ ID NOs: 71-76, 185, the first cistron encoding CD46 selected from the group consisting of 200, and 253-258; Provided herein are nucleic acids comprising a second cistron, a CAG promoter selected from SEQ ID NOs: 126-128, and a complement control cassette comprising an hsGH polyA sequence having the sequence of SEQ ID NO: 113. In embodiments, the nucleic acid comprises a polyA sequence located 5' or 3' to all of the polycistronic cassette. In an embodiment, the polyA sequence located 5' or 3' to all of the polycistronic cassettes is SV40 pA having the sequence of SEQ ID NO: 119. In embodiments, the nucleic acid comprises a fluorescent protein located 5' or 3' to all of the polycistronic cassette. In an embodiment, the fluorescent protein located 5' or 3' to all of the polycistronic cassettes is a green fluorescent protein having the sequence SEQ ID NO: 111. In embodiments, CD46 is CD46da having the nucleic acid sequence of SEQ ID NO:72. In embodiments, THBD is THBDda having a sequence selected from SEQ ID NOs: 99-102. In embodiments, TFPI comprises TFPI and CD4 transmembrane domains. In an embodiment, TFPI has the sequence SEQ ID NO:94. In embodiments, a UCOE separates the complement control cassette from the apoptosis and cellular immunity cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In embodiments, UCOE is CBX3 having the sequence SEQ ID NO: 21 * It is UCOE.

[0171]

[0256] In embodiments, (a) the innate immunity cassette encodes a B2M HLA-E fusion protein, wherein the nucleic acid sequence encoding the B2M HLA-E fusion protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; a first cistron encoding CD47, a second cistron encoding CD47, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NO: 77-83, 180, and 259, an ssUBC promoter having the sequence of SEQ ID NO: 141; an innate immune cassette comprising an hsHBB polyA ("hsHBB pA" or "HBB pA") sequence selected from any one of numbers 114-116 and 191, and combinations thereof; (b) an inflammation and apoptosis cassette; and the nucleic acid sequence of the first cistron encoding A20, HO1, is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188, and the nucleic acid sequence of HO1 is selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188. a second cistron encoding HO1 selected from the group consisting of 183 and 189; and a third cistron encoding PD-L1, the nucleic acid sequence of PD-L1 being selected from the group consisting of SEQ ID NOs: 89-91. cistron, an ssHSPA8 promoter selected from SEQ ID NOs: 139-140, 142-145, and an inflammation and apoptosis cassette comprising a btGH polyA sequence having a sequence of any one of SEQ ID NOs: 112, 120-122, 159, 190; (c) a complement control cassette, wherein the nucleic acid sequence of CD46 is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258, the first cistron encoding CD46, the nucleic acid of CD55; a second cistron encoding CD55, whose sequence is selected from the group consisting of SEQ ID NO: 84, 85, 107, and 184; a nucleic acid sequence of CD59 encoding CD59, whose sequence is selected from SEQ ID NO: 86 and SEQ ID NO: 108; a third cistron, a CAG promoter selected from SEQ ID NOs: 126-128, and a complement control cassette comprising a btHBB polyA sequence having the sequence of SEQ ID NO: 160; and (d) a coagulation cassette comprising a nucleic acid sequence of THBD. is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266, and the nucleic acid sequence of TFPI is selected from the group consisting of SEQ ID NOs: 94-96, 103, and 187. A nucleic acid comprising a second cistron encoding TFPI, an ssICAM2 promoter having a sequence of SEQ ID NO: 167, and a coagulation cassette comprising an hsGH polyA sequence having a sequence of SEQ ID NO: 113 or SEQ ID NO: 161 is herein provided. In an embodiment, TFPI has the sequence SEQ ID NO:96. In embodiments, a UCOE separates the complement control cassette from the inflammation and apoptosis cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In embodiments, UCOE is CBX3 having the sequence SEQ ID NO: 21 * It is UCOE. In embodiments, the nucleic acid comprises a polyA sequence located 5' or 3' to all of the polycistronic cassette. In embodiments, the polyA sequence located either 5' or 3' to all of the polycistronic cassettes is SV40 pA having the nucleic acid sequence of SEQ ID NO: 119 or SEQ ID NO: 162.

[0172]

[0257] In embodiments, (a) a coagulation and innate immunity cassette, wherein (i) the THBD nucleic acid sequence encodes a THBD protein selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a first cistron, (ii) a second cistron encoding a CD47 protein, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NOs: 77-83 and 180; a third cistron encoding an EPCR protein selected from the group consisting of 96, 103, and 187; (iii) an ssUBC promoter selected from SEQ ID NO: 141, 168, and 178; and (iv) SEQ ID NO: 113 and (b) an apoptotic and cellular immunity cassette comprising an hsGH polyA sequence selected from 161; (b) an apoptotic and cellular immunity cassette, wherein the nucleic acid sequence of A20 is SEQ ID NOs: 64-65, 104, 182, and 188; (ii) the nucleic acid sequence of HO1 encodes an HO1 protein selected from the group consisting of SEQ ID NOs: 63, 109, 165, 183, and 189; (iii) a ssHSPA8 promoter selected from SEQ ID NOs: 139-140 and 142-145, and (iv) a btGH polyA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190. an apoptosis and cellular immunity cassette, and (c) a complement control cassette, wherein (i) the CD46 nucleic acid sequence is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258; (ii) a second cistron encoding a CD55 protein, wherein the nucleic acid sequence of CD55 is selected from the group consisting of SEQ ID NO: 84, 85, 107, and 184; (iii) SEQ ID NO: 126. Provided herein are nucleic acids comprising a complement control cassette comprising a CAG promoter selected from ~128, and (iv) an hsHBB polyA sequence selected from SEQ ID NOs: 114-116, 191. In embodiments, the UCOE separates the apoptosis and cellular immunity cassette from the complement control cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In embodiments, the nucleic acid comprises a polyA sequence that is 5' to all of the polycistronic cassette. In an embodiment, the polyA sequence that is 5' to all of the polycistronic cassettes is btHBB pA having the nucleic acid sequence of SEQ ID NO: 160. In embodiments, the nucleic acid comprises a polyA sequence that is 3' to all of the polycistronic cassette. In embodiments, the polyA sequence that is 3' to all of the polycistronic cassettes is SV40 pA having the nucleic acid sequence of SEQ ID NO: 162 or 119.

[0173]

[0258] In embodiments, (a) a coagulation and innate immunity cassette, wherein (i) the THBD nucleic acid sequence encodes a THBD protein selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; a first cistron, (ii) a second cistron encoding a CD47 protein, wherein the nucleic acid sequence of CD47 is selected from the group consisting of SEQ ID NOs: 77-83 and 180; a third cistron encoding an EPCR protein selected from the group consisting of 96, 103, and 187; (iii) an ssUBC promoter selected from SEQ ID NO: 141, 168, and 178; and (iv) SEQ ID NO: 113 and (b) an apoptotic and cellular immunity cassette comprising an hsGH polyA sequence selected from 161; (b) an apoptotic and cellular immunity cassette, wherein the nucleic acid sequence of A20 is SEQ ID NOs: 64-65, 104, 182, and 188; (ii) a second cistron comprising LEA29Y, wherein the nucleic acid sequence of LEA29Y is SEQ ID NO: 186; (iii) SEQ ID NO: 139-140 and 142. ssHSPA8 promoter selected from ~145; and (iv) an apoptotic and cellular immunity cassette comprising a btGH polyA sequence selected from SEQ ID NOs: 112, 120-122, 159, 190; (c) a complement control cassette comprising: , (i) a first cistron encoding a CD46 protein, wherein the nucleic acid sequence of CD46 is selected from the group consisting of SEQ ID NOs: 71-76, 185, 200, and 253-258; (ii) the nucleic acid sequence of CD55 is a second cistron encoding a CD55 protein selected from the group consisting of numbers 84, 85, 107, and 184; (iii) a CAG promoter selected from SEQ ID NOs: 126 to 128; and (iv) SEQ ID NOs: 114 to 128. Provided herein are nucleic acids comprising a complement control cassette comprising an hsHBB polyA sequence selected from 116, 191. In embodiments, the UCOE separates the apoptosis and cellular immunity cassette from the complement control cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In embodiments, the nucleic acid comprises a polyA sequence that is 5' to all of the polycistronic cassette. In an embodiment, the polyA sequence that is 5' to all of the polycistronic cassettes is btHBB pA having the nucleic acid sequence of SEQ ID NO: 160. In embodiments, the nucleic acid comprises a polyA sequence that is 3' to all of the polycistronic cassette. In embodiments, the polyA sequence that is 3' to all of the polycistronic cassettes is SV40 pA having the nucleic acid sequence of SEQ ID NO: 162 or 119.

[0174]

[0259] In embodiments, (a) a coagulation cassette comprising: (i) a nucleic acid sequence encoding a THBD protein, wherein the nucleic acid sequence encoding a THBD protein is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; (ii) a second cistron encoding a TFPI protein, wherein the nucleic acid sequence encoding the TFPI protein is selected from the group consisting of SEQ ID NO: 94-96, 103, and 187; (iii) SEQ ID NO: 141; 168, 178; (iv) a coagulation cassette comprising an hsGH polyA sequence selected from SEQ ID NOs: 113 and 161; (b) an innate immunity cassette comprising: (i) a B2M HLA-E fusion; (ii) a first cistron encoding a B2M HLA-E fusion protein, wherein the nucleic acid sequence encoding the protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) the nucleic acid sequence encoding the CD47 protein is SEQ ID NO: 77; a second cistron encoding a CD47 protein selected from the group consisting of ~83, 180, and 259; (iii) a ssHSPA8 promoter selected from SEQ ID NO: 139-140, 142-145; and (iv) SEQ ID NO: 112, 120-122, 159, 190, and (c) a complement control cassette, wherein (i) the nucleic acid sequence encoding the CD46 protein is SEQ ID NO: 71. (ii) a first cistron encoding a CD46 protein selected from the group consisting of ~76, 185, 200, and 253-258; (ii) a nucleic acid sequence encoding a CD55 protein having SEQ ID NOs: 84, 85, 107, and 184; (iii) a CAG promoter selected from SEQ ID NOs: 126-128; and (iv) an hsHBB polypeptide selected from SEQ ID NOs: 114-116 and 191. Provided herein are nucleic acids comprising one or more polycistronic cassettes selected from the group consisting of complement control cassettes comprising the A sequence. In embodiments, a UCOE separates the innate immunity cassette from the complement control cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In embodiments, the nucleic acid comprises a polyA sequence that is 5' to all of the polycistronic cassette. In an embodiment, the polyA sequence that is 5' to all of the polycistronic cassettes is btHBB pA having the nucleic acid sequence of SEQ ID NO: 160. In embodiments, the nucleic acid comprises a polyA sequence that is 3' to all of the polycistronic cassette. In embodiments, the polyA sequence that is 3' to all of the polycistronic cassette is SV40 pA having the nucleic acid sequence of SEQ ID NO: 162 or 119.

[0175]

[0260] In embodiments, (a) a coagulation cassette comprising: (i) a nucleic acid sequence encoding a THBD protein, wherein the nucleic acid sequence encoding a THBD protein is selected from the group consisting of SEQ ID NOs: 97-102, 166, and 265-266; (ii) a second cistron encoding a TFPI protein, wherein the nucleic acid sequence encoding the TFPI protein is selected from the group consisting of SEQ ID NO: 94-96, 103, and 187; (iii) SEQ ID NO: 141; 168, 178; (iv) a coagulation cassette comprising an hsGH polyA sequence selected from SEQ ID NOs: 113 and 161; (b) an innate immunity cassette comprising: (i) a B2M HLA-E fusion; (ii) a first cistron encoding a B2M HLA-E fusion protein, wherein the nucleic acid sequence encoding the protein is selected from the group consisting of SEQ ID NO: 62, 66, 105; (ii) the nucleic acid sequence encoding the CD47 protein is SEQ ID NO: 77; a second cistron encoding a CD47 protein selected from the group consisting of ~83, 180, and 259; (iii) a ssHSPA8 promoter selected from SEQ ID NO: 139-140, 142-145; and (iv) SEQ ID NO: (c) an innate immunity cassette comprising a btGH polyA sequence selected from 112, 120-122, 159, 190; (c) a complement control cassette, wherein (i) the nucleic acid sequence encoding the CD46 protein is SEQ ID NO: 71- (ii) a first cistron encoding a CD46 protein selected from the group consisting of 76, 185, 200, and 253-258; (ii) a nucleic acid sequence encoding a CD55 protein from SEQ ID NOs: 84, 85, 107, and 184; (iii) a CAG promoter selected from SEQ ID NOs: 126 to 128; and (iv) an ocHBB polyA sequence having the nucleic acid sequence of SEQ ID NO: 192. a complement control cassette, and (d) an inflammation and apoptosis cassette, wherein (i) the nucleic acid sequence of A20 encodes an A20 protein selected from the group consisting of SEQ ID NOs: 64-65, 104, 182, and 188. a first cistron, (ii) a second cistron encoding an HO1 protein, wherein the HO1 nucleic acid sequence is selected from the group consisting of SEQ ID NO: 63, 109, 165, 183, and 189; (iii) SEQ ID NO: 136~ 138, 179, and (iv) one or more polycistronic inflammatory and apoptosis cassettes comprising an hsHBB polyA sequence selected from SEQ ID NOs: 114-116 and 191. Provided herein are nucleic acids that include cassettes. In embodiments, a UCOE separates the innate immunity cassette from the complement control cassette. In embodiments, the UCOE has a sequence selected from SEQ ID NOs: 19-22, 157, and 193. In embodiments, the nucleic acid comprises a polyA sequence that is 5' to all of the polycistronic cassette. In an embodiment, the polyA sequence that is 5' to all of the polycistronic cassette is btHBB pA having the nucleic acid sequence of SEQ ID NO: 160. In embodiments, the nucleic acid comprises a polyA sequence that is 3' to all of the polycistronic cassette. In embodiments, the polyA sequence that is 3' to all of the polycistronic cassettes is SV40 pA having the nucleic acid sequence of SEQ ID NO: 162 or 119.

[0176] III. Cells, tissues, organs, and animals

[0261] Porcine xenografts are broadly compatible with human organ size and physiology and are ethically acceptable to the general public in the United States. However, xenografted pig tissue suffers from hyperacute rejection due to the presence of preformed antibodies against pig antigens, increased complement activation and coagulability, and congenital and adaptive reactions due to molecular incompatibility. It triggers a complex series of events that result in graft rejection, including an increased immune response. The present disclosure uses genetic engineering approaches to address the current drawbacks of xenotransplantation.

[0177]

[0262] In particular, there are several immunological and functional difficulties involving innate and adaptive immune function. Molecular incompatibility between pig donor tissue and human physiology results in complement and coagulation-mediated dysfunction leading to acute xenograft failure. Preformed antibodies against the α-1,3-galactosylgalactose (αGal) epitope initiate hyperacute graft rejection through complement activation. Genetic inactivation of the glycoprotein GGTA1 can reduce this rapid graft collapse. Protection is further improved by overexpression of genes for human complement regulatory protein (hCRP) CD46 (membrane cofactor protein), CD55 (complement decay accelerating factor), and CD59 (MAC inhibitory protein).

[0178]

[0263] Most non-Gal xenoantibodies recognize the sialic acid N-glycolylneuraminic acid (Neu5Gc), which is synthesized by CMAH proteins. This gene is inactive in humans and therefore porcine Neu5Gc is immunogenic in humans. Therefore, porcine CMAH will likely have to be inactivated for clinical success of xenotransplantation. While expression of complement regulators and knockout of GGTA1 reduce hyperacute rejection, these genetic modifications do not affect acute vascular rejection (AVR).

[0179]

[0264] Coagulation dysfunction, including thrombotic microangiopathy and systemic consumptive coagulopathy, is primarily due to molecular incompatibility in the coagulation systems between pigs and non-human primates (NHPs) due to knockout of GGTA1. and has even been sustained by overexpression of hCRP.

[0180]

[0265] Despite attempts by other researchers to generate transgenic pigs for safe xenotransplantation, these transgenic pigs are limited due to construct capacity limitations and transcriptional interference between the transgenes. It had only a limited number of transgenes. These methods have proven insufficient to overcome xenograft incompatibility. For example, US Patent Publication No. 2018 / 0249688 utilized polycistronic expression vectors with different combinations of transgenes. Importantly, these polycistronic vectors contain only four transgenes and were used to produce pigs with six genetic modifications, including KO of alpha Gal (GTKO). The present disclosure utilizes a combination of KO, KI, and gene replacement strategies. First, PERV-free pigs were produced that expressed more than six transgenes from a single locus.

[0181]

[0266] The examples described and disclosed herein provide a platform for achieving higher numbers of genetic modifications within the same pig. From this study, pig cells were genetically modified with more than six transgenes to generate immunologically compatible cells, tissues, organs, pigs, and progeny. CRISPR-Cas9 was used to functionally knock out a number of genes, including GGTA1, CMAH, and β4GALNT2, removing glycans recognized by human preformed anti-pig antibodies. Using piggyback-mediated integration or CRISPR-mediated integration, the polycistronic cassettes described herein (e.g., coagulation cassettes, complement control cassettes, innate immunity cassettes, innate immunity and inflammation and apoptosis cassettes, Cellular Immunity and Coagulation Cassette, Apoptosis and Coagulation Cassette, Apoptosis and Cellular Immunity Cassette, Inflammation and Apoptosis Cassette, Complement Regulation and Innate Immunity Cassette, Complement Regulation and Inflammation and Apoptosis Cassette). Furthermore, the porcine endogenous retrovirus (PERV) gene in pig cells was knocked out via CRISPR-Cas9.

[0182]

[0267] In embodiments, provided herein are cells comprising a polycistronic cassette described herein. In embodiments, provided herein are cells comprising the nucleic acids described herein. In embodiments, the cells are pig cells. In embodiments, the cells are primary pig cells. In embodiments, the cells are clonal. In embodiments, clonal cells are selected and genotyped. Cells with the correct genotype are expanded to support pig cloning. Cells containing one or more of the polycistronic cassettes described herein at genomic safe harbor loci are cloned into pigs by somatic cell nuclear transfer. In embodiments, provided herein are genetically modified animals comprising cells that include one or more of the polycistronic cassettes described herein. In embodiments, genetically modified animals are housed with non-genetically modified animals. In embodiments, the genetically modified animal is housed with another genetically modified animal. Progeny resulting from breeding a genetically modified animal with another genetically modified or non-genetically modified animal are provided herein. In embodiments, provided herein are cells, tissues, or organs derived from progeny.

[0183]

[0268] In embodiments, the pig donor cells utilized to generate the transgenic pigs are substantially free of PERV, exhibit knockouts of GGTA1, CMAH, and β4GALNT2, or contain the polycistronic cassette described herein. exhibiting one or more knock-ins or exhibiting any combination of the above-mentioned characteristics.

[0184]

[0269] The present disclosure provides cells, tissues, organs, and animals with multiple modified genes and methods of producing them. In embodiments, the cells, tissues, organs are obtained from or are animals. In embodiments, the animal is a mammal. In embodiments, the mammal is a non-human mammal. In embodiments, the non-human mammal is a horse, primate, pig, cow, buffalo, bison, cow, sheep, goat, dog, or cat. In embodiments, the non-human mammal is an ungulate. In embodiments, the ungulate is a horse, rhino, tapir, cow, pig, giraffe, camel, deer, sheep, hippopotamus, whale, dolphin, or porpoise. In embodiments, the mammal is a porcine mammal.

[0185]

[0270] Genetic modifications according to the present disclosure improve molecular compatibility between donor and recipient and reduce adverse events including hyperacute rejection, acute humoral rejection, thrombotic microangiopathy, and chronic vasculopathy. useful for. For example, hyperacute rejection occurs within a very short time interval, typically minutes to hours after transplantation, and is due to preformed antibodies that activate complement and graft endothelial cells, which lead to procoagulant causes changes in blood flow, leading to congestion and eventual destruction of the transplanted organ. In certain embodiments, cells, tissues, organs, and animals exhibit reduced hyperacute rejection.

[0186]

[0271] In embodiments, the present disclosure provides one or more cells, tissues, organs, or animals that have a large number of altered genes. In embodiments, the cell, tissue, organ, or animal is genetically modified such that a number of genes are added, deleted, inactivated, destroyed, portions thereof are excised, or the genetic sequence is altered. has been done. In embodiments, the cell, tissue, organ, or animal has about 5 to 20 modified genes, such as about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, It has about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 modified genes. In embodiments, the 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 modified genes are derived from a single locus. expressed. In embodiments, 5, 10, or 12 modified genes are expressed from a single locus. In an embodiment, the 12 modified genes are expressed from a single locus. In embodiments, the cell, tissue, organ, or animal has more than 20, more than 15, more than 10, more than 5, more than 3, or more than 2 altered genes. In embodiments, the cell, tissue, organ, or animal has more than 10, more than 5, more than 3, more than 2, or more than 1 altered genes. In embodiments, the cell, tissue, organ, or animal has one copy of the modified gene, and in other embodiments, the cell, tissue, organ, or animal has one or more copies of the modified gene. Two or more copies, e.g. >2, >3, >4, >5, >6, >7, >8, >9, >10, >15, >20, >25, >30 of the modified gene. , has more than 35, more than 40, more than 50, more than 60, more than 70, more than 80, more than 90, or more than 100 copies. In embodiments, the cell has from 1 copy to about 100 copies, from 1 copy to about 90 copies, from 1 copy to about 80 copies, from 1 copy to about 70 copies, from 1 copy to about 60 copies of one or more modified genes. , 1 copy to approximately 50 copies, 1 copy to approximately 40 copies, 1 copy to approximately 30 copies, approximately 5 copies to approximately 20 copies, approximately 10 copies to approximately 15 copies, approximately 10 copies to approximately 15 copies, or approximately 1 copy ~Has approximately 5 copies.

[0187]

[0272] In embodiments, the present disclosure provides one or more cells, tissues, organs, or animals having one or more multiple copies of a modified gene. For example, a cell, tissue, organ, or animal may contain 2, 3, 4, 5, 6, 7, 8, 9, about 10, about 15, about 20, about 25, It may have about 30, or more.

[0188]

[0273] In embodiments, the one or more cells are primary cells. In embodiments, the one or more cells are somatic cells. In embodiments, the one or more cells are postnatal cells. In embodiments, the one or more cells are adult cells (eg, adult ear fibroblasts). In embodiments, the one or more cells are fetal / embryonic cells (eg, embryonic blastomeres). In embodiments, one or more cells are germline cells. In embodiments, the one or more cells are oocytes. In embodiments, the one or more cells are stem cells. In embodiments, the one or more cells are from a primary cell line. In embodiments, the one or more cells are selected from the group consisting of epithelial cells, hepatocytes, granulosa cells, adipocytes. In certain embodiments, the one or more cells are fibroblasts. In embodiments, the fibroblasts are female fetal fibroblasts. In embodiments, the one or more cells are in vitro. In embodiments, the one or more cells are in vivo. In embodiments, the one or more cells are a single cell. In embodiments, one or more cells are members of a cell colony. In embodiments, the cells are islet cells.

[0189]

[0274] In embodiments, the one or more cells are pig cells. Non-limiting examples of breeds of origin for pig cells or breeds from which pig cells are derived include the following pig breeds: American Land Race, American Yorkshire, Aksai Black Pied, Angeln Saddleback, Appalachian English, Arapawa Island. , Auckland Island, Australia Yorkshire, Babi Kampung, Vershuen, Bantu, Basque, Bazuna, Peking Black, Belarusian Black Pied, Belgian Landlace, Bengali Brown Shannaji, Bentheim Black Pied, Berkshire, Bissaro, Bangur, Black Slab Nian, Black Canarian, Breitbo, British Land Lace, British Lop, British Saddleback, Bulgarian White, Cambro, Cantonese, Celtic, Chatmurciano, Chester White, Chiangmai Black Pig, Choctaw Hog, Creole, Czech Improved White, Danish Land Race, Danish Protest, Darman Chipade, Liyan, Duroc, Dutch Land Race, East Land Race, East Balkan, Essex, Estonian Bacon, Fengin, Finish Land Race, Forest Mountain, French Land Race, Gascon, German Land Lace, Gloucestershire Old Spot, Gottingen Mini Pig, Grice, Guinea Hog, Hampshire, Hunte, Hereford, Hezuo, Hogan Hog, Huntington Black Hog, Iberian, Italian Land Lace, Japanese Land Lace, Jeju Black, Jinhua, Kakechian, Kele, Kemerovo, Korean Native, Kruskopolje, Kunekune, Lacombe, Large Black, Large Black White, Large White, Latvian White, Leikoma, Lithuanian Native, Lithuanian White, Lincolnshire Kali Coated, Livny, Malhad de Arcovaca, Mangalica, Meishan, Middle White, Minzu, Minokawabuta, Monkay, Moralo Manyora, Moura, Mukota, Mulefoot, Murom, Milhorod, Nerodeinebrody, Neijian, New Zealand, Ninthian, North Kokejian, North Siberian, Norwegian Landrace, Norwegian Yorkshire, Ossaboo Island , Oxford Sandy and Black, Pak Chong 5, Filipino Native, Pietrain, Polish China, Red Wattle, Saddleback, Semirechensk, Siberian Black Pied, Small Black, Small White, Spot, Surabaya Babi, Swabian Hole, Swedish Land Lace, Swarovi Ride Mangalitsa, Taihu Pig, Tamworth, Tuok Niu, Tibetan, Tokyo-X, Tibirsk, Tuloporzhe, Ukraine Spotted Steppe, Ukraine White Steppe, Urzum, Vietnamese Potbelly, Welsh, Wessex Saddleback, West French White, Winsnia, Uzhshanmu, Includes Yanan, Yorkshire, and Yorkshire Blue and White. In embodiments, the pig cells are Yorkshire and Yucatan pig cells.

[0190]

[0275] In embodiments, a cell, tissue, organ, or animal of the present disclosure has one or more genes modified by addition, deletion, inactivation, destruction, excision of a portion thereof, or a portion of the gene sequence. It has been genetically modified so that the parts have been changed.

[0191]

[0276] In embodiments, a cell, tissue, organ, or animal of the present disclosure comprises one or more mutations that inactivate one or more genes. In embodiments, the cell, tissue, organ, or animal has one or more mutations or epigenetic changes that result in decreased expression or elimination of one or more genes having one or more mutations. include. In embodiments, one or more genes are inactivated by genetically modifying nucleic acids present in a cell, tissue, organ, or animal. In embodiments, inactivation of one or more genes is confirmed by assay. In embodiments, the assay is an infectivity assay, a reverse transcriptase PCR assay, RNA-seq, real-time PCR, or a junction PCR mapping assay.

[0192] specific genotype

[0277] In order to provide safe and effective cells, tissues, organs, and animals for clinical use in humans, the cells, tissues, organs, and animals of the present disclosure (e.g., donor pigs) can be enhanced to make them human-compatible. genetically engineered to have complement (ie, complement toxicity), coagulation, inflammatory (ie, apoptosis / inflammation), immune (ie, cytotoxicity), and / or immunomodulatory systems. Novel combinations of knock-out (KO), knock-in (KI) (referred to herein instead as transgene (TG)), and / or genomic replacement strategies can enhance complement, coagulation, inflammatory, and immune , and / or provide an immunomodulatory system. Expression of genes that make pig cells and organs compatible with humans is assessed using a variety of methods. Non-limiting examples of such methods include flow cytometry, immunohistochemistry, and RNA sequencing.

[0193]

[0278] Cells, tissues, organs, and animals lacking expression of key xenocarbohydrate antigens, eg, by gene KO, reduce or eliminate humoral rejection during xenotransplantation. Three major heterologous carbohydrate antigens include GGTA1, CMAH, and B4GALNT2, which are produced by glycosyltransferases / glycosylhydrolases. The purpose of loss of function of these genes is to reduce and / or eliminate the binding of preformed anti-swine antibodies to the endothelium of the pig graft.

[0194]

[0279] Insertion of critical complement, coagulation, inflammatory, immune, and / or immunomodulatory factors into one or more genomic loci, such as a safe harbor genomic locus, such as AAVS1, may disrupt the human complement system, as well as the natural It helps control the functions of killer (NK), macrophages, and T cells. Non-limiting examples include KI overexpression of hCD46, hCD55, and hCD59 to inhibit the human complement cascade, e.g. porcine vWF sequences to prevent unregulated platelet sequestration and thrombotic microangiopathy. Humanization of vWF by humanization of the A1 domain and / or flanking regions of B2M-HLA-E SCT to provide protection against cytotoxicity of human NK cells and humanization of porcine cells, and immunosuppressive agents. KIs of CD47, CD39, THBD, TFPI, and A20 that function as immunomodulators, immunomodulators, and / or anticoagulants.

[0195]

[0280] In embodiments, the cells, tissues, organs, or animals of the present disclosure are genetically modified such that one or more genes or portions thereof are modified by addition, deletion, inactivation, destruction, excision of the portions thereof. ing. In embodiments, the present disclosure provides isolated cells, tissues, organs, or animals having multiple altered genes. In embodiments, the modified genes include alpha GGTA1, β4GalNT2, CMAH, THBD, TFPI, CD39, HO1, CD46, CD55, CD59, major histocompatibility complex class I, E single chain trimer (HLA-E SCT ), A20, PD-L1, CD47, swine leukocyte antigen 1 (SLA-1), SLA-2, SLA-3, vWF, B2M, DQA, DRA, PROCR, B2M, HLA-E, CTLA-4 (e.g. LEA29Y ), and one or more of XIAP.

[0196]

[0281] In embodiments, the modified gene is GGTA1, B4GalNT2, CMAH, or any combination thereof. In embodiments, GGTA1, B4GalNT2, and / or CMAH are gene KO'd. In embodiments, the modified genes include the MHC-I genes SLA-1, SLA-2, and SLA-3, the MHC-II genes DQA and DRA, endogenous vWF, CD9, asialoglycoprotein receptor, at least one complement inhibitor genes (eg, C3, CD46, CD55, and CD59), and any combination thereof. In embodiments, CD46, CD55, and / or CD59 are gene KI.

[0197]

[0282] In one embodiment, the cells, tissues, organs, or animals of the present disclosure include CD46, CD55, CD59, THBD, TFPI, EPCR, CD39, B2M, HLA-E, CD47, A20, PD-L1, HO1, CTLA- 4 (eg, LEA29Y), XIAP, or any combination thereof. In one embodiment, the cells, tissues, organs, or animals of the present disclosure are further genetically modified, e.g., by gene KO, such that expression of GGTA1, B4GalNT2, CMAH, or any combination thereof is reduced or absent. has been done.

[0198]

[0283] Cells, tissues, organs, or animals of the present disclosure can be genetically modified by any method. In embodiments, cells, tissues, organs, or animals of the present disclosure are modified using nucleic acids that include multiple polycistronic cassettes. Non-limiting examples of suitable methods for the knockout (KO), knockin (KI), and / or genome replacement strategies disclosed and described herein include Cas9, Cas12a (Cpf1), or other Using CRISPR endonucleases, Argonaute endonucleases, transcription activator-like (TAL) effector and nucleases (TALENs), zinc finger nucleases (ZFNs), expression vectors, transposon systems (e.g. piggyback transposase), or any combination thereof CRISPR-mediated genetic modification.

[0199]

[0284] Cells, tissues, organs, or animals of the present disclosure may be PERV-free. For example, cells, tissues, organs, or animals of the present disclosure may have a PERV copy functionally deleted from their genome. Cells, tissues, organs, or animals of the present disclosure may have PERV copies functionally inactivated in their genome. PERV represents a risk factor when pig cells, tissues, or organs are transplanted into human recipients. PERV is released from normal pig cells and is infectious. PERV-A and PERV-B are polytropic viruses that infect cells of several species, especially humans (e.g. they are xenotropic), whereas PERV-C only infects pig cells. It is a homotropic virus. Non-limiting methods for functionally deleted PERV copies are disclosed and described in Niu 2017 and WIPO Publication WO 2018 / 195402, both of which are herein incorporated by reference in their entirety. In embodiments, the pig is genetically engineered to be free of PERV-A, PERV-B, or PERV-C (or any combination thereof).

[0200]

[0285] In embodiments, additional genes of the cells, tissues, organs, or animals of the present disclosure are modified by addition, deletion, inactivation, disruption, excision of portions thereof or portions of the gene sequence. In embodiments, the modifications are made in the following genes: MHC-I genes SLA-1, SLA-2, and SLA-3, MHC-II genes DQA and DRA, endogenous vWF, CD9, asialoglycoprotein receptor, and C3. and expression of one or more of the following transgenes: PD-L1, exogenous vWF, HLA-E, HLA-G, B2M, and CIITA-DN. In embodiments, the modifications include deletions of one or more of the following genes, alpha-galactosyltransferase 1, GGTA1, β4GALN2, and CMAH, and the following transgenes, CD46, CD55, CD59, CD47, HO1, A20, TNFR1 -One of Ig, CD39, THBD, TFPI, EPCR, PD-1, CTLA-4 (e.g. LEA29Y), CD73, SOD3, CXCL12, FasL, CXCR3, CD39L1, GLP-1R, M3R, IL35, IL12A, and EB13 or containing multiple expressions. In embodiments, the modified genes include CD46, CD55, CD59, CD47, HO1, A20, TNFR1-Ig, CD39, THBD, TFPI, EPCR, PD-1, CTLA-4 (e.g., LEA29Y), CD73, SOD3, CXCL12, FasL, CXCR3, CD39L1, GLP-1R, M3R, IL35, IL12A, and EB13.

[0201]

[0286] In embodiments, a cell, tissue, organ, or animal of the present disclosure comprises one or more genetically modified genes. A genetically modified gene may include one or more nucleotide additions, one or more nucleotide deletions, or one or more nucleotide mutations. In embodiments, the genetically modified gene is disrupted. In embodiments, transcription and / or translation of the genetically modified gene is prevented. In embodiments, the genetically modified gene is inactivated. In embodiments, the cell, tissue, organ, or animal comprises a transgene or a portion thereof that was not present in the wild-type cell, tissue, organ, or animal. In embodiments, the transgene is an exogenous gene. In embodiments, the transgene is an endogenous gene. In embodiments, a cell, tissue, organ, or animal of the present disclosure comprises one or more nucleic acids comprising one or more polycistronic cassettes described herein.

[0202]

[0287] In embodiments, the modified gene is an MHC class I gene. In embodiments, the modified MHC class I genes include one or more of the following: SLA-1, SLA-2, SLA-3, and B2M. In embodiments, the modified gene is SLA-1, SLA-2, and / or SLA-3. In embodiments, the modified gene is B2M. In embodiments, the modified MHC class I genes include one or more of the following: SLA-1, SLA-2, SLA-3, and B2M. In embodiments, the modified B2M, SLA-1, SLA-2, and / or SLA-3 genes, and / or portions thereof, are human HLA-E genes, human HLA-G genes, human B2M genes, and / or replaced by the human (dominant-negative mutant class II transactivator) CIITA-DN gene, and / or parts thereof. In embodiments, the modified gene is conditionally and / or inducibly modified. In embodiments, conditional promoters and / or inducible promoters are used to conditionally and / or inducibly modify one or more modified genes. In embodiments, a B2M, SLA-1, SLA- Provided herein is an isolated cell, tissue, organ, or animal comprising the SLA-2, or SLA-3 gene, or any combination of those genes.

[0203]

[0288] In embodiments, provided herein are cells, tissues, organs, or animals that include modified MHC class II genes. In embodiments, the modified MHC class II gene is DRQ, DRA, or any combination thereof. A genetically modified MHC class II gene may include one or more nucleotide additions, one or more nucleotide deletions, or one or more nucleotide mutations. In embodiments, the genetically modified MHC class II gene is disrupted. In embodiments, transcription and / or translation of the genetically modified class II gene is prevented. In embodiments, the genetically modified MHC class II gene is inactivated. In embodiments, the cell, tissue, organ, or animal comprises an MHC class II transgene or portion thereof that was not present in the wild-type cell, tissue, organ, or animal. In embodiments, the modified gene is conditionally and / or inducibly modified. In embodiments, conditional promoters and / or inducible promoters are used to conditionally and / or inducibly modify one or more modified genes. In embodiments, the isolated cell, tissue, organ, or animal comprises conditionally altered DRQ and / or DRA genes, or any combination thereof.

[0204]

[0289] In embodiments, provided herein are cells, tissues, organs, or animals that include modified vWF genes and / or vWF-related genes. Genetically modified vWF genes and / or vWF-related genes may include one or more nucleotide additions, one or more nucleotide deletions, or one or more nucleotide mutations. In embodiments, the genetically modified vWF gene and / or vWF-related genes are disrupted. In embodiments, transcription and / or translation of the genetically modified vWF gene and / or vWF-related genes is prevented. In embodiments, the genetically modified vWF gene and / or vWF-related genes are inactivated. In embodiments, the cell, tissue, organ, or animal comprises a vWF gene and / or vWF-related gene transgene or portion thereof that was not present in the wild-type cell, tissue, organ, or animal. In embodiments, the modified vWF gene and / or portion thereof is replaced with a human vWF gene and / or portion thereof. In embodiments, the modified vWF gene, modified vWF-related genes, and / or portions thereof are replaced with human vWF genes, one or more vWF-related genes, and / or portions thereof. In embodiments, the modified vWF gene and / or vWF-related genes are conditionally and / or inducibly modified. In embodiments, conditional promoters and / or inducible promoters are used to conditionally and / or inducibly modify one or more modified genes. In embodiments, the isolated cell, tissue, organ, or animal is capable of conditionally altering vWF, vWF-related genes, portions thereof, or any combination thereof; replacing the gene with the human vWF gene, at least a portion of the human vWF gene, one or more other human vWF-related genes, at least a portion of one or more human vWF-related genes, or any combination thereof. include. In e...

Claims

1. (a) a first polycistronic cassette comprising (i) a first cistron encoding an EPCR protein, and (ii) a second cistron encoding a thrombomodulin (THBD) protein; (b) a second polycistronic cassette comprising (i) a third cistron encoding an A20 protein, and (ii) a fourth cistron encoding an HO1 protein; and (c) a third polycistronic cassette comprising (i) a fifth cistron encoding a CD46 protein, (ii) a sixth cistron encoding a CD55 protein, and (iii) a seventh cistron encoding a CD47 protein. A nucleic acid molecule comprising:

2. (a) a first polycistronic cassette comprising (i) a first cistron encoding a TFPI protein, (ii) a second cistron encoding an EPCR protein, and (iii) a third cistron encoding a thrombomodulin (THBD) protein; (b) a second polycistronic cassette comprising (i) a fourth cistron encoding a B2M HLA-E fusion protein, and (ii) a fifth cistron encoding a CD47 protein; and (c) a third polycistronic cassette comprising (i) a sixth cistron encoding a CD46 protein, and (ii) a seventh cistron encoding a CD55 protein. A nucleic acid molecule comprising:

3. (a) a first polycistronic cassette comprising (i) a first cistron encoding a B2M HLA-E fusion protein, and (ii) a second cistron encoding a CD47 protein; and (b) a second polycistronic cassette comprising (i) a third cistron encoding a TFPI protein, and (ii) a fourth cistron encoding a THBD protein; (c) a third polycistronic cassette comprising (i) a fifth cistron encoding a CD46 protein, and (ii) a sixth cistron encoding a CD55 protein. A nucleic acid molecule comprising:

4. (d) a fourth polycistronic cassette comprising (i) a seventh cistron encoding a CTL A-4 protein, and (ii) an eighth cistron encoding a CD39 protein. The nucleic acid molecule of claim 3, further comprising:

5. (d) a fourth polycistronic cassette comprising (i) a seventh cistron encoding an A20 protein, and (ii) an eighth cistron encoding a PDL1 protein. The nucleic acid molecule of claim 3, further comprising:

6. (d) a fourth polycistronic cassette comprising (i) a seventh cistron encoding a XIAP protein, and (ii) an eighth cistron encoding a CD39 protein. The nucleic acid molecule of claim 3, further comprising:

7. (d) a fourth polycistronic cassette comprising (i) a seventh cistron encoding an A20 protein, and (ii) an eighth cistron encoding a CTL A-4 protein. The nucleic acid molecule of claim 3, further comprising:

8. The nucleic acid molecule of any one of claims 3 to 7, wherein the TFPI protein comprises a fusion between a TFPI domain and a CD4 transmembrane domain or a fragment thereof.

9. The nucleic acid molecule of any one of claims 3 to 8, wherein the TFPI protein does not include the P-selectin cytoplasmic tail or a fragment thereof.

10. The nucleic acid molecule of any one of claims 3 to 8, wherein the TFPI protein comprises a fusion between a TFPI domain, a CD4 transmembrane domain or a fragment thereof, and a P-selectin cytoplasmic tail or a fragment thereof.

11. The nucleic acid molecule according to any one of claims 1 to 10, wherein the CD47 protein is CD47 isoform 1 or CD47 isoform 2.

12. The nucleic acid molecule according to any one of claims 1 to 11, wherein the CD47 protein comprises a mutation compared to SEQ ID NO:

201.

13. The nucleic acid molecule of any one of claims 1 to 12, wherein the CD46 protein is a CD46 isoform selected from the group consisting of CD46 C1, CD46 C2, CD46 BC1, CD46 BC2, and CD46 ABC1.

14. The nucleic acid molecule according to any one of claims 1 to 13, wherein the cistron encoding the CD46 protein or the cistron encoding the THBD protein comprises a splice site mutation.

15. The nucleic acid molecule of claim 14, wherein the cistron encoding the CD46 protein contains a splice site mutation and encodes CD46_LL, CD46da1, CD46da2, CD46da, or CD46i.

16. 16. The nucleic acid molecule of any one of claims 1 to 15, further comprising a ubiquitous chromatin opening element.

17. The ubiquitous chromatin opening elements are Can6-3, A2CBX3, CBX3, and CBX3. * 17. The nucleic acid molecule of claim 16, which is SRF1 or SRF1.

18. 18. The nucleic acid molecule of any one of claims 1 to 17, wherein the cistron of the first polycistronic cassette, the cistron of the second polycistronic cassette, and the cistron of the third polycistronic cassette are expressed from a single locus.

19. 19. The nucleic acid molecule of any one of claims 1 to 18, which is integrated into a genomic safe harbor locus selected from the group consisting of AAVS1, CCR5, and Fos5.

20. The nucleic acid molecule of any one of claims 1 to 19, further comprising a ssUBC promoter.

21. 21. The nucleic acid molecule of claim 20, wherein the ssUBC promoter comprises any one of the sequences of SEQ ID NOs: 141, 168 and 178.

22. A nucleic acid molecule comprising a contiguous nucleic acid sequence having at least 95% identity to any one of SEQ ID NOs:23-46, 172-177, or 201-230.

23. 23. The nucleic acid molecule of claim 22, wherein the contiguous nucleic acid sequence has at least 95% identity to SEQ ID NO:

30.

24. 23. The nucleic acid molecule of claim 22, wherein the contiguous nucleic acid sequence has at least 95% identity to SEQ ID NO:

31.

25. 23. The nucleic acid molecule of claim 22, wherein the contiguous nucleic acid sequence comprises SEQ ID NO:

34.

26. 23. The nucleic acid molecule of claim 22, wherein the contiguous nucleic acid sequence comprises SEQ ID NO:

40.

27. A nucleic acid molecule encoding a thrombomodulin (THBD) protein, a CD46 protein, a CD55 protein, and a CD47 protein, comprising an ssUBC promoter.

28. A nucleic acid molecule encoding a CD46 protein, comprising a sequence having a mutation at any one of positions 141, 144 and 1099 compared to SEQ ID NO:

258.

29. A nucleic acid molecule encoding a CD46 protein and comprising any one of SEQ ID NOs:72-75, or 255.

30. A nucleic acid molecule encoding a THBDda protein and comprising any one of SEQ ID NOs: 99-102, 166, and 266.

31. A nucleic acid molecule encoding a TFPI protein, or a TFPI fusion protein, comprising any one of SEQ ID NOs:94-96, 103, and 187.

32. A method for genetically modifying a cell, the method comprising introducing into the cell a nucleic acid molecule according to any one of claims 1 to 31.

33. 33. The method of claim 32, comprising knocking out a porcine endogenous retrovirus (PERV) element.

34. The method of claim 32 or 33, comprising knocking out the glycoprotein alpha-1,3-galactosyltransferase (GGTA1) gene, the cytidine monophosphate-N-acetylneuraminic acid hydrolase (CMAH) gene, or the beta-1,4-N-acetylgalactosaminyltransferase 2 (beta4GALNT2) gene.

35. A cell comprising a nucleic acid molecule according to any one of claims 1 to 31.

36. The cell of claim 35, which is a non-human cell.

37. 37. An organ comprising the cell of claim 35 or 36.

38. A non-human animal comprising a cell according to claim 35 or 36.

39. (a) providing a liver from a genetically modified pig comprising the nucleic acid molecule according to any one of claims 1 to 31; (b) perfusing the liver ex vivo with a perfusion solution comprising plasma, whole blood, red blood cells, hemoglobin, human serum albumin, or a combination thereof, thereby producing a perfused liver; 2. An ex vivo method of liver perfusion comprising:

40. A perfused liver comprising a nucleic acid molecule according to any one of claims 1 to 31 for the treatment of a subject comprising a damaged, defective or absent liver.